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ABSTRACT
Background: Tuberculosis progresses despite potent Thl responses. A putative 
explanation is the presence of a subversive Th2 response. However interpretation is 
confounded by a novel cytokine, IL-452, a splice variant and inhibitor of IL-4. 
Methods: The expression of Thl cytokines (IFN-y), IL-452, Th2 cytokines (IL-4) and 
sCD30 was investigated in whole blood, lung lavage and mononuclear cell cultures 
from donors with TB, TB-HIV co-infection, and matched controls.
Results: After validation of a fluorogenic real-time RT-PCR assay, the half-life of IL- 
4 mRNA, but not IL-452, was found to be prolonged in TB vs controls (P<0.002). 
mRNAs for IL-4 and IL-452 were elevated in unstimulated cells from blood and lung 
lavage of patients vs controls (p<0.005). Patients with TB expressed significantly 
greater mRNA levels of both cytokines in T-cells (p<0.05 compared to controls where 
expression was predominantly in non-T cells). Radiological disease correlated with 
the IL-4/IFN-y ratio and sCD30 (p<0.005). Tuberculosis antigen upregulated 
expression of IL-4 relative to IL-452 in mononuclear cell cultures from tuberculosis 
patients (P<0.05). By contrast, though HIV-TB co-infected donors had increased IL-4 
in blood and lung lavage, in lung the predominant form was IL-452. After 
chemotherapy, in tuberculosis and in HIV-TB co-infection, IL-4 mRNA levels 
remained unchanged whilst IL-452 increased (p<0.05).
Conclusions: A Th2-like response, prominent in T cells, and driven by TB antigen, is 
present in TB and is modulated by treatment; suggesting a role for IL-4 and its 
antagonist, IL-452 in the pathogenesis of TB and their ratio as a possible marker of 
disease activity. Furthermore, enhancement of IL-4 mRNA stability, a hitherto 
undescribed regulatory mechanism in human TB, may facilitate the 
immunopathological effect of IL-4. The specific antigens inducing the IL-4 response 
require identification to facilitate future vaccine development strategies. Further 
studies are required to determine whether IL-4 facilitates systemic HIV progression in 
co-infected patients.
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1.1 Outline and objectives of the study
Tuberculosis (TB) is the commonest serious infectious disease worldwide and is 
responsible for ~ one fatality every 15 seconds! Despite an effective battery of drugs 
and the BCG vaccine, TB continues to flourish and ~ 40% of those with active disease 
fail to receive or complete treatment [1]. With the emergence of multi-drug resistant
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TB, human immunodeficiency virus (HIV) and the failure of control and treatment 
programmes novel approaches to therapy are urgently needed. Therefore, some have 
argued that only a widely available vaccine offers any hope of controlling the 
worldwide pandemic. Although M. tuberculosis has been studied for over a century, 
surprisingly little is known about how a few organisms can evade, sometimes 
indefinitely, a highly sophisticated immune system.
Clinical experience indicates that, besides the virulence of the organism, host 
immunity plays an important role in the interaction with M. tuberculosis. Indeed, the 
majority of those exposed do not become infected [2-4], most people who become 
infected do not develop the disease [5] and many that develop tuberculosis have no 
obvious defect in host immunity [6]. In fact, Type 1 cytokines such as interferon-y 
and IL-12, which are thought to be pivotal for successful host defence against 
M.tuberculosis, are prominent at the site of disease in those who do develop active TB 
[7, 8]. So why do these individuals contract the disease in the first place and why does 
it progress despite a vigorous type 1 response in the host? Moreover, why do some 
people appear to have natural resistance to the disease despite having a repeated high 
level of exposure [9]? Clearly, other factors that parallel IFN-y production must be 
important for successful host defence. The aim of the current project is to shed further 
light on these crucial questions.
There are different T-lymphocyte and cytokine responses associated with the complex 
immuno-pathology of tuberculosis. Similarly, there are different hypotheses that may 
explain how M. tuberculosis may subvert protective immune responses (discussed 
later in this chapter) [10]. One tenable hypothesis (recently reviewed in detail in [11- 
13]), supported by increasing data, is that in susceptible individuals mycobacterial 
antigens invoke a small but significant IL-4 response that undermines the immune 
system thus allowing M. tuberculosis to evade cellular mycobactericidal host 
responses [14-16]. To clarify, this is not perceived to be a ‘see-saw’ like Th2 
mediated downregulation of Thl responses but an IL-4 mediated sabotage of 
protective macrophage responses within the framework of a dominant Thl response. 
Although controversial, there is a growing body of evidence that an inappropriate Th2
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(IL-4) response is present in those with TB [17-19], particularly in countries close to 
the equator [20-24].
Understanding this host response may lead to new immunotherapeutic approaches to 
prevention and treatment. Whilst it has been demonstrated that TB antigens drive the 
Th2/ IL-4 response in the peripheral blood cells of tuberculin skin test (TST) + 
healthy volunteers [25, 26], there are few and discordant data from donors with active 
tuberculosis [18, 21, 27-30]. If these findings are confirmed in donors with TB, it 
would be instructive to determine which specific antigens or epitopes drive IL-4. 
These epitopes/ antigens may be suitable for manipulation or deletion to facilitate the 
design of therapeutic or prophylactic vaccines, develop immunotherapeutic 
interventions that may have the potential to shorten current chemotherapeutic regimes 
or be an adjunct to the treatment of MDR- TB. Furthermore, defining whether (and 
which) TB antigens drive IL-4 would be important to develop strategies in reducing 
fibrosis, lung remodelling and necrosis [31], which is responsible for much of the 
morbidity associated with ‘open pulmonary’ tuberculosis. This has implications for 
prevention and spread of TB.
Previous work, though there are conflicting data [25, 27, 28, 30, 32], has suggested 
that expression of IL-4 is increased in tuberculosis compared to healthy controls. 
However, these studies do not take into account the presence of a natural antagonist 
and the only proven splice variant of IL-4, IL-452 [33]. Moreover the discordant 
results are due to different culture conditions, cell types studied, antigen preparations 
used and a number of technical factors related to the measurement of IL-4, which is a 
low copy number cytokine and often beyond the detection limit of most assays [34] 
unless pre-stimulation protocols are used. The latter has its own set of problems [35]; 
the various technical aspects are discussed later. To circumvent the low sensitivity of 
immunoassays investigators, in mid-1990s, turned to reverse transcription polymerase 
chain reaction (RT-PCR), which amplifies reverse transcribed mRNA. However, this 
technique whilst good for qualitative purposes was notoriously unreliable for mRNA 
quantification [36]. There were also a number of additional technical drawbacks 
(discussed later).
21
More recently newer methods, using real time fluorogenic RT-PCR and microfluidic 
technology, have become available to measure levels of gene expression [37]. The 
new technology allows reliable and accurate quantification over a wide dynamic 
range [37]. It has, in the last few years, also become apparent that validation of 
reference genes used for normalisation (standardisation) of the raw PCR data is a 
prerequisite for accurate and meaningful study of gene expression [38] (the concept of 
normalisation is explained in detail in chapter 2, section 2.1). The use of unvalidated 
references may result in erroneous findings and misleading conclusions [39] 
(discussed in detail in chapter 2). Furthermore, there are now reliable and more 
precise methods to delineate latently infected contacts from non-infected healthy 
controls, another shortcoming of earlier studies [40, 41]. The above-mentioned 
methodological caveats and the inherent difficulty in reliably and accurately 
measuring IL-4 have, in part, been responsible for conflicting reports about the 
presence of a Th2 response in tuberculosis [17, 19, 27, 28]. Moreover, for practical 
reasons, three other factors confound the interpretation of existing data: (i) heavy 
reliance on in vitro and animal models, (ii) use of healthy or exposed subjects rather 
than human donors with the disease and (iii) reliance on data derived from whole 
blood rather than from samples acquired from the site of disease, the lung. Notably, 
previous studies have not studied IL-4 and IL-452 within the context of HIV and 
HIV-TB co-infection. If IL-4 is fundamental to vaccine design then these studies 
may be crucial as HIV and TB are intertwined pandemics; in developing countries ~ 
60% of TB cases are co-infected with HIV [ 1 ].
Accordingly, the objectives of the current project were:
(i) To first develop and validate a sensitive quantitative real-time PCR assay to 
overcome many of the drawbacks of earlier techniques attempting to measure IL-4 
and IL-452 in unstimulated cells (chapter 2 and 3). Once the assay was developed and 
validated, it was shown that use of conventional reference genes (like GAPDH) for 
data normalisation, as opposed to validated ones, might generate statistically different 
inter-group conclusions (chapter 2).
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(ii) To gain further insight into the regulation of IL-4 the half-lives of IL-4 and IL- 
452 mRNA were studied. Prolongation of IL-4 mRNA half-life has been shown in 
murine models of hypersensitivity pneumonitis [42] and the p38 signalling pathway 
may regulate the half lives of cytokines like IL-6 [43]. It was hypothesised that 
prolongation of the half-life of IL-4 mRNA was a putative regulatory mechanism 
modulating the biological effect of IL-4, possibly via the p38 signalling pathway. The 
results of these experiments indicated that in TB compared to control donors, the half- 
life of the mRNA encoding the agonist IL-4 was prolonged but not that of the 
antagonist, IL-452, via a p38 independent pathway (chapter 4).
(iii) The next step was to establish whether, using the newly designed and 
validated assay, the gene expression of IL-4 and IL-452 was elevated in biological 
samples from patients with active tuberculosis compared to healthy controls and to 
correlate these findings with clinical parameters (chapter 5). Moreover, a further 
objective was to establish whether Th2 cytokines were differentially expressed in the 
different body compartments (whole blood and lung lavage). Significantly, this was 
done immediately ex vivo after stabilisation of the sample to fix in vivo profiles. 
Furthermore, IL-4 and IL-452 mRNA levels were investigated in relation to anti-TB 
treatment (chapter 5).
(iv) Having found that IL-4 and IL-452 mRNA were up regulated in whole blood 
and lung lavage the next step was to determine the cell sub-populations making IL-4 
and IL-452 in TB and whether IL-452 is expressed in CD8+ T cells of TB patients, as 
it is in systemic sclerosis [44]. These data revealed that, compared to healthy 
volunteers where most of the IL-4 was produced by non-T cells, the unstimulated T 
cells from TB subjects produced significantly more IL-4 mRNA than did cells from 
control subjects (chapter 6).
(v) To study the antigen-specificity of IL-4 and the biological relevance of these 
results, the ability of TB antigens to induce IL-4 and IL-452 expression in peripheral 
blood lymphocytes from patients with tuberculosis were studied. These data indicated 
that in subjects with active disease TB antigen drives the expression of IL-4 rather 
than IL-452. The results of these experiments are discussed in chapter 7.
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(vi) The recent finding that IL-4/ IL-452 ratio is significantly decreased in subjects 
with LTBI who remain healthy suggest that the ratio may be a marker of protection. 
Accordingly, we hypothesised that The IL-4/ IL-452 ratio would be significantly 
increased in subjects with active tuberculosis (blood and alveolar lavage cells). The 
enhanced stability of IL-4 (but not IL-452), the preferential induction of IL-4 (and not 
IL-452) in antigen driven cultures and the significant change in IL-4/ IL-462 ratio 
with anti-TB treatment support this contention. However, the observation that the IL- 
4/IL-462 ratio remained unchanged in active tuberculosis, compared to healthy 
controls, may not be entirely compatible with this hypothesis. The implication of this 
finding is discussed further in chapter 5 and 9.
(vii) As the HIV and TB pandemics are inextricably intertwined IL-452 expression, 
hitherto unstudied in HIV and HIV-TB co-infection, was also examined. These 
experiments revealed body compartment-specific differences between IL-4 and IL-52 
expression that may be important in the progression of HIV-TB co-infection (chapter 
8 ).
(viii) In parallel soluble CD30 expression (a surrogate Th2 marker), not previously 
investigated in alveolar lavage or HIV-TB co-infection, was studied in TB and TB- 
HIV co-infection (chapters 5 and 8).
1.2. History, epidemiology and pathogenesis of tuberculosis
History and Origins of Mycobacterium Tuberculosis
Whole genome comparisons have revealed that the ‘modern’ TB strains are direct 
descendants of tubercle bacilli that existed before the M. africcmum and M. bovis 
lineage separated from the M. tuberculosis lineage by progressive gene deletion [45]. 
The progenitor species may have been co-evolving with humans for ~ 3 million years
[46]. Skeletons, dated to between 4000 and 1000 BC, suggestive of tuberculosis of the 
spine (Pott’s disease), have been found in Egypt, Jordon, Italy, Denmark and France
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[47]. The oldest mummy with clear evidence of pulmonary tuberculosis dates back to 
between 1000 and 400 B.C. [48].
Although there is some data based on nucleic amplification techniques, there is little 
direct evidence to support the existence of pulmonary tuberculosis before 1000 B.C. 
Medical papyri from Egypt dating to 1600 B.C, which describe many chest diseases, 
make no reference to pulmonary tuberculosis. Similarly, ancient texts like the Old 
Testament or the Rig Vedas of the Hindus, written before 1000 B.C, do not refer to 
pulmonary tuberculosis. The earliest record comes from a clay tablet from the library 
of the Assyrian king, Assurbanipal (668 B.C.), which makes reference to 
haemoptysis, cough and night sweats. Inhabitants of the Indus river valley called the 
disease jayashma (wasting); the Greeks named it pthisis. The more recent latin 
derivation in the English-speaking world was ‘consumption’. These data suggest that 
pulmonary tuberculosis was a well-recognised clinical entity by the second half of the 
r l millennium BC. It is worth noting that tuberculosis, while endemic in Europe since 
the early 1600’s, was virtually unknown in Sub-Saharan Africa and the Indian 
subcontinent till the latter half of the 19th century [49].
To the ancient Hindus (people inhabiting the Indus river valley), tuberculosis was 
caused by stress in people with inherited susceptibility [47]; Hippocrates (5th century 
B.C) also suggested an inherited susceptibility. Francastoro in 1547 proposed the 
modem theory of contagion by microorganisms and in 1868 Villemon demonstrated 
that the cause of TB exists in an innoculable agent. In was only in that 1881 Koch 
isolated the tuberculosis bacterium [50]. It was another 60 years before Schatz and 
colleagues published their papers on streptomycin, which would lay the foundations 
for a reliable cure for tuberculosis.
Epidemiology
The WHO has estimated that tuberculosis causes 2.9 million deaths and 8 million new 
cases every year [1]. In developing countries, it causes one fifth of all adult deaths, 
one quarter of avoidable deaths and seven percent of all deaths. Remarkably, only ~ 
60% of cases are cured and ~ 40% of cases remain untreated. After a continuous 
decline over 70 years there has also been an increase in the prevalence of tuberculosis
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in the Western Europe and USA. This has been due to several factors including the 
emergence of HIV infection, cross-border migration, increasing drug abuse, socio­
economic decline, delayed diagnosis and deteriorating public health infrastructure. Of 
particular concern is the emergence of MDR TB. Consequently, despite an effective 
array of drugs and the BCG vaccine, TB rates continue to burgeon worldwide. The 
WHO has now declared TB to be a ‘global public health emergency’ and there is an 
obvious and urgent need for more effective control measures.
The causative agent, Af. tuberculosis, is transmitted by droplet spread. Variables that 
determine transmission of infection include cough, the presence of cavitation, smear 
positivity (suggesting at least 5 to 10 thousand organisms/ml of sputum), length of 
contact, intensity of exposure and the innate and CMI responses of the host. The two 
distinct phases of tuberculosis are those of infection and disease. In those with 
established infection viable bacilli lie dormant within macrophages and other cell 
types within the lung and elsewhere [51]. These individuals may be identified by 
means of a positive tuberculin reaction and more reliably by peripheral T-cell antigen- 
specific IFN-y responses [40]. Generally, in high burden countries like the Gambia 
[521 and India [9] only about a third of high risk exposed subjects have positive 
antigen specific IFN-y responses or TSTs [3]. If we accept these as sensitive measures 
of LTBI then it implies that most exposed subjects do not become infected. 
Furthermore, most people who become infected do not develop the disease (-90%).
However, a minority of infected individuals may develop progressive disease or 
reactivate their latent foci of tuberculosis at some stage in the future, when the 
balance between mycobacterial persistence and host cellular responses is disturbed. 
The estimated lifetime risk of developing reactivation disease is individuals not 
infected by HIV is approximately 10% (2 to 23%) [53]. It is noteworthy that infected 
persons may revert to a PPD negative status over time (5% per year) but it is unclear 
whether these persons eradicate persisting organisms [54]. Approximately 5% 
develop progressive primary disease, usually within 2-5 years of becoming infected
[2]. Notably, a significant proportion has no obvious defect in host immunity such as 
malnutrition, chronic organ dysfunction or immuno-suppression.
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The cause of active tuberculosis (re-infection from recent transmission vs re­
activation of latent TB infection) in adults was controversial before the 1990s and was 
largely based on epidemiological modelling using historical tuberculin skin test data 
from the Netherlands [55]. The traditional view was that endogenous reactivation was 
responsible for 90% of adult tuberculosis [56]. More recently the use of molecular 
RFLP genotyping using IS6110 insertion sequence patterns, has revealed that 30% to 
50% of adult tuberculosis is due to recent transmission [57, 58]. The prevalence of 
recent transmission was found to be approximately 40 to 50% in communities with a 
high prevalence of tuberculosis [59, 60]. In such communities 75% of cases of 
tuberculosis relapse are due to re-infection [61, 62]. In developed countries like the 
UK and Denmark 14% and 35% respectively, of tuberculosis cases was ascribed to 
recent transmission in a large studies (over 2000 isolates in each study) [63, 64]. By 
contrast, in the urban setting of New York City the prevalence of recent transmission 
was approximately 40% to 50% [58, 65]. Collectively these data suggest that in 
populations where the incidence of clinical tuberculosis is low reactivation 
predominates whilst, in populations with a high prevalence of tuberculosis or urban 
pockets in Western countries, recent transmission is increasingly important. This 
underscores the need to track and clinically follow-up close contacts of index cases. In 
summary, disease may develop because of progressive primary infection or later 
reactivation of LTBI, which in high burden settings constitute a minority of cases. 
The natural history of untreated infection is one of death within 5 years in 50%, self­
cure in 30% and the remaining 20% persisting with chronic disease.
Pathogenesis
In a proportion of exposed individuals the infection progresses in the lung 
parenchyma and associated bronchopulmonary nodes (Ghon complex) [10]. 
Approximately 3 to 4 weeks later, the reason for this delay being unclear, T cells 
primed in the lymph nodes activate macrophages (also called CMI). The organisms 
either are destroyed completely or remain viable in latent foci. The fate of inhaled 
bacilli are summarised in figure 1.1.
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Figure 1.1. Fate of mycobacteria inhaled into the alveoli of the human lung. Presumably 
mycobacteria are destroyed by innate immune responses or CMI may be induced within the 
context of a granuloma. CMI may contain but not completely eradicate the organism (LTBI). 
In the minority progressive disease occurs. The factors that determine the fate of inhaled 
mycobacteria are poorly understood.
Host immunity plays an important role in the host-pathogen interaction in patients 
with TB; it is believed that when the balance between mycobacterial persistence and 
host cellular response is disturbed, latent infection may reactivate [10]. There are also 
genetic factors that determine initial infection rates and subsequent progression and 
these are likely to be important in apparently immunocompetent individuals. 
Nevertheless, what factors permit successful infection of the host remains unclear and 
the candidate genes that underpin these observations remain obscure. There is some 
evidence that genetic factors governing innate resistance to infection is important 
[66]. Indeed, some people appear to have natural resistance to the disease despite 
having a repeated high level of exposure [2, 3]. This is supported by data indicating 
that HIV impairs innate resistance thereby allowing much higher rates of tuberculous 
infection. Collectively, these data suggest that in most people exposed to M. 
tuberculosis, the organisms are destroyed either in the airways or presumably by the
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early innate immune response in the lungs. Of the significant minority that become 
infected most contain the infection and do not develop active disease.
Nevertheless, in clinical practice in the UK most people who develop the disease 
outside the setting of HIV have no obvious defect in host immunity such as 
malignancy, starvation, diabetes mellitus or iatrogenic immunosuppression. So why 
do these people develop tuberculosis? One favoured notion is that there are 
inadequate bactericidal mechanisms due to a suboptimal Thl response. However, 
most patients with tuberculosis have a vigorous Thl response at the site of disease [7] 
and polymorphisms of IFN-y and IL-12 are rare in clinical practice [67-69J. An 
alternative hypothesis implicates incapacitation of the macrophage mycobactericidal 
machinery; however, conclusive evidence from human studies is sparse and the 
immunological mechanisms facilitating these observations remain unclear. Another 
tenable hypothesis that may explain these observations is that, in susceptible 
individuals, certain conserved TB antigens corrupt the existing Thl response by 
introducing in parallel a subversive Th2 response that results in progressive infection 
and immunopathology. Evidence for this hypothesis will be presented later (section
1.7.). What follow s is a summary of our existing understanding of the immunology of 
tuberculosis infection and disease.
1.3. Diagnosis of latent TB infection
It is estimated that a third of the world's population is infected with M. tuberculosis. 
These individuals are asymptomatic and usually have normal chest radiographs. LTBI 
is classically diagnosed by performing a tuberculin skin test (TST) which measures 
CMI as a DTH hypersensitivity reaction to purified protein derivative (PPD), a 
precipitate of the protein fraction of a standardised batch of M.tuberculosis culture 
medium filtrate. When injected intradermally memory T cells that have encountered 
mycobacterial antigens in the past, not necessarily M.tuberculosis specific, will home 
in to the injection site initiating a DTH reaction. This is visible in 2 to 5 days as 
measurable local swelling and in some cases even ulceration. More recently 
peripheral blood derived T-cell IFN-y responses to M. tuberculosis specific antigens 
[(early secreted antigenic target 6 kDa (ESAT-6) and culture filtrate protein 10 (CFP-
29
10)] have been investigated for the diagnosis of LTBI. The TST suffers from a 
number of problems which IFN-y assays are designed to solve (table 1.1).
Furthermore, due to anergy, the TST is often unhelpful in individuals with chronic 
organ dysfunction, diabetes, malnourished or debilitated patients and those taking 
immunosuppressive treatments. Diagnosis of LTBI by the new test is based upon a 
vigorous T cell IFN-y response, measured by ELISPOT assay or ELISA, to relatively 
M. tuberculosis specific antigens, ESAT-6 and CFP-10. Both the proteins are encoded 
on the region of difference (RD1) domain, a region associated with virulence and 
attenuation of BCG [70]. An ESAT-6 receptor has not been described and the precise 
function of these secreted proteins remains unclear (reviewed in [70]). Their 
expression is absent in BCG and most environmental mycobacteria except M. 
marinum, M. szulgai and M. kansasii; homologues of these proteins are also found in 
the genome of M. leprae [71].
There are two commercial assays available, which both measure overnight IFN-y 
responses (< 24 hours) to overlapping ESAT-6 and CFP-10 peptides. The T SPOT TB 
assay (Oxford Immunotec. Oxford, England, see http:/Avww.oxfordimmunotec.com) 
is an ELISPOT assay that uses peripheral blood mononuclear cells and has European 
CE Mark approval. QuantiFERON *-TB Gold (Cellestis, Victoria, Australia) is an 
ELISA utilizing whole blood and has both European CE Mark and American FDA 
approval (figure 1.2). The older QuantiFERON'-TB, which measured IFN-y 
responses to PPD. is now superseded by QuantiFERON '-TB  Gold, which is also 
available in a field friendly version, QuantiFERON '-TB  Gold In-Tube, although 
there are no published data using the latter version (see http://www.cellestis.com).
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Table 1.1. Comparison of factors impacting upon utility of the Tuberculin Skin Test and IFN- 
v assay
Parameter
1. Specificity
2. Workload
3.Chemoprophylaxis
4. Subjectivity
5. Booster 
phenomenon
6. Cost
7. Longitudinal 
efficacy data
8. Other factors
Tuberculin skin test
Cross-reactivity with BCG and 
environmental bacteria
Requires return visit for which 
attendance is poor
Casts a wide net- may result in 
‘over treatment'
Results dependent upon observer 
and technique and (1. above)
Yes
High in developed countries; low' in 
developing countries
Plentiful
Prone to breakage of cold chain and 
syringe reuse in resource poor 
setting __  __
IFN-y assay ___
Relatively M. tuberculosis 
specific
Single visit
May avoid unnecessary 
treatment and toxicity
Provides ‘yes'/ ‘no' 
answer
No
Affordable in developed 
countries
Limited (1 study)
Requires basic laboratory 
expertise
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T SPOT TB assay 
Purified PBMCs
Figure 1.2. The methods used for the 
two commercially available IFN-y 
assays. In the T SPOT TB ELISPOT 
assay (A), PBMCs are separated from 
blood and incubated with antigen in 
plates of which the wells are precoated 
with an antibody that captures the IFN-y.
For the QuantiFERON-TB Gold ELISA 
assay (B), the antigens are added to 
whole blood, and the supernatant is 
assayed for IFN-y using a sensitive 
enzyme-linked immunosorbent assay.
Thus the former yields the total number 
of cells secreting IFN-y, while the latter 
yields the total quantity of IFN-y 
released. Numerous variants of these 
protocols are possible.
QuantiFERON®-TB Gold 
Whole blood
Incubate in the presence of 
M. tuberculosis antigens
Effector T-cells produce IFN-y
IFN-y binds to antibody on 
the base of ELISPOT wells
Spots developed and 
counted (manually or in 
reader). Results as Spot 
Forming Cells (SPC)
Incubate in the presence of 
M. tuberculosis antigens
Supernatant removed, and 
IFN-y measured by ELISA
Absorbance measured in 
ELISA reader 
Results as IFN-yml
Effector T-cells produce IFN-y
The test relies on the principle that effector lymphocytes, which have very recently 
encountered antigen in vivo, will produce interferon-y within hours when they 
encounter M. tuberculosis specific antigens. By contrast, memory T cells are more
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likely to require several days in the presence of antigen before IFN-y is produced [72, 
73]. Therefore incubation of whole blood or PBMCs is for ~ 24 hours (16-20 hours 
for T-SPOT TB, 16 -24 hours for QuantiFERON~ -TB Gold). This is to ensure that 
effector T cell responses are being measured. If longer incubation times are used it is 
possible for infection that has been treated or resolved to yield positive tests. This 
may explain the discordant results of studies that evaluated the change in IFN-y 
responses with anti-TB treatment. [74-79]. Another crucial point is that the prevailing 
literature shows a marked heterogeneity in the type of assay used [enzyme linked 
(ELISA) versus immunospot (ELISPOT)], the type of antigen used (peptide versus 
protein), the number of antigens used (cocktails versus ESAT-6 and CFP-10 and PPD 
alone) and the type of test (in-house versus standardized protocol and reagents). These 
factors, particularly the latter, may account for inter-laboratory variability and is 
important to control for if valid comparison between investigators are to be made. 
Consequently, for practical and meaningful interpretation of tests that are available to 
the clinician or other investigators it is preferable to use a regulatory approved 
standardised assay that incorporate both ESAT-6 and CFP-10 antigens, and that use 
incubation times of < 24 hours. Hence, a standardised assay was chosen for the 
current study.
The lack of a gold standard for diagnosing LTBI was a problem that investigators 
faced when trying to determine performance outcomes of the IFN-y assay. It is 
assumed that sensitivity should be at least as good as, or better, than in active 
tuberculosis, which tends to have lower IFN-y levels due to the immunosuppressive 
effect of disease itself and trafficking of cells out of the peripheral blood compartment 
[78]. Based upon this arguable assumption the sensitivity was determined to be 
between 78 and 100% when both ESAT-6 and CFP-10 antigens were used in either an 
ELISPOT or ELISA overnight incubation assay [74, 80-83]. In a recent contact 
tracing study ELISPOT was found to be as sensitive as the TST for the diagnosis of 
LTBI [84], Specificity was determined by studying T cell IFN-y responses in study 
subjects who were asymptomatic and at low' risk for LTBI. Specificity in these 
populations when both antigens were used, either in overnight ELISPOT or ELISA 
format, was 89 to 100% [80-83, 85]. Compared w ith the TST, the specificity of IFN-y 
assay was considerably higher in BCG vaccinated individuals [83-85]. Although there
33
is no gold standard for LTBI, we know that the risk of LTBI is closely related to 
proximity and duration of exposure to infectious pulmonary tuberculosis cases. 
Investigators have therefore used precisely quantified TB exposure as a surrogate gold 
standard for LTBI [41. 85-87]. Ewer and colleagues, in one of the largest such studies, 
using an overnight ELISPOT assay incorporating both antigens and performed 8 
weeks post-exposure in a school tuberculosis outbreak, found that ELISPOT 
correlated significantly better with duration and proximity of TB exposure than did 
TST, suggesting increased sensitivity with ELISPOT [41]. Furthermore ELISPOT but 
not TST w as independent of BCG vaccination status indicating higher specificity than 
TST. The authors suggest that the higher specificity of the IFN-y assay allows for 
more precise targeting of anti-TB treatment in low prevalence countries. Concordance 
between the TST and IFN-y assay was 89% [41] and similar in other studies using 
overnight incubation with both antigens (74 to 94%) [9, 52, 81]. There is a paucity of 
data on assay reproducibility, changes in responses over time and with treatment of 
LTBI, and how often indeterminate results occur (failure of the test's internal positive 
control). However, a recent study reported that in an unselected hospital population 
being evaluated for LTBI using a standardised ELISA assay, ~ 25% (mainly subjects 
with some form of immunosuppression) had indeterminate reactions [88]. In another 
immunosuppressed (HIV+) but smaller cohort, only 3% of participants were found to 
have indeterminate reactions when using an ELISPOT assay [89].
IFN-y assays have also been investigated in other mycobacterial infections: positive 
IFN-y responses to either ESAT-6 or CFP-10 antigens are found in patients with 
clinically active M. marinum and M. kansasii disease [83, 90], individuals with high 
environmental mycobacterial exposure such as Bower sellers and tropical fish tank 
owners [90] and Brazilian subjects with leprosy [91-93]. It has been shown in low7 
burden countries that a significant proportion of positive TSTs are due to M. avium 
infection [94, 95] but the IFN-y assays remain negative in the face of proven M avium 
disease [96]. Consequently, the standardised IFN-y assays will need validation in 
populations who come from or reside in countries where both tuberculosis and leprosy 
are endemic, and where there is a high environmental mycobacterial load [97].
Collectively these data indicate that, when a combination of antigens are used (ESAT- 
6 and CFP-10) in either overnight ELISA or ELISPOT format, IFN-y assays have a
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high sensitivity for diagnosing presumed LTBI and agreement between the TST and 
IFN-y assays are good. Nevertheless, in the absence of a gold standard the absolute 
sensitivity of the IFN-y assay, and the TST for that matter, for diagnosing LTBI 
remains unclear. However, IFN-y assays when compared with the TST have greater 
specificity in BCG vaccinated subjects and in the case of T-SPOT TB display a 
stronger association with TB exposure. IFN-y assays are less biased by environmental 
mycobacteria like M. avium, which is responsible for significant number of false 
positive TST reactions [95]. This specificity will facilitate more accurate targeting of 
treatment for LTBI. To what extent a heavy burden of environmental mycobacteria 
and M. leprae influence the performance of IFN-y assays requires further study [97]. 
Despite the shortcomings of the TST, large studies have shown that treatment of 
LTBI, as defined by the TST, substantially reduces the risk of developing active 
disease [2, 98, 99]. Consequently, the important clinical question is whether treatment 
of those identified as having LTBI by the IFN-y assay will actually reduce the 
incidence of subsequent clinical tuberculosis (TB). Secondly, relevant to both 
industrialized and developing nations, it remains to be determined whether IFN-y 
responses are predictive for high risk of progression to active tuberculosis. Long term 
and appropriately powered prospective studies are required, and currently underway, 
to answer these questions.
In summary, the antigen specific IFN-y assay has revolutionised the diagnosis of 
LTBI in low prevalence countries. It retains specificity in those who are BCG 
vaccinated or have a false positive TST due to environmental mycobacteria. Two 
standardised commercially available tests will make future comparisons between 
studies considerably more meaningful. The implications for research into host 
immunity are significant: sharpening of the blurred TST based distinction between 
infected and uninfected exposed contacts will facilitate the investigation of correlates 
of protective host immunity.
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1,4. Immunology of tuberculosis
There is a large interplay of different cell types and cytokines in tuberculosis infection 
and immunity. In most people an intricately orchestrated cellular immune cascade 
successfully eradicates the organisms; even in infected individuals the immune system 
is able to maintain the pathogen in a state of latency in the majority. However, it is 
still unclear what specific mechanisms lead to successful host defense and what 
precisely constitutes correlates of protective immunity.
Whilst being invaluable to our current understanding of tuberculosis related 
immunology prevailing data are complicated by several factors. For example some of 
the immunological pathways pertaining to mice, in which cavitation (a major 
determinant of transmission) does not occur, may not be applicable to humans. The 
ability of murine macrophages [100] but not human ones [101] to cause bacteriostasis 
of M. tuberculosis is a case in point. Moreover, human leucocytes responding to heat 
killed antigen preparations of M.tuberculosis may respond very poorly to live bacteria 
[102], Lymphocyte responses and mycobacterial antigen profiles may vary according 
to bacterial strains, culture conditions [103] and the viability organisms when live 
mycobacteria are used. Furthermore, in vitro studies in artificial laboratory micro­
environments are non-physiological and such data may not necessarily be 
extrapolated to the in vivo human model. Finally, immunological pathways delineated 
in human whole blood may not reflect the conditions at the site of disease (lung or 
lymph nodes). Nevertheless, the ever-increasing accumulation of scientific knowledge 
is likely to elucidate new immunological pathways and molecules critical for host 
defence. Theses findings will likely facilitate new immunotherapeutic interventions to 
manage TB. This may involve the development of prophylactic or therapeutic 
vaccines, administration of pro-inflammatory cytokines such as aerosolised IFN-y 
used in treatment resistant MDR-TB [ 1041, neutralising antibodies to 
immunosuppressive cytokines or inhibitors of molecules like TNF-a that may cause 
immunopathology e.g. thalidomide used to treat TNF mediated granulomatous 
diseases like erythema nodosum leprosum and sarcoidosis.
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There are different T-lymphocyte responses, cell sub-types and cytokines associated 
with the complex immuno-pathology of tuberculosis. They will be discussed within 
the framework presented in table 1.2.
Table 1.2. Cytokines and cell types implicated in host defense against M .tuberculosis
Type 1 cytokines (IFN-y, IL-12, IL-23)
IL-462
TNF-a
Type 2 cytokines (IL-4, IL-13)
Other cytokines and chemokines
Macrophages, Dendritic cells
CD4+ T cells, CD8+ T cells, y5 T cells, CD1 restricted T cells, regulatory T cells 
Other cell types (fibroblasts, epithelial cells, granulocytes)
1.4.1. Effective granuloma formation. Macrophages & Thl cytokines
The different clinico-pathological phases of tuberculosis and their immunological 
equivalents may be viewed, as ‘a series of battles between host and invader' [105]. 
The first cell types encountered by inhaled mycobacteria are the alveolar 
macrophages; phagocytosis is mediated by various host receptors including toll-like- 
receptors, macrophage mannose receptor, CD 14, complement receptor 3, Fc 
receptors and cholesterol [ 106-108]. Other cell types like epithelial cells, neutrophils, 
endothelial cells and fibroblasts may also be infected with M. tuberculosis [51] and 
may serve as reservoirs for bacterial multiplication.
Lung y6 T cells, NK T cells and granulocytes are important early arrivals that precede 
the second wave of expanded, IFN-y and TNF-a producing, effector T cell 
populations [109-111]. Collectively these cells and molecules initiate cross talk
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between the innate (antigen presenting cells, TLRs, defensins, surfactant protein etc) 
and adaptive immune systems (primed T cells). Consequently a chemokine and 
cytokine cascade which, attracts other macrophages and later T cells to the site of 
infection, is initiated [112] (figure 1.3).
Fibrous capsule
Chemokines
NKT
Figure 13. Principle cell types and cytokines involved in competent granuloma formation. 
NK T cells (NKT), CD4+ T cells, CD8+ T and y5 T cells produce Type 1 cytokines that 
activate macrophages, which are mycobactericidal. Granulocytes (not shown) may be 
important in early granuloma formation. Mycobacteria (rods) may be present within cells or 
extracellularly. Mycobacterial killing can occur by macrophage apoptosis, cytotoxic T-cell 
lysis (jagged arrow) or directly through granulysin (star) mediated destruction. TNF-a is a 
likely requisite for macrophage mycobactericidal activity, necrosis and formation of the 
fibrous capsule. Cellular recruitment into the granuloma is facilitated by a chemokine 
gradient.
Antigen presenting cells (macrophages and dendritic cells) produce IL-12; polarising 
cells to a Thl type of response. IL-12 is a requisite for M. tuberculosis induced 
murine T cell proliferation [113], is crucial for IFN-y induction [114] and mutations
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of genes for IL-12 or its receptor have been associated with mycobacterial disease in 
humans [114, 115]. The activated and expanding population of T cells produce IFN-y, 
which activate mycobacterium-laden macrophages (also called CMI or acquired 
cellular resistance) [101, 116]. 1,25-dihydroxy vitamin D3 may be important for this 
activation in humans [117] possibly by activation of anti-bactericidal peptides.
There is plasma exudation and a fibrin clot is formed [118, 119]. Macrophage 
aggregation to form an early granuloma core is mediated by hyaluronic acid [120], 
which binds to macrophages via CD44 [121]. Detailed histological analyses of 
developing granulomata in the rabbit model [122] led to the view that macrophage 
activation driven by cell-mediated immunity is followed by destruction of the same 
macrophages, which then accumulate as caseous necrosis and is often associated with 
death of the contained bacilli. An alternative view is that granulocytes are early 
arrivals that mediate the cell lysis that forms the core of developing caseous necrosis 
[111, 123, 124]. Recent pathological studies of granulomas in tuberculous human 
lungs indicate that the peripheral lymphocyte zones of the granuloma have secondary 
lymphoid follicles analogous to those found in lymph nodes [111].
Macrophages and other cell types like fibroblasts, endothelial cells and neutrophils 
also produce proteases [metalloproteinases (collagenase, gelatinase and stromelysin); 
the lysosomal proteinases (cathepsins); and the plasminogen/ plasmin system and its 
activator urokinase]. Such enzymes may facilitate granuloma formation by mediating 
the antigen processing, removal of ECM and cellular debris, and the processing of 
cytokines and hormones [125]. They are tightly regulated at multiple levels including 
transcription, proenzyme formation, signalling control, and by tissue inhibitors of 
metalloproteinases (TIMP) [126, 127],
Within the granuloma both T cells and macrophages secrete TNF-a and lymphotoxin 
a3. Not only is TNF-a crucial for murine host defence [128, 129], but it also 
facilitates the structural integrity of the granuloma by mediating the formation of the 
encapsulating fibrous wall [130] together with TGF-(3 [131, 132] (figure 1.4). 
Macrophages also secrete insulin- like-growth-factor-1 (IGF-1), fibroblast-GF, 
fibronectin and platelet-derived-GF [108, 133]. These growth factors are chemotactic
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and support macrophage proliferation and hence laying down of ECM comprising 
collagen, fibronectins and glycosaminoglycans [134, 135]. The granuloma develops a 
caseous centre surrounded by a concentric zone of inflammatory cells encircled by 
collagen and newly laid extracellular matrix. Granulomas are present in varying 
stages of development and the granulomas may contain mycobacterium-laden 
macrophages in diverse stages of maturity. Caseous necrosis, which occurs at about 2 
to 3 weeks in the rabbit model [122], and its associated low oxygen content create 
unfavourable conditions for mycobacterial multiplication [1361. This together with 
macrophage activation and CD3+ effector mechanisms culminates in mycobacterial 
sterilisation. It was shown in 1927 that healed primary lesions are usually sterile 
w ithin 5 years, though latent bacilli may persist in other, superficially normal, parts of 
the human lung [51, 137].
Controlled dissolution of the granuloma follows mycobacterial containment, though 
this may be incomplete if there has been massive production of caseum. Proteases 
cleave components of the ECM. Macrophages phagocytose the partly degraded ECM 
components, which are terminally degraded w ithin the lysosome or transported out of 
the lung [ 138, 139]. Minor residual scarring may remain.
1.4.2. Dysregulated granuloma turnover and liquefactive necrosis
In a significant minority, those with progressive primary and reactivation disease, 
macrophage and other innate mycobactericidal mechanisms fail despite high levels of 
IFN-y. The putative mechanisms involved and the potential role for IL-4 are discussed 
below (section 1.5 and 1.6). Instead of co-ordinated mycobactericidal granuloma 
formation there is liquefactive necrosis. This forms an ideal culture medium for 
mycobacteria; they multiply extracellularly to large numbers [105] as macrophages 
are unable to survive in necrotic tissue, partly because of its toxic fatty acid content 
[136], The proteolytic enzymes 1140] compromise the integrity of the fibrous 
granuloma capsule. Caseous material may discharge into surrounding blood vessels 
and airways with dissemination systemically and to the outside environment via 
cough induced respiratory droplets. The cavity often has an external zone of collagen 
internal to which is a zone of granulation tissue rich in fibroblasts, inflammatory cells 
and capillaries [ 105].
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Although the exact mechanisms of liquefaction are unknown, the available data 
suggest that dysregulated proteolysis and release of cellular lysosomal contents [MO- 
142], direct mycobacterial toxicity (virulence factors like polyketide toxins and 
ESAT-6), the Koch [143] and Shwartzman phenomena [144], and host effector cells 
and cytokines are key players (figure 1.4). Granulocytes may be important facilitators 
of early necrosis [111, 123] in murine and human models. As discussed below, local 
tissue damage will be more likely if the macrophages undergo necrosis rather than 
apoptosis. Furthermore, certain deletional mutants of M. tuberculosis have unchanged 
ability to proliferate within the host, but induce much less immunopathology 
suggesting that mycobacterial virulence factors actively induce tissue damaging CMI 
responses [145, 146].
Fibrous capsule
Liquefactive. 
necrosis
Apoptosis
Mycobacterial 
antigens/ toxin/ 
virulence factors
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Figure 1.4. Factors that may contribute to dysregulated granuloma formation. Mycobacterial 
antigens mediate uncoupled protease metabolism activity, apoptosis, the Koch phenomenon, 
and perhaps cell lysis mediated by ESAT-6, and induce cytokine release (TNF-a, mixed 
Thl/Th2 and TGF-p), which collectively facilitate liquefactive necrosis and deranged 
extracellular matrix (ECM) turnover. Mycobacteria (solid capsules) multiply extracellularly, 
compromise the fibrous granuloma capsule and may discharge into a bronchial lumen or 
blood vessel.
41
1.4.3. The Koch phenomenon
Koch showed that tuberculous guinea pigs developed necrosis locally and at distant 
sites of infection upon re-challenge with tuberculin and high tuberculin reactivity 
occurs in experimental animals with liquefaction [ 147], Similarly the tuberculin test is 
frequently necrotic in humans with tuberculosis but not in healthy BCG vaccinated 
individuals [105]. More recently, an elegant study showed that M. tuberculosis- 
infected mice developed increased lung inflammation and elevated TNF-a levels 
when rechallenged with mycobacterial antigens [148]. Moreover, when prophylactic 
vaccine candidates are tested for therapeutic effects in mice with tuberculosis they 
develop increased immunopathology [149] and classical Koch reactions characterised 
by cellular necrosis within granulomata [150]. One explanation may be the systemic 
Shwartzman reaction, which referred originally to cutaneous necrosis at a site of a 
previous endotoxin injection after intravenous injection of LPS [151]. Indeed, M. 
tuberculosis-infected C57BL/6 mice, which do not conventionally develop necrosis in 
this model, develop caseous necrosis after inoculation with LPS [152].
TNF-a
There are several lines of evidence to suggest that TNF-a is crucial for host defence 
against tuberculosis and containment of latent infection: TNF-a together with IFN-y 
activates murine macrophages [1 16], facilitates encapsulation of the granuloma [130] 
and monoclonal antibodies to TNF-a cause reactivation of latent infection in mice 
and humans [ 129, 153].
Although TNF-a is essential for immunity to tuberculosis, in progressive human 
disease TNF-a is associated with fever and wasting and correlates with disease 
activity and immunopathology [ 154-157]. Human cells containing M. tuberculosis are 
rendered exquisitely sensitive to killing by TNF-a [155, 158], As already outlined, 
TNF-a can up regulate metalloproteinases and urokinase and thereby facilitate 
proteolysis of structural lung elements. However, under what conditions is the 
protective TNF-a molecule toxic? Data, as outlined in section 1.6 below, support the
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synergistic role of Th2 cytokines in such toxicity and as a crucial facilitator of the 
Koch phenomenon, an entity that has never satisfactorily been explained 
immunologically.
1.4.4. Other cell types and cytokines relevant to TB immunology:
Dendritic cells
Dendritic cells (DC), the sentinels of lung immunity, are abundant in the airway, 
alveoli and lung parenchyma [159]; they possess pattern recognition receptors 
including TLRs and are able to internalise M.tuberculosis [160]. DC-specific 
intracellular adhesion molecule 3 grabbing nonintegrin (DC-SIGN) is one of many 
adhesion molecules that can bind M. tuberculosis [161, 162] and whose expression is 
upregulated by IL-4 [163] and IL-13 [164]. The early innate immune response 
includes interaction with y5 and CD1 restricted T cells, which produce macrophage 
activating effector cytokines. Antigen presentation may occur within the context of 
MHC class II molecules, group 1 CD1 molecules (glycolipid antigens) [165] and 
antigens from apoptotic cellular fragments may be presented by MHC class I 
molecules via the exogenous pathway [166]. Stimuli like TNF-a result in maturation 
of DCs to a phenotype that is capable of antigen presentation and T cell stimulation 
[167]. DCs then home in to the lymphoid organs where T cell growth and 
differentiation of antigen specific T cells occurs.
Significantly, unlike other APCs DCs can initiate and direct an immune response. 
Antigen can polarise T cell responses toward Thl in the presence of DC derived IL-12 
[ 168-170] and IFN-y [ 171 ] or Th2 in the presence of IL-4 [172]. The type of organism 
and antigen specificity plays a role: different antigenic components of the same 
microbe may cause Thl or Th2 polarisation by murine DCs [ 173]. BCG induces IL-4 
production by DCs generated from infected monocytes suggesting that mycobacterial 
antigens can induce DC mediated Th2 polarisation [174]. Further evidence that 
dendritic cells may direct T-cell differentiation comes from evidence that certain DC 
subsets (CD1lc+ CD 14-) may polarise T cells to a Th2 phenotype [175]. Recently, 
evidence has emerged that APC use the Notch pathway to instruct T cell
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differentiation. Notch directs Th2 differentiation by inducing GATA3 and by directly 
regulating IL-4 gene transcription [176]. Finally DCs may also play a role in inducing 
peripheral tolerance to self antigens and driving Treg [177]; it remains to be 
determined if this function interacts with host resistance to mycobacteria.
CD4+ and CD8+ T cells
CD4+ T cells are essential for host defense against mycobacteria. Both mice and 
humans deficient in CD+ T cells rapidly reactivate dormant M.tuberculosis 
organisms; HIV+ subjects with CD4+ lymphopenia are exquisitely susceptible to TB 
infection [178. 179]. Human T cells are crucial for IFN-y dependent macrophage 
activation and may also have direct mycobactericidal effects via a cytotoxic T cell 
response [180]. There are relatively few data on the cytokine profiles generated by 
PBMCs from TB patients. In vitro studies have produced conflicting results about 
cytokine production by CD4+ T cells with some studies reporting predominance of 
Thl cytokines while others report a mixed Thl and Th2 like response in peripheral 
blood (the discordant data are discussed in detail in section 1.7.2.). Nevertheless, 
these data have a number of limitations: they must be interpreted within the context of 
translocation of antigen specific CD4+ T cells to the lung, the data may not be 
meaningful without measuring the Th2 antagonist IL-452 and some techniques like in 
situ hybridisation are relatively insensitive for IL-4 detection.
Murine CD8+ T cells are instrumental to successful host immunity against 
tuberculosis [181, 182]. There are 3 effector functions of CD8+ cells: production of 
type 1 cytokines that activate macrophages, lysis of M.tuberculosis laden 
macrophages and direct killing of mycobacteria. The latter is mediated by perforin 
and a granule associated protein, granulolysin [183]. There are no studies addressing 
the question of IL-462 production in CD4 and CD8+ T cells in tuberculosis.
y5 and CD1 restricted T cells
y5 T cells are thought to be important in the early phase of the immune response to 
murine tuberculosis [110, 184]. Activation is followed by release of type 1 cytokines
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and granulysin-mediated lysis of macrophages and dendritic cells [185]. In addition 
to TNF-a and type 1 cytokines, y5 T cells may also produce IL-4 and IL-10 [186],
In contrast to the MHC family of proteins, which present peptide antigens, the CD1 
family of proteins serve as an antigen-presenting pathway for glyco-lipid based 
antigens. Structurally the CD1 molecule is a hetrodimer and is widely distributed on 
haemopoetic cells including thymocytes, monocytes (but not macrophages), dendritic 
cells and B cells [187], A large part of the T cell population (CD4-CD8-; CD4+; 
CD8+ T cells) can recognise CD1 restricted antigens [188]. Mice deficient in group 2 
proteins (CDld) do not show increased susceptibility to TB [189]. Nevertheless, there 
is a higher frequency of CD1 restricted T cells in those with tuberculosis compared to 
controls [190]. CD1 restricted T cells produce macrophage activating type 1 cytokines
[110] and also display granulolysin mediated cytotoxic lymphocyte activity [191]. 
These effector functions may contribute to early innate mycobacterial killing. NKT 
cells may also produce IL-4 in the early phase of infection. It is intriguing to speculate 
that in susceptible individuals, as demonstrated in a encephalomyelitis model [192], 
mycobacterial antigens drive NKT cell mediated IL-4 production, which facilitates 
the subversion of mycobactericidal innate immune responses.
Transforming growth factor ft
Various cell types including activated macrophages, fibroblasts, dendritic cells, 
neutrophils and activated lymphocytes produce and are sensitive to the effects of 
TGF-p. which exists as 3 isoforms (p i, p2 and P3), binds to one of two receptors 
(type I and II), and signals through transmembrane serine/threonine kinases and 
transcription factors (SMAD proteins) [193]. Levels of the mature protein are 
regulated by protease (e.g. plasmin) mediated cleavage of latency-associated peptide 
(LAP) from the bioactive dimer [ 1931.
In immunocompetent individuals TGF-P enhances monocyte chemotaxis, augments 
the expression of Fc receptors and takes part in the reversible fibrous encapsulation of 
the granuloma [131, 132]. On the other hand it has anti-inflammatory properties that 
modulate adhesion, apoptosis, proliferation and differentiation of various cell types
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including lymphocyte proliferation and IFN-y induced macrophage activation [194]. 
TGF-p is induced by mycobacterial antigens [195] and TGF-p expression is increased 
in PBMCs, monocytes and granulomas from patients with tuberculosis [196]. Data 
suggest that TGF-P enhances intracellular growth of M.tuberculosis in humans [197] 
and inhibits the antimycobacterial effects of TNF-a [198]. The putative role of TGF-p 
and IL-10 in suppressing protective host responses is discussed in section 1.5 and the 
putative role of IL-4 in facilitating TGF-p mediated immunopathology is discussed in 
section 1.7.5.
Other cytokines and chemokines
Studies in KO mice have highlighted the importance of pro-inflammatory cytokines 
like IL-1 [199] and transcription factors (CCAAT/enhancer binding protein and NF- 
kB), which are common pathways for the expression of multiple cytokine genes 
including IL-1 p. IL-6 and TNF-a [200] for efficient mycobacterial control. However 
KO models of IL-6, a B-cell growth and differentiation factor, suggest that IL-6 is 
not essential for protective immunity [201]. IL-8 is chemotactic for neutrophils, 
lymphocytes and basophils; IL-8 is elevated in tuberculosis, correlates with TB 
disease severity [202] and is associated with tissue necrosis in TB (discussed in 
section 1.7.5.1).
Data on the role of IL-13 in tuberculosis are sparse. IL-13 has similar properties to 
IL-4, namely, downregulation of Thl responses and inflammatory cytokines, and IgE 
class switching. IL-13 and IL-4 bind to receptors that share the IL-4 receptor a  chain. 
IL-13 is upregulated in exposed contacts [203] and those with active tuberculosis and 
correlates with IL-4 levels [17].
Chemokines are cytokines that recruit inflammatory cells to a site of infection; 
adhesion molecules facilitate this action. Expression of a variety of chemokines and 
their receptors (RANTES, MCP-1, fractalkine, M IP-la, M IP-lp) are up regulated in 
various cell types and in the different body compartments of patients with tuberculosis 
[204], Collectively, these data imply an intricate system of signalling between 
different compartments that coordinate effective granuloma formation and a
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competent host immune response.
1.4.5. Apoptosis in tuberculosis
Several reports documenting apoptosis of M.tuberculosis infected human 
macrophages in vitro and ex vivo, indicate that only live bacilli, rather than heat killed 
components of M.tuberculosis, can initiate apoptosis [205-207], suggesting that a 
secreted product of bacterial metabolism may be responsible. Apoptosis of infected 
macrophages is facilitated by TNF-a though other mechanisms (Fas-FasL interaction, 
purinergic receptors, ATP, FLCF) have also been shown to activate pathways of cell 
death.
Apoptosis may be beneficial to the host. Both in mice [208] and in man [209] CD8+ 
cytotoxic T cells that use the granule-mediated pathway to induce apoptosis (as 
opposed to the Fas-FasL pathway) lead to killing of the contained mycobacteria [210]. 
Apoptosis induced by ATP [211, 212], TNF-a independent of IFN-y [129], Fas 
Ligand [213] and hydrogen peroxide [214] all promote killing of virulent M. 
tuberculosis within macrophages, whereas the necrotic mode of death does not [213, 
215], Moreover, several reports suggest that apoptosis reduces bacterial viability 
compared to H2 O2 or complement mediated killing [213]. Apoptotic blebs may 
facilitate antigen presentation by dendritic cells [166] and phagocytosis of apoptotic 
vesicles may enhance bacterial killing compared to sonicate induced necrosis of 
macrophages [216],
By contrast other reports suggest that apoptosis is deleterious to the host. Reduced 
apoptosis of lymphocytes has been shown to correlate with improvement on anti-TB 
treatment [217] and reduced burden of M.avium infection in mice [218]. 
Consequently, it has been suggested that apoptosis may play a role in weakening 
protective responses and contributing to immunopathology by deletion of protective T 
cell clones or alternatively lack of deletion of immunosuppressive clones [219]. 
Apoptosis may also facilitate immunopathology. Indeed, large numbers of apoptotic T 
cells and macrophages are seen in caseous foci [220], which unlike necrotic cells, are 
usually removed with minimal inflammation. Furthermore, it is also possible that
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when a sufficient percentage of the cells are undergoing apoptosis, the normal 
clearance mechanism fails, and apoptotic cells can themselves contribute to caseum. 
IL-4 may facilitate this process by sensitising M.tuberculosis reactive lymphocytes to 
TNF mediated apoptosis [26] (discussed in greater detail in section 1.5).
1.4.6. Genetic influence on susceptibility and resistance to tuberculosis
The remarkable decline in tuberculosis death rates of American Indians of the 
Qu'appelle valley, who had no longstanding historical exposure to TB, indicate that 
natural selection drives the differential survival of phenotypes [221]. Furthermore, the 
increased susceptibility of Afro-American subjects to tuberculosis despite equivalent 
exposure [222], studies in twins [223], and the differential disease outcome and 
susceptibility after accidental immunisation of 251 German infants with a virulent 
strain of M.tuberculosis [221], all suggest that genetic factors play a role in host 
susceptibility. The failure to convert to tuberculin sensitivity in many individuals, 
despite repeated high-level exposure, supports this contention [9]. Nevertheless, the 
genes that govern susceptibility remain obscure.
MHC genes that have been found to be associated with disease susceptibility include 
HLA DR2 in different populations and the DQB 1*0503 allele in Cambodians [66]. 
Non-HLA gene polymorphisms include those of IFN-y and its receptor, IL-12 
receptor, the IL-1 gene complex, mannose binding protein and the vitamin D receptor 
[66], Data suggest that genetic factors govern the ability of host innate immune 
responses to prevent infection. Nramp 1 (natural resistance associated macrophage 
protein) is expressed in the endosomal/ lysosomal compartment of mouse 
macrophages and serves as a membrane cation pump [224]. Human Nramp 1 shares 
8897 of the mouse nucleotide sequence, encodes a membrane transport protein and is 
strongly expressed in lung neutrophils. Although Nramp 1 deficient mice do not 
display greater susceptibility to TB [225] studies in human tuberculosis have shown 
Nramp 1 polymorphisms to be associated with susceptibility in Gambians but not in 
Cambodians [226, 227], Similarly, IFN-y gene polymorphisms are no commoner in 
Gambians with TB compared to healthy control donors [68]. These findings indicate 
that associations between tuberculosis and polymorphisms are strongly influenced by
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ethnicity. Notably, there are few data on IL-4 gene polymorphisms and their 
relationship to disease susceptibility. Data from a Peruvian group published in 
abstract form suggest that an IL-4 gene polymorphism may modulate the risk for 
developing disseminated forms of tuberculosis [228]. However, details remain 
unpublished and it remains unclear whether this represents a loss or gain of function 
mutation; attempts to contact the authors have been unsuccessful.
1.4.7. Thl /Th2 paradigm
There are 2 overlapping subgroups of CD4+ T cells that differ in the production of 
their cytokine profile i.e. the Thl and Th2 groups of cells [229, 230]. The Thl cells 
produce IL-2 and interferon gamma (IFN-y) and are crucial for delayed 
hypersensitivity and tend not to produce IL-4. Th2 cells on the other hand produce IL- 
4, IL-5, IL-6 and IL-13 and are important for B cell, eosinophil and mast cell growth 
and differentiation. In humans, unlike mice, other cytokines like IL-10 and TNF-a are 
produced by both groups of cells. Both Thl and Th2 groups have cross-regulatory 
influences that favour the predominance of one group over another. For example, 
IFN-y (Thl) inhibits murine Th2 cell proliferation and Th2 cells inhibit cytokine 
synthesis of Thl cells [231]. ThO cells are thought to produce both type 1 and type 2 
cytokines; it is unclear if they are an independent population or precursors of the Thl 
and Th2 phenotypes. However, evidence suggests that Thl and Th2 cells are derived 
from common precursors [232]. It has also been reported in murine iti vitro studies 
that ‘committed’ cells can be influenced to change their cytokine profiles [233, 234].
The Thl / Th2 paradigm has been demonstrated in diseases such as leishmaniasis and 
leprosy [235] where the pattern of cytokine expression is associated with different 
disease manifestations. An ineffective immune response in leprosy (lepromatous 
leprosy with florid skin lesions, high bacterial load and poorly formed granulomas) is 
typified by a Th2 type profile (IL-4) whereas a more resistant immune response 
(tuberculoid with limited skin lesions, paucibacillary disease and well formed 
granulomas) is characterised by a Thl profile [235]. In general, Thl responses 
promote protection against intracellular pathogens and parasites whilst Th2 responses 
promote protection against intestinal nematode parasites. However, non-infectious
49
diseases like asthma, Crohn’s disease, organ transplantation and idiopathic pulmonary 
fibrosis are also associated with Th2 profiles. It is worth noting that, whilst the 
dominant cytokine in many of these diseases including asthma is IFN-y, Th2 
cytokines are significantly expressed. Consequently, the Thl/Th2 dichotomy does not 
simply imply a seesaw type down-regulation of one subset and up regulation of 
another. Indeed in TB we postulated that a small but significant IL-4 response, within 
the context of a dominant Thl profile, sabotages protective host immunity [12, 236].
1.5. Putative mechanisms by which mycobacteria may subvert host immune 
responses
(i) Reactive oxygen and nitrogen intermediates
The dominant view has been that mycobacterial killing is mediated via reactive 
oxygen and nitrogen intermediates and oxidative effector molecules [237, 238]. 
Nevertheless, actual killing is difficult to demonstrate in human models and much of 
the data pertains to correlation with mycobacterial stasis. Furthermore, the exact 
mechanisms mediating these pathways and their importance in humans are unclear. 
However, mycobacteria possess a peroxidase/ phosphonitrate reductase system that 
may resist reactive host intermediates [239]. Mycobacteria are also able to alter their 
metabolism by switching to fatty acid oxidation thus reducing their oxygen 
requirements and the production of hemolysin may mediate mycobacterial escape into 
the cytoplasm [221, 240]. This mycobacterial compounds (glycolipids, LAM and 
sulphatids) may drive pathways that hinder the effective functioning of reactive 
intermediates. These mechanisms include inhibition of phagolysosome fusion and 
acidification [241], inhibition of antigen loading into CD1 proteins that requires a low 
pH environment [188]. How mycobacteria regulate and manipulate these pathways is 
unclear. Chan and co-workers suggest that a putative mechanism may involve 
mycobacterial antigens down regulating the transcriptional activation of IFN-y 
inducible genes [242]. However, as discussed below, IFN-y expression at the site of 
disease is prominent and mycobacterial antigens like ESAT-6 are potent inducers of 
IFN-y. A detailed discussion about the putative role of IL-4 in relation to macrophage 
mycobactericidal functions is outlined in (vii) below.
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(ii) Anti-mvcobacterial peptides
CD8+ and NK T cells may directly kill mycobacteria; this is facilitated by perforin 
(forms a pore) and effected by granulysin (figure 1.3 [191]). Granulysin is a peptide 
present in the cytotoxic granules of NK cells and certain T cells and is directly 
cytotoxic (damages cell membranes) to intracellular bacteria including M. 
tuberculosis [191]. Another group of anti-bacterial peptides are the defensins; those 
found in neutrophil granules have been designated human neutrophil peptides (HNP). 
In in-vitro cultures defensins are lethal to M.tuberculosis [243], and in a murine 
model enhance mycobacterial killing and substantially reduce the required anti- 
mycobactericidal drug dose [244]. The protective role of other anti-mycobacterial 
peptides like the cathelicidins is under investigation. Nevertheless, the pathways that 
underpin the production of these peptides require further investigation. It is unknown 
whether host cytokines like IL-4 can modulate these pathways.
(iii) Defects in IFN-y and Thl pathways
It is clear that IFN-y (produced by CD4, CD8 and NK cells) is important for 
mycobacterial destruction as mice and humans with genetic defects of these cytokines 
or their receptors are more susceptible to mycobacterial infections [245, 246]. Patients 
with MDR TB with failing treatment regimens have responded to aerosolised IFN-y 
[104] and IFN-y induction has been shown to be reduced in PBMCs from TB patients 
[29]. Consequently, sub-optimal IFN-y responses and ensuing failure to activate 
macrophages has been postulated as a putative mechanism to explain mycobacterial 
persistence and disease progression. However genetic mutations of IFN-y or its 
receptor in humans with pulmonary tuberculosis are rare in clinical practice [68] and 
most patients with active disease still have strongly positive DTH responses. Notably, 
in vitro models in humans have failed to show mycobacterial killing in monocytes 
following the addition of IFN-y [101, 247]. In those with active disease rapid 
induction of a potent IFN-y response to ESAT-6 is an almost universal consequence 
of infection [74]. Moreover, granulomas from TB patients have abundant IFN-y and 
IL-12 [248]. Although low IFN-y levels have been demonstrated in patients with 
active disease, these studies have invariably used peripheral blood cells [29, 78].
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However, at the site of disease, the lungs, preliminary evidence indicates that levels of 
IFN-y are high [7]. These data support the indispensable role of IFN-y for protective 
immunity but also a hypothesis that it is not failure of protective Thl responses but 
their deliberate induction to perpetuate immunopathology and concurrently their 
sabotage, which may explain the destabilisation of an effective host response.
(iv)TGF-B
IFN-y mediated mycobactericidal activity of human macrophages is enhanced in the 
presence of TGF-p neutralising antibodies [249]. These data suggest that unbalanced 
TGF-p production is capable of suppressing successful host immune responses to 
tuberculosis by macrophage deactivation and T-cell inhibition. TGF-p may also be 
associated with tissue damage and fibrosis [131, 250]. But under what conditions does 
TGF-p facilitate immunopatholgy and /or mycobacterial proliferation? Existing data 
lend support to the hypothesis that Th2 cytokines, like IL-13, may drive TGF-p 
thereby sabotaging a balanced and coordinated host response (see section 1.7. for a 
more detailed discussion). Certain types of regulatory T cells also produce TGF-P 
(discussed below).
(v) Regulatory T cells and IL-10
It has been proposed that disease progression and susceptibility is facilitated by 
regulatory T cell (Treg) activity because peripheral blood T cells often respond less 
vigorously to antigens of M. tuberculosis than do cells from healthy contacts [251, 
252]. Some of these are “anergic” TB patients who are skin-test negative and whose 
T cells secrete IL-10, but release little IL-2 or IFN-y in response to M. tuberculosis 
[253-255]. Some T cells that secrete IFN-y in the lungs of tuberculosis patients also 
secrete IL-10 [256], and might be the recently discovered Thl-like Treg that express 
both t-bet (transcription factor and Thl marker) and Foxp3 rather than true Thl cells 
[257, 258]. Other types of regulatory T cells that have been described include 
naturally occurring Treg [259, 260], Trl cells [253, 254], Th3 cells [251], regulatory 
NK T cells [261] and the list is growing. Naturally occurring Treg [260] and Trl 
(likely but not definitively proven) regulatory cells [253, 254] have been described in
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association with tuberculosis. What these cells have in common is the ability to 
downregulate proliferative and pro-inflammatory functions of other cells; they 
generally produce IL-10.
IL-10, an anti-inflammatory cytokine, which inhibits human T cell proliferation, 
down regulates macrophage MHC class II expression, Thl cytokine production 
[262], inhibits the microbicidal activity of macrophages [262] and down regulates 
CD1 expression on dendritic cells. Th3 type TGF-p secreting CD4+ lymphocytes, one 
of many Treg subtypes, may concurrently produce IL-10 and also small amounts of 
IL-4 [258]. However, the role of IL-4 in this context is unclear. In progressive disease, 
IL-4 causes increased, rather than diminished, immunopathology in BALB/c mice 
[14].
Collectively, these data indicate that regulatory T cells are present in patients with 
TB, but their importance remains unclear. It is possible that excessive early Treg 
function might result in a delayed development of protective Thl activity, as in some 
malaria models [263]; however, the malaria parasite proliferates very fast, and a delay 
of a day or two can be critical, but this is less likely to be true for M. tuberculosis. 
Nevertheless, though a few TB patients are certainly anergic, most have tissue 
necrosis, a powerful IFN-y response and recruitment of antigen-responsive T cells at 
the site of disease [7, 8, 264, 265]. Schwander and colleagues showed that there are 
high IFN-y levels and strong proliferative responses in the human lung but the 
opposite occurs in the periphery [264]. This might suggest that in the chronic phase of 
progressive of tuberculosis, the extent of Treg activity is not the critical factor that 
determines outcome. Wherever the patients’ immune systems lie on the Treg axis, 
they still have TB.
Already entertained are the possibilities of too much Treg in the very early phase of 
infection or too little Treg during progressive phase of disease because of the 
extensive immunopathology seen in TB. Another possibility is a wrong type of Treg 
response so that there is inappropriate facilitation of Th2 responses. Further studies 
are required to clarify which of these possibilities predominate and whether Treg 
responses represent cause or effect in TB. It also seems logical to determine, at the
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levels of DCs, which antigens drive regulatory responses and T-helper differentiation 
in TB (discussed later).
(vi) Apoptosis
As already outlined, apoptosis may be beneficial for the host and facilitate 
mycobacterial killing (whereas necrosis is not). This may also explain why treatment 
with neutralising antibodies to TNF-a, which facilitates apoptosis, can cause 
reactivation of tuberculosis [153]; decreased expression of iNOS in the presence of 
anti-TNF might also be involved. It is therefore not unreasonable to suggest that 
defects in apoptosis pathways may enhance disease progression. Indeed, M. 
tuberculosis has mechanisms that tend to inhibit apoptosis. Mannose-capped 
lipoarabinomannan (Man-LAM) stimulates phosphorylation of Bad, a pro-apoptotic 
protein, and so inhibits apoptosis [266]. Another group has shown that Man-LAM 
inhibits apoptosis by a mechanism involving calcium-dependent signalling [267]. 
Recently cathepsins have been shown to modulate apoptosis in human pulmonary 
epithelial cells [268] though their role in TB has not been investigated.
Virulent M. tuberculosis seeks to evade apoptosis by causing infected human 
macrophages to release increased levels of soluble TNF receptors, leading to 
formation of inactive TNF-a-TNF receptor complexes [269, 270]. This strategy used 
by M. tuberculosis to avoid apoptosis is likely to be enhanced by IL-4, because IL-4 
downregulates expression of TNF-a in human monocytes/macrophages [271, 272] 
and increases the release of soluble TNF receptors [271]. Whether IL-4 in TB causes 
a switch from apoptosis to necrosis, increases soluble TNF-a production and 
facilitates survival of M. tuberculosis requires further study.
Nevertheless, whether apoptosis is protective or deleterious remains contentious and 
there are conflicting data. However, there is evidence that apoptosis may facilitate 
deletion of protective T cell clones and IL-4 production is also linked to TNF- 
mediated lymphocyte apoptosis in Mycobacterium-reactive human T cells thereby 
contributing to immunopathology [26]. CD 30 expression and TNF mediated 
lymphocyte apoptosis were both down regulated by blocking IL-4 in this model. 
Collectively, these data suggest that IL-4 may modulate apoptosis in a cell-specific
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manner. IL-4 may down-regulate beneficial macrophage apoptosis but enhance 
protective CD4+ T cell apoptosis.
(vii) Th2 cytokines (IL-4)
As already outlined, there is no dispute that Thl cytokines are crucial for successful 
host defence against TB but neither are they sufficient to prevent disease progression. 
Discussed further in section 1.7 is the contention that M. tuberculosis induces a potent 
Thl response to enhance immunopathology and hence propagation, and then 
deliberately undermines this response by deactivating protective macrophage 
functions. Evidence for the notion that IL-4 exacerbates immunopathology and 
augments the Koch phenomenon is also discussed. The putative mechanisms by 
which IL-4 subvert protective immunity is shown in table 1.3.
Table 13. Why is expression of IL-4 detrimental to immunity to TB?
Inappropriate type of macrophage activation [273, 274] that may be less 
mycobactericidal
Decreased expression of, and signalling through, Toll-like receptor 2 
(TLR2).[275]
Down regulated inducible nitric oxide synthase (iNOS) [276]; iNOS might be 
fundamental to the induction and maintenance of latency [277].
IL-4 favours necrosis rather than apoptosis, which is mycobactericidal by 
down regulating the expression of TNF-a in human monocytes/macrophages 
(discussed under apoptosis in section 1.5 above)
In mixed Thl + Th2 lesions, IL-4 facilitates TNF-a toxicity (discussed in 
detail under immunopathology in section 1.7.4.)
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1.6. IL-4 and IL-4delta2 (IL-462)
1.6.1. Biological properties of IL-4
Compared to the effects of Thl cytokines, the prototype Th2 cytokine, IL-4, 
antagonises IFN-y production, inactivates macrophages by down-regulation of CD 14 
and Fey. receptors [278, 279], down regulates IL-2 receptor expression in T 
lymphocytes [280] and inhibits transcription of the IL-2 gene [281]. Notably, IL-4 
causes an alternative form of macrophage activation [274]. Consequently, cytokines 
like IL-4 have the ability to circumvent protective host immune responses. IL-4 also 
enhances B cell MHC Class II expression, growth and differentiation; production of 
non-complement-fixing IgG isotypes (IgGl in mice and IgG4 in humans); induces 
expression of CD23 (low affinity IgE receptor) and together with IL-13 facilitates IgE 
class-switching [282]. IL-4 acts synergistically with other Th2 cytokines like IL-13 
that share some of the properties of IL-4, IL-5 which is enhances eosinophil 
production in the bone marrow [282].
1.6.2. Th2 differentiation and source of IL-4
Until recently, it has been widely accepted, based on several studies that IL-4, itself, 
stimulates the development into a type 2 phenotype by binding to IL-4Ra. This notion 
implies that differentiation of naive CD4 T cells to Th2 cells requires a source for the 
IL-4 that would prime the T cell response. There are several possible sources 
including mast cells, basophils, eosinophils, and NK T cells, though none in particular 
have been found to be necessary for the development of an in vivo IL-4 response 
[283]. However, it is now becoming clearer that an IL-4 independent mechanism of 
Th2 differentiation exists. As already discussed (section 1.4; DCs), microbes by 
ligation of pattern recognition molecules on APC or by provoking tissues to release 
mediators, can modulate T hl/ Th2 differentiation. Thus, during antigen presentation 
to T cells, in addition to association of the TCR and MHC II proteins on APC (signal
1) and ligation of co-stimulatory molecules (signal 2), differentiation of T cells is also 
initiated (signal 3). Indeed, protein extract derived from the helminth Schistosoma
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mansoni induced the development of Th2 cell-promoting effector DCs (DC2) that 
promote the development of Th2 cells via the enhanced expression of 0X40 ligand, 
whilst toxin Vibrio cholerae induced development of Thl inducing effector DCs 
(DC1) via an 0X40 ligand-independent, still unknown mechanism [284]. Notably, 
immature DCs derived from BCG-infected precursors acquire a mature phenotype, 
produce IL-10 and IL-4, and direct a Th2-like immune response [174].
Collectively, these data indicate that microbial compounds can govern the molecular 
basis of Thl [285] Th2 [174, 284] polarization via DCs. It remains unclear whether 
different DC lineages drive the final commitment of T cells or whether the same 
subset of DCs can promote either a Thl or a Th2 response [286-289]. Factors that 
may determine which Th response is generated include the nature and load of micro 
organism, type of pattern recognition receptors engaged, factors released by tissue and 
inflammatory cells (damage signals), physical interactions with other cell types, death 
of infected cells and duration of the TCR engagement [286].
In addition to those previously mentioned other cell types that produce IL-4 include 
CD4+ and CD8+ T cells, yd T cells, B cells, eosinophils, basophils, DCs and 
sometimes macrophages (when exposed to virulent Beijing strains) [290]. Finally it is 
worth mentioning that attention has been focused recently on the neglected 
observation that IL-4 can be involved in driving Thl responses [291] and CTLs [292]. 
This can be IL-4 administered externally or IL-4 from CD1 lb+CDl lclo APCs, which 
are present at an early stage of Thl response induction [293]. IL-4 present at later 
stages downregulates Thl responses [291], and this may be happening in TB, where 
at least some of the Th2 cytokines are coming from T cells [19, 29]. However, none 
of the literature on this topic is interpretable, because the workers involved did not 
distinguish between IL-4 and IL-482. It is possible that the “IL-4” involved in a very 
early stage of Thl differentiation is in fact IL-482.
1.6.3. The IL-4 receptor and associated signalling pathways
The IL-4 receptor component, IL-Ra (CD 124) pairs with other components to form 
receptor heterodimeric complexes. IL-4Ra can combine with the yc chain to form the
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receptor for IL-4 (predominates on haemopoietic cells; designated type I IL-4 
receptor). Association of IL-4Ra with IL-13Ral constitutes a common receptor for 
both IL-4 and IL-13 (found on non haemopoetic and haemopoetic cells; designated 
type II IL-4 receptor), and IL-13Ra2 alone can bind IL-13 and forms a ‘decoy’ 
receptor [294]. Two known downstream signalling pathways, the Stat-6 pathway and 
those mediated by binding to the insulin-interleukin-4 receptor (I4R) motif, alone or 
in combination, modulate the varied effector functions of the IL-4Ra (gene 
expression, proliferation and differentiation). The most well-known domain adaptors 
that bind to I4R, though other have also been described [294], are members of the 
insulin receptor substrate family (IRS family; IRS 2 being the most prominent) and 
She, which mediate growth promoting and regulatory signals through IL-4Ra. 
Downstream signalling of these pathways (IRS and She) is mediated by the 
phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
cascades, respectively.
Binding of IL-4 to the receptor initiates a cascade of kinase-mediated phosphorylation 
reactions that facilitates the binding of the transcription factor Stat6 to the cytoplasmic 
domain of IL-4Ra. Stat6 undergoes dimerization and translocation to the nucleus, 
where it activates the transcription of IL-4 and IL-13-responsive genes [294]. Stat-6 
also induces GATA-3 and c-Maf, which have similar effects on IL-4 and IL-13 
transcription, as opposed to STAT-4 and t-Bet, which are Thl inducing transcription 
factors [295]. There are also pathways (Shp-1), which negatively regulates Stat 6- 
mediated receptor signalling [294]. Notably, studies using mice that were deficient for 
IRS-2, Stat6 or both revealed that both Stat6 and IRS-2 contribute to naive CD4 T- 
cell proliferation in response to IL-4 [296].
1.6.4. Regulation of IL-4
1.6.4.1. Transcriptional regulation and mRNA stability
As already outlined, ligation to type I and type II receptors, mediates the activation of 
complex Stat6 dependent and independent signalling pathways, which culminate in 
transcription of IL-4 responsive genes. Presumably, the flexibility in the signalling
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cascade facilitates the modulation of IL-4 effects in different tissues, though the 
regulation of these pathways is incompletely understood. Steady state mRNA levels 
are dependent on transcription rates and mRNA stability (rates of degradation). 
Stability of mRNA is influenced by many of its components, including the 5' cap, the 
3' poly-(A) tail, sequences within the 3' untranslated region (UTR), sequences within 
the 5’ UTR and sometimes motifs within the protein-coding sequence itself.
However, more recently interest has focussed on the MAPK pathway and its effect on 
cytokine regulation. So far 3 distinct MAPK pathways have been described in 
mammalian cells (extracellular signal related kinase, ERK 1 & 2; c-Jun-terminal 
kinase 1 and p38a MAPK); the p38 MAP kinases play an important role in cellular 
responses to external stress [297-299]. mRNAs for TNF-a and IL-1 contain AU 
binding proteins in the 3' UTR, which block translation and facilitate rapid turnover 
of transcripts [298-300]. Activation of p38a MAPKs results in phosphorylation and 
release of the AU rich proteins allowing translation and secretion of cytokines like 
TNF and IL-1 to occur. Consequently, inhibitors of p38 MAPK (pyridinyl imidazole 
class of compounds) prevent translation, cause rapid turnover of transcripts and 
decrease the half life, and therefore have anti-inflammatory effects. It is worth noting 
that AU binding proteins are one of many factors that regulate mRNA stability and 
p38 independent pathways of AU protein phosphorylation have been described [301- 
303]. There are no data on whether the half-life of IL-4 is prolonged in TB and 
whether the transcriptional regulation is MAPK dependent.
1.6.4.2. Soluble IL-4 receptors (sIL-4R)
The extracellular domain of the human IL-4R, soluble IL-4R (sIL-4R), which is 
formed after proteolysis of the membrane-bound receptor [304] neutralises IL-4 in 
vitro [305] and in vivo [306]. Soluble cytokine receptors can have inhibitory effects 
because they block access to the receptor on the cell membrane. Alternatively, they 
can enhance cytokine effects by acting as a carrier, prolonging half-life, and releasing 
cytokine to the membrane receptors in a delayed fashion. This had been described for 
soluble IL-6 receptors [307] but is also true of soluble IL-4 receptors. Indeed, no IL-4 
bioactivity could be determined in supernatants of T cells activated in the presence of
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IL-4 for 6 days. In contrast, the same cultures carried out in the presence of sIL-4R 
showed marked IL-4 bioactivity [308]; implying that IL-4/sIL-4R complexes liberated 
free IL-4 even during prolonged culturing.
Contrary to expectation, sIL-4R alpha levels are increased in BAL from stable 
asthmatic children compared with nonatopic controls [309] and also in subjects with 
allergic rhinitis [310]. These data suggest that the serum half-life of sIL-4R is higher 
than that of IL-4 and it might therefore be a simple and more stable surrogate marker 
of IL-4 activity. In summary, sIL-4R is both an antagonist and also a protective 
molecule that can enhance agonistic functions of IL-4 [308]; low concentrations of 
sIL-4R enhance IL-4-driven effects and high concentrations neutralized IL-4. There 
are no studies examining the levels of either membrane-bound or soluble IL-4Ra in 
tuberculosis.
1.6.4.3. Possible role of natural antibodies to IL-4
The same principal may also be true for antibodies to IL-4. Some antibodies protect 
the IL-4, and act as carriers [311]. The same idea has been applied to prolong the life 
of recombinant IL-4 in the mouse [312]. It is well known that even normal 
individuals can have antibodies to cytokines [313]; these can be of high affinity. 
Interestingly, natural antibodies to human IL-4 have not been investigated [313]. It is 
intriguing to speculate that M. tuberculosis might act as an adjuvant and drive 
production of natural antibodies to IL-4, which then prolong the half life and activity 
of IL-4. Whether developing country subjects with high serum IL-4 levels, detectable 
by ELISA, also have high circulating antibody to IL-4 requires investigation.
1.6.5. !L-4delta2 (IL-4S2)
In addition to the regulatory mechanisms already described (transcriptional, sIL-4R 
and possibly natural antibodies to IL-4) IL-452 may function as a supplementary 
regulator of IL-4. IL-462 is a naturally occurring and only proven splice variant of IL- 
4, which lacks exon 2 (48 base pairs) [33, 314] resulting in part deletion of the mature 
protein (48 bp coding for amino acid residues 22 to 37 with consequential omission of
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a double stranded anti-parallel (3-sheet normally found in IL-4) [33]. IL-482 mRNA 
found in primates, rabbits, woodchucks, cows and mice [33, 315, 316]. A murine IL-4 
mutant protein with Cl 18 deletion abrogates STAT6 phosphorylation and IL-4- 
induced IgE production in vitro; furthermore, modifications in the C-terminal region 
of IL-4 produce mutants that bind to the IL-4Ra with high affinity but do not induce 
cellular responses [317]. Furthermore, alternative splicing of mRNA encoded by a 
single gene is a well described regulatory mechanism that controls gene expression 
and generates structural and functional diversity of proteins [318, 319], which may be 
differentially expressed in certain tissues, or during different stages of development, 
or cell activation [320-322]. Indeed, recombinant IL-482, cloned and expressed in 
yeast, functions as a natural competitive antagonist of human IL-4 (analogous to IL-1 
and the IL-lra), binds to the IL-4Ra chain only, and may be the dominant form of IL- 
4 mRNA in human alveolar lavage cells where it is associated with scleroderma- 
induced interstitial fibrosis [44, 314, 323]. Recombinant human IL-482 appears to 
inhibit IL-4-induced human T cell proliferation, which is greatest at lower 
concentrations of IL-4 [314, 324]. Moreover, in B-cells IL-482 blocks IL-4-induced 
IgE synthesis and CD23 expression. By contrast IL-482 is possibly an agonist on 
human fibroblasts [44]. IL-482 is also expressed in PBMC samples from normal 
human donors, thymic samples and endobronchial biopsies [26, 325, 326]. The 
relative proportion of IL-482 to IL-4 mRNA varies between different cell sources in 
the same donors and changes with stimulation [325, 327].
Final proof that the IL-482 protein is produced in vivo has not yet been obtained and 
the clinical significance of IL-482 remains unknown. Meaningful evaluation of 
existing work on IL-4 in man is challenging, as the antibodies used in flow cytometry 
or ELISA assays may bind either or both cytokines. The agonist IL-4 and the 
antagonist IL-82 are easily distinguished by RT-PCR [328], but most published work 
uses primers that will amplify both cytokines. IL-482 has been studied in human 
scleroderma [44], gastritis [329], transplantation [330] and bronchial asthma where 
IL-482 rises very little but IL-4 mRNA itself rises lOOOx more [331]. IL-482 mRNA 
expression in TB is discussed in section 1.8. below. Collectively, the observations in 
bronchial asthma and allergic rhinitis demonstrate the therapeutic potential of IL-4 
mutant protein receptor antagonists, anti-IL-4 antibodies and sIL-4R.
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1.6.6. Soluble CD30 (sCD30) and surrogate markers of Th2 differentiation
In addition to IL-4, IL-5 and IL-13 surrogate markers of a Th2 phenotype include 
expression of the chemokine receptors CCR4, CCR8 and CCR3 on type-2 cells [332], 
MDC/CCL22 (macrophage-derived chemokine), human IgE and IgG4, the IgE 
receptor (CD23) expressed on B cells, and soluble CD30 (sCD30) and membrane 
bound CD30. However, some of these markers are transiently expressed and none are 
exclusively expressed on Th2 cells alone.
CD30 is a widely distributed (CD4, CD8, y5 T cells, B cells, NK cells, CD4RO+ 
memory cells) membrane glycoprotein belonging to the TNFR superfamily; the 
extracellular domain is a binding substrate for CD30 ligand. The cytoplasmic domain 
binds TRAF (TNF receptor-associated factor) which mediates signal transduction 
[333]. Downstream kinase mediated phosphorylation reactions activate NFkB, though 
other pathways have also been described [333]. CD30 expression is low in healthy 
donors; only about 0 to 2% of PBMCs express CD30 [333]. sCD30 is derived from 
proteolytic cleavage from the membrane bound form. The functional relationship 
between sCD30 and membrane CD30 is uncertain.
Several previous studies, demonstrating increased CD30 or sCD30 in Th2 conditions, 
suggested that this was a Th2-specific marker (reviewed in [333]). However, the 
emergence of further data suggested that CD30 is present on activated T cells of ThO, 
Thl and Th2 profiles. Based on flow cytometric studies it was shown that Th2 
skewed-cells show higher receptor density and these are present on the cell surface 
longer than on Thl cells [334]. Ligation of the CD30 receptor induces increased co­
expression of the IL-4 receptor [335], whilst blockade of CD30-CD30 ligand 
interaction inhibits development of Th2 cells, lowers the production of IL-4 and IL-5, 
and shifts production toward the Thl profile [336]. Functionally therefore high sCD30 
and CD30 receptor expression is preferentially active during Th2-dependent reactions. 
Nevertheless, the pleiotropic effects of CD30 are also cell sub-type dependent; for 
example CD30 receptor ligation induces IFN-y in CD45RO+ memory T cells and 
increased IL-8 in yS T cells [333].
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In addition to facilitating cell differentiation CD30 mediated signalling is important in 
several different activities of T cells including anti CD3 induced proliferative 
responses [337, 338], apoptosis [338] and induction of HIV gene expression in 
infected T cells [339]. M. tuberculosis sonicate up regulates CD30 expression and 
induces IL-4 dependent TNF mediated apoptosis in peripheral blood lymphocytes 
from healthy donors [26]. sCD30 levels are elevated in the serum of adult [340] and 
paediatric [341] subjects with active TB compared to community controls and the 
level decreases with treatment [340]. Differential expression of sCD30 in alveolar 
lavage fluid and peripheral blood compartments has not previously been studied in 
tuberculosis and is discussed further in relation to data presented in chapter 5.
1.6.7. Measurement of IL-4 and IL-452
Difficulties in measuring IL-4, which may account for the failure of earlier studies to 
find IL-4, are discussed in detail in chapter 2 (section 2.1.1.) Briefly, there are a 
number of technical reasons why IL-4 detection is difficult (short half life, activity at 
low concentrations, rapid internalisation, failure to distinguish between free and 
bound IL-4). Notably, the interpretation of existing data is undermined by the failure 
to take into account the natural antagonist of IL-4, IL-452. Furthermore, the use of 
pre-stimulation protocols to detect IL-4 is Thl biased and unphysiological. To 
overcome these problems investigators have turned to PCR. However, conventional 
PCR has its own set of technical hitches. These problems and the development and 
validation of an assay to overcome them are discussed in Chapter 2.
1.7. The Th2 response and immunity to tuberculosis
Encouragingly, a few TB vaccine candidates are now entering clinical trials. 
However, some workers are sceptical because these vaccines have been designed with 
little reference to the immunopathogenesis of TB, and without understanding why the 
existing vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) is failing in 
developing countries. This is a high-risk strategy because the new vaccines might fail 
for the same reasons. It will be tragic if we have been designing vaccines based on
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studies of patients in Europe and the USA, and consequently the vaccines fail to elicit 
protection under the different immunological conditions of developing countries.
The following section first outlines the nature of the protective Thl response. 
Thereafter the available data pertaining to IL-4 expression in TB are reviewed. The 
hypothesis that the production of IL-4, superimposed on a Thl-cell response, is able 
to convert it from a protective response to an immunopathological one that is essential 
for the pathogenesis and spread of TB, is also discussed. Furthermore, the hypothesis 
that progression from latency to disease will correlate with a decrease in IL-482 
(antagonist) relative to IL-4 (agonist), is reviewed. It is suggested that vaccines that 
only induce Thl might work in strict pathogen-free laboratory conditions, but 
vaccines for humans (post-exposure) will need to focus on immunoregulation and 
downregulation of pre-existing IL-4 responses. Finally, based on available evidence, 
it is argued that successful vaccines for countries close to the equator might need to 
eliminate the pre-existing IL-4 component. These ideas and the hypothesis have been 
reviewed in detail [12, 236, 342].
1.7.1. Immunity: is the size of the Thl response the critical factor?
Th 1 activity and TNF-a are essential for immunity to M. tuberculosis. Genetic defects 
in receptors for IFN-y or IL-12 lead to increased susceptibility [343, 344] and 
neutralising TNF-a with therapeutic monoclonal antibodies can lead to reactivation of 
latent disease [153]. Therefore, at first glance, it seems logical to seek vaccines that 
maximise the Thl response. However, it is logical only if TB occurs because of a 
failure to generate a Thl response or the Thl response does not develop fast enough. 
That there are prominent Thl responses in TB, and further enhancing this response is 
unlikely to be helpful, is discussed in relation to the data presented in chapter 5.
64
1.7.2. IL-4 and IL-452 in tuberculosis infection and disease
1.7.2.1. Active tuberculosis: Whole blood and peripheral mononuclear cells
In the last decade, studies about the expression of IL-4 in TB have been conflicting 
and the issue has remained controversial. Furthermore, the findings of poor 
proliferative responses and low IFN-y levels in whole blood dominated reports and 
the conflicting IL-4 data were ignored. Surcel et al found increased production of IL-4 
by ELISPOT, in response to stimulation of PBMCs with mycobacterial antigens in 
UK donors with TB, but reduced proliferation and no change in EFN-y producing 
cells when compared to control subjects [18]. Similarly, Schauf and colleagues 
detected IL-4 mRNA by RT-PCR in most N. American TB patients but none in 
controls [345]. Remarkably, a number of reports emerged from developing countries 
(Argentina, Venezuela and China [a large study of over one hundred patients]) 
indicating that IL-4, but not IFN-y, was elevated to the extent that it was detectable by 
ELISA in the serum of patients with TB compared to controls [20, 22, 346]. Such 
high levels of IL-4 are not detected even in asthma patients in the UK. Other studies 
also from developing countries (Mexico, The Gambia and India) using flow 
cytometry after intracellular cytokine staining (ICCS), showed that PBMCs stimulated 
by TB antigen produced significantly greater levels of IL-4 compared to control 
subjects [21,24, 29, 347].
More recent data suggest that in addition to Thl cytokines, there is indeed an IL-4 
response in human TB both in Europe [17, 19] and in Africa [340, 348]. van Crevel et 
al showed that IL-4 was elevated (with little difference in IFN-y levels) in 
PMA/calcium-ionophore stimulated CD4 and CD8 cells from Indonesian patients 
with tuberculosis compared to healthy controls [19]. Notably, the primers and 
immunoassays used in all the studies described so far did not distinguish between IL- 
4 and IL-452. Seah et al, using a semi-quantitative nested RT-PCR assay, showed that 
IL-4 and IL-452 production is increased in British subjects with pulmonary TB, and 
correlates with immunopathology [17, 349]. Furthermore, Sousa and colleagues found 
elevated levels of Th2-driven IgG4 antibodies, in high titres, in the Yanomami Indians 
of the Brazilian Amazon [350]. TB patients also have several IL-4-dependent
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phenomena, including IgE antibody to M. tuberculosis [351], increased expression of 
DC-specific intercellular adhesion molecule (ICAM)-grabbing non-integrin (DC- 
SIGN) [161, 163], and antibody to cardiolipin [352]. Collectively, the investigators of 
these studies concluded that patients with tuberculosis had a Th2 type response in 
peripheral blood
By contrast, other studies failed to find significantly raised IL-4 levels in subjects with 
tuberculosis compared to healthy volunteers [25, 27, 30, 32, 264, 353-355]. 
Investigators from the USA using RT-PCR [27, 28] and immunohistochemistry [354] 
failed to show increased expression of IL-4 mRNA in donors with active TB. Verbon 
and co-workers from the Netherlands failed to demonstrate detectable IL-4 by ELISA 
in 84 subjects with active TB [32]. Other investigators from developing countries 
(Mexico, China) using RT-PCR [30, 355] and ELISA [264] also failed to find 
elevated IL-4 expression in subjects with tuberculosis.
The conflicting data may be attributable to a series of technical problems related to 
the measurement of IL-4 (outlined in section 1.6.7 but discussed in detail in chapter
2). Studies which detected elevated IL-4 mRNA levels compared to controls [17, 186] 
and those that failed to do so [27, 28, 30, 355] used conventional semi-quantitative 
RT-PCR protocols. The unreliable quantification and other drawbacks of this 
technique are discussed in detail in chapter 2.
Taken together two conclusions can be drawn from the studies that have been 
reviewed. Firstly, there is reasonable evidence to suggest that that IL-4 levels are up 
regulated in TB, though there are conflicting data. This suggests that a carefully 
validated approach, that takes into account various technical and other factors, needs 
to be developed for the reliable detection of IL-4 (discussed in detail in chapter 2). 
Secondly, IL-4 levels in TB patients close to the equator are generally raised, to the 
extent that it is detectable by ELISA (the validity of these findings and possible 
adjuvant effect of helminth infection is discussed in detail in section 1.7.5.2 below). 
Nevertheless, whether IL-4 represents cause or an immunological bystander effect 
requires further clarification. The studies reviewed here are discussed further in 
relation to the data presented in chapter 5.
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1.7.2.2. Active tuberculosis: Broncho-alveolar lavage
Despite most antigen-specific cells being located at the site of disease, usually the 
lung, most studies have acquired samples from peripheral blood due to ease of sample 
acquisition. Consequently, there have been few studies that have examined cytokine 
profiles in lung lavage [24, 264, 265, 356-359]. Remarkably, in relation to a disease 
that kills ~3 million humans annually there are only 2 published studies comparing 
compartment-specific (blood vs lung) cytokine profiles in active TB [24, 264]. Older 
studies (prior to the year 2000) using either in situ hybridisation, cyto- 
immunochemistry or immuno-assays failed to detect IL-4 in BAL fluid [357-359] or 
in TB antigen stimulated alveolar lavage cells [264]. By contrast, other studies [24, 
265, 356] show raised EL-4 levels in donors with pulmonary TB. Mazzarella and 
colleagues, using ICCS in PMA stimulated alveolar lavage cells from Italian patients 
found that the percentage of IL-4-secreting cells averaged 14 % in samples from 
cavitary disease, but only 2-3% in samples for noncavitary disease [356]. Sharma and 
co-workers, using similar methods, found IL-4 to be upregulated in alveolar lavage 
cells in Indian patients with tuberculosis [24].
Collectively the data regarding IL-4 expression in BAL fluid are conflicting. The 
reasons for this and the study findings presented here are discussed in detail in 
relation to the findings presented in chapter 5.
1.7.2.3. Contacts of patients with TB
Is expression of IL-4, or of the potential antagonist IL-452, increased in latent TB, and 
if so, how does this differ from what happens in those in whom the disease 
progresses? Recent studies have focused on healthy individuals in The Gambia and 
Ethiopia, whose peripheral blood mononuclear cells produce IFN-y responses to the 
TB-specific antigen, ESAT-6. These individuals have latent TB and it has emerged 
that they have significantly raised levels of mRNA encoding IL-452 in their 
unstimulated PBMCs [360, 361]. In The Gambia, expression of IL-4 is also increased 
[361]. Furthermore, a study of healthcare workers in Portugal has revealed that those 
individuals whose peripheral blood mononuclear cells synthesised IL-4 in response to 
M. tuberculosis in vitro went on to develop overt TB within 2-4 years [15]. The
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methods used, however, will not have distinguished between IL-4 and IL-452. It 
remains unclear whether a high IL-4, rather than IL-452, predisposes to disease; the 
findings of these studies are further discussed in relation to the data presented in 
chapter 5 and chapter 7.
1.7.3. Bovine TB and mouse models
Infection of cattle with Mycobacterium bovis generates both IFN-y and IL-4 
responsiveness to PPD and to ESAT-6 [362]. Similarly, the extent of lung pathology 
correlates with the production of IL-4 by peripheral blood mononuclear cells in vitro 
in response to PPD [363]. Interestingly, when cattle were immunised with a DNA 
vaccine, and then 3 weeks and 6 weeks later, vaccinated again with the protein 
encoded by the DNA vaccine emulsified in oil, they were more susceptible than non­
immunised controls. This increased susceptibility correlated with an increased IL-4 
response to subsequent challenge [363].
The relevant mouse models are those in which, as in humans, IL-4 production is 
observed during the progressive phase of the disease [364, 365]. These models of 
immunopathology are discussed further in the next section. Nevertheless, there are 
also knockout models that show no effect of IL-4 or STAT-6 on disease progression 
and immunopathology [366, 367]. These discordant findings are discussed further in 
relation to data presented in chapter 5.
1.7.4. Th2 cytokines and immunopathology
Various cell types, cytokines and other factors (toxic effect of mycobacteria, Koch 
phenomenon, Schwartzman reaction, MMP dysregulation etc) have been implicated 
in the genesis of TB- related immunopathology (these have been discussed in section
1.4.2 and recently reviewed in detail [31]). What is discussed here is the relationship 
between immunopathology and Th2 cytokines.
1.7.4.1. Necrosis and cavitation
The data demonstrating the presence of Th2 cytokines in human tuberculosis have 
already been reviewed (section 1.7.2). In TB-infected mice, susceptibility to toxic 
effects TNF-a injected into the footpads coincided temporally with the emergence of
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Th2 cytokines in the lungs [368]. IL-4 may also regulate TNF-a mediated enteropathy 
in Trichinella spiralis infection [369] and necrosis in a schistosomiasis model 
coincides precisely with the superimposition of Th2 response on an existing Thl 
pattern [370]. Murine (BALB/c) models of TB showed high IFN-y levels early in 
infection, with increased levels of IL-4 during the chronic phase of infection, which 
was characterised by progressive fibrosis and necrosis [364, 371]. The Th2 response 
may exacerbate tissue damage by enhancing the pathological effect of TNF-a [368]. 
More recent evidence, from IL-4 gene knockout in BALB/c mice, showed an absence 
of TNF-a-mediated toxicity following TNF-a challenge in the absence of IL-4 [14].
Collectively these murine data suggest that under the influence of superimposed Th2 
cytokines TNF-a is toxic in dominantly Thl-mediated lesions. It is not unreasonable 
to suggest that a similar mechanism operates in humans. This observation can explain 
the paradoxical role of TNF-a in TB. Indeed, TNF-a is crucial for protection against 
TB in animals [372] and in humans [153]. Nevertheless, in progressive human 
disease, as in progressive TB in the BALB/c mouse [14], it is toxic, and drugs that 
shorten the half-life of the mRNA encoding TNF-a lead to weight gain and 
symptomatic relief [373]. Because IL-4 levels are raised in progressive human 
disease, it is likely that, as in mice, IL-4 is involved in the toxicity of TNF-a. 
Examples of interactions between IL-4 and TNF-a in other diseases, and possible 
mechanisms for proinflammatory interactions between these cytokines, are described 
in table 1.4
In humans with TB studies of lavage fluid show the presence of IL-4 producing Th2 
lymphocyte subsets in those with cavitary tuberculosis [356] and the presence of Thl 
cytokine profile in non-cavitary disease [357]. Similarly expression of IL-4 in 
peripheral blood lymphocytes correlates with cavitary disease [19].
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T able 1.4. Synergism between interleukin-4 (IL-4) and TNF-a, and exacerbation of 
immunopathology in tuberculosis.
Putative mechanisms of TNF-a mediated toxicity in IL-4 containing lesions.
• Upregulation of inflammatory cell recruitment by induction of vascular cell 
adhesion molecule-1 (VCAM-1) in endothelial cells [374].
• Induction of cortisol-resistance in lymphocytes [375].
• TNF-a mediated apoptosis is observed in TB antigen driven CD30+ T cells in an 
IL-4 dependent manner [26].
Examples of TNF-a mediated immunopathology in mixed T hl/ Th2 lesions
• Thl/Th2 granulomata of Schistosomiasis are sensitive to systemic cytokine release 
triggered by lipopolysaccharide (LPS) [376, 377]
• Gut immunopathology due to Trichinella spiralis infection is facilitated by TNF-a in 
a mixed Thl/ Th2 response (no immunopathology observed in IL-4 knockout mice 
[369]).
In other murine knockout models of immunopathology induced by mycobacteria, y/8 
T cells [201] a/p positive T cells, IL-12, IFN-y and TNF-a [378, 379] also seem to be 
essential for necrosis of granulomata. It has been suggested that caseous necrosis is a 
protective mechanism to reduce the logarithmic growth of the organisms [105, 210]. 
However, it is apoptosis rather than necrosis that destroys M. tuberculosis (discussed 
below), so it is intriguing to speculate that M. tuberculosis has evolved components 
that exploit the host’s tissue-damaging protective responses by driving a Th2 response 
and necrosis (summarised in figure 1.5). It is interesting that particularly virulent 
Beijing strains of M. tuberculosis cause human monocytes to express IL-4 and IL-13 
[290].
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Figure 1.5. The roles of the “subversive” Th2-like component of the immune response in 
progressive human tuberculosis. This Th2-like IL-4 response, modulated by IL-452, may be 
primed by environmental mycobacteria and helminths, and is most striking in developing 
countries. Following exposure to M. tuberculosis, certain cell wall components and protein 
antigens are then able to drive and enhance this IL-4 response, which may contribute to 
deactivation of macrophages, and to necrosis and Fibrosis.
1.7.4.2. Fibrosis in tuberculosis
TNF-a , TGF-P and the Pathogenesis of fibrosis
Extensive deposition of ECM occurs in the guinea pig model of tuberculosis [380]. 
Available data suggest that TGF-p together with TNF-a plays a key role in the 
formation of the fibrous wall that encapsulates the tuberculous granuloma [130-132]. 
The importance of TGF-P with respect to pulmonary fibrosis has been established in 
human [250, 381] and animal models [382, 383]. However, it seems that TGF-p, 
while necessary, is not sufficient for fibrosis. The importance of other molecules like 
TNF-a in lung fibrosis is illustrated by models of bleomycin and hypersensitivity
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pneumonitis where anti-TNF-a antibodies ameliorate lung fibrosis [384, 385]. The 
potential role of other cell types in lung fibrosis has recently been reviewed [31].
Within the context of TB and lung fibrosis, two paradoxes immediately arise. The 
first is the presence of increased ECM at the periphery of the granuloma but 
dissolution in the central part of the granuloma. Possible explanations include a 
cytokine gradient within the granuloma (low IFN-y levels but high TNF-a in the 
central part of the granuloma) [386] and selective binding of cytokines to 
glycosaminoglycans in different parts of the granuloma [387]. The second paradox is 
the presence of fibrosis where there are high IFN-y levels, which down regulate TGF- 
p and production of collagen by fibroblasts [388, 389]. The answer may lie in the 
significant Th2 response that develops, parallel to and within the framework of a Th 1 
response.
Role of Th2 cytokines in fibrosis
IL-4 and IL-13 are profibrotic and enhance collagen production by fibroblasts [389]. 
Mice when infected with saprophytic mycobacteria only develop peribronchial and 
interstitial fibrosis when primed for IL-4 [364]. As already outlined, even a single 
epitope (16 amino acids) inducing a Th2 response can drive fibrosis in a murine 
model of tuberculosis [16]. In all human diseases characterised by marked pulmonary 
fibrosis there is expression of type 2 cytokines [systemic sclerosis, idiopathic 
pulmonary fibrosis, radiation-induced pulmonary fibrosis, chronic lung allograft 
rejection (reviewed in [390]. The same is true in the bleomycin murine model and in 
schistosomiasis, where fibrosis and tissue remodelling do not occur if induction of 
type 2 cytokines by the ova is blocked by pre-immunisation with ova + IL-12 [391]. 
These observations have led to the “type 2 cytokine hypothesis of fibrosis” [390]. 
This paradigm implies an initial Thl type response to antigenic challenge, followed 
by a Th2 response that seeks to ‘wall o ff  or isolate a persistent antigen from the host 
[377, 392, 393]. M. tuberculosis may be exploiting this host response to remain 
immunologically ‘sealed o ff in fibro-caseous foci.
The Th2 phenotype causes fibroblast activation and collagen deposition in human
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[394, 395] and animal models [383, 396]. Collagen synthesis in granulomata is 
stimulated by Th2 cytokines (IL-4, IL-13 and IL-482) and reciprocally inhibited by 
Thl cytokines like IFN-y and IL-12 [391, 397]. Moreover granulomatous 
inflammation and fibrosis is significantly reduced in Stat6-/- mice [398]; IL-4 and IL- 
13 are the major activators of Stat6. Fibrosis is particularly pronounced in mice over­
expressing IL-13 [390]. This cytokine, like IL-4 and IL-482 [44], activates fibroblasts 
and promotes collagen formation. However IL-13 also drives expression and, 
activation of TGF-P [390]. Significantly the increase in expression of type 2 
cytokines in human TB extends to IL-13 which like IL-4 and IL-482, is increased 80- 
100 fold [17, 349].
Collectively, the data presented in the previous 2 sections demonstrate a strong 
association between Th2 cytokines and immunopathology. This is significant because 
fibrosis, necrosis and lung remodelling is a major cause of lung morbidity worldwide, 
it enhances disease progression and is the principle mechanism by which disease 
spread occurs.
1.7.5. Th2 cytokines and implications for vaccine design
1.7.5.1. Antigens that drive IL-4 and implications for vaccine design
Table 1.5 lists the vaccines currently entering clinical trials. Notably, vaccines that 
down regulate IL-4 (though they may drive Thl) are active therapeutically in murine 
TB whereas those that exclusively augment Thl responses may actually worsen the 
disease [149]. Details of these vaccines, the putative mechanisms by which they may 
enhance protective responses, including the possible induction of IL-482, is discussed 
further in relation to data presented in chapter 7.
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Table 1.5. Types of new tuberculosis vaccine that are entering clinical trials (81)
1) Boost responses to antigen 85 A or B (Ag85)
• Recombinant BCG over-expressing Ag85.
• Boost response to Ag85, more than BCG does normally.
• Modified vaccinia virus Ankara expressing Ag85 [399, 400]. This might be 
given to subjects who have already received BCG in infancy to boost both 
CD4+ and cytotoxic CD8+ responses to Ag85.
2) Boost responses to M. tuberculosis proteins recognised by healthy PPD+ donors.
• Recombinant fusion-protein. Boosts CD4+ and CD8+ T-cell responses to 
Mtb72F, a 72-kDa polyprotein consisting of Mtb32 and Mtb39
• Fusion protein of ESAT-6 and Ag85B
3) Boost BCG-induced CD8+ T-cell responses.
• Recombinant BCG expressing listeriolysin [401]. The listeriolysin lyses the 
phagosome membrane. Then BCG can enter the cytosol for processing by the 
MHC class I pathway and presentation to CD8+ T cells.
4) Boost responses to the "common" mycobacterial antigens
• Killed Mycobacterium vaccae. This is being tested as a prophylactic vaccine 
for the first time, in patients infected with HIV. It can drive regulatory T cells 
that downregulate Th2 in allergy models [402].
5) Boost CD4+ and CD8+ T-cell responses to the 65 kDa heat-shock protein (hsp65)
• DNA vaccine encoding hsp65. Induces CD4+ and CD8+ T-cell responses, and 
downregulates Th2-cell responses in animal models of TB [403].
1.7.5.2. Failure of BCG close to the equator
It has been known for decades that the efficacy of BCG vaccination varies in different 
parts of the world. In general it is least effective in developing countries where it is 
most needed [404]. There has been no universally accepted explanation for this
74
phenomenon. However, in these countries there is a background of Th2 response to 
some components of M. tuberculosis. This was clearly demonstrated in blood samples 
from Malawians in which PPD induced IL-5 secretion, whereas little IL-5 was seen in 
samples from the UK run in parallel (Dockrell H., personal communication). Worse 
still, BCG vaccination failed to down-regulate the IL-5 response (Dockrell H., 
personal communication). This Th2 activity might be attributable to the exposure of 
mother and child to helminths. BCG induced a Th2-biased response in babies that had 
been sensitised in utero to antigens of Wuchereria bancrofti or Schistosoma 
haematobium, because their mothers were suffering from these infections [405]. 
Presumably, contact with cross-reactive environmental mycobacteria would do the 
same thing in these babies. However, these organisms also induce a Thl response in 
Malawi that is demonstrably protective [406], and the possible interplay between the 
Thl and Th2 components is crucial.
Furthermore, there are discordant results of attempts to measure IL-4 in tuberculosis 
cases from developed and developing countries. Indeed, as already outlined in section
1.7.2 the levels of IL-4 detected in tuberculosis patients, or released by their 
lymphocytes when stimulated with mycobacterial antigen in vitro, differ markedly in 
different studies. At one extreme, in peri-equatorial countries, ELISA may detect free 
IL-4 easily in the patient’s serum or in supernatants of patient’s PBMCs cultured with 
tuberculosis antigen in vitro. At the other extreme, in the USA or Europe, IL-4 is not 
detected at all or only using sensitive quantitative RT-PCR, or by flow cytometry after 
non-specifically stimulating the cells. The method of IL-4 detection and geographical 
location is shown in Figure 1.6, and a list of the relevant studies is shown in table 1.6. 
Clearly some of the patients studied in Europe or the USA will themselves have come 
initially from developing countries, but the distinction remains in the studies 
reviewed, perhaps reflecting that ongoing environmental exposure is important.
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Figure 1.6. Geographical distribution of tuberculosis patients in whom IL-4 production was 
significantly increased (i.e. detectable by simple ELISA assay or equivalent method; black 
triangles), or required RT-PCR or pre-stimulation and flow cytometry (red circles). The 
location of the sites, and the references, are listed in Table 1.6. The dashed lines are drawn at 
approximately 30° North and South of the equator. One study using PBMCs from Indonesian 
subjects detected IL-4 after stimulation with PMA and ionomycin (not shown; serum IL-4 
values are not given and it is unclear if stimulation with TB antigen was attempted [19]).
Collectively, these data suggest that levels of IL-4 are strikingly high in patients close 
to the equator, where BCG most often fails and mortality during treatment is highest. 
Environmental mycobacteria, in the presence of helminth infections, prime a mixed 
Th 1 and IL-4 background response. This immunity gained from the environment may 
impair the replication of a live mycobacterial vaccine and thereby limit its efficacy. 
Furthermore, high dose exposure to M. tuberculosis in developing countries might 
drive a sufficiently large IL-4 component to compromise the Thl-cell effector 
response, and modify it so that it facilitates immunopathology. Furthermore, the 
background Th 1 responses may explain the failure of BCG and the higher infecting 
dose required in developing countries. Indeed, in countries like Mexico and Brazil 
[403, 407] a high dose is required to infect laboratory mice (105— 106 colony-forming 
units whereas small doses, 102 or 103 colony-forming units, used in Northern 
laboratories fail to cause infection or merely cause stable latent infection [407]).
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Table 1.6. IL-4 and method of detection (specified in the ‘assay method’ column) in patients 
with tuberculosis in developed and developing countries. In all cases peripheral mononuclear 
cells were used unless otherwise specified. One study using PBMCs from Indonesian subjects 
detected IL-4 after stimulation with PMA and ionomycin (serum IL-4 values are not given 
and it is unclear if stimulation with TB antigen was attempted [19]).
Abbreviated
reference
Country Assay method Comment
Developed
countries
*Schauf V et al., USA RT-PCR Non-quantitative PCR
1993 [345]. using unstimulated cells
*Bames PF et al., USA RT-PCR IL-4 not detected in cell
1993, [186]. culture supernatants.
*Verbon A et al., Netherlands Serum IL-4 not Only serum evaluated.
1999, [32]. detect by ELISA
*Seah GT et al., UK Nested RT-PCR Unstimulated cells.
2000, [17].
*Surcel HM et al., UK ELISPOT Stimulation with TB
1994 [18]. antigen.
*Silveira H et al., Portugal RT-PCR IL-4 not detected in cell
1997 [408]. culture supernatants.
Developing
countries
*Jimenez-Martinez Mexico FACS- stimulation ELISA not performed.
MC et al., 2004 [21]. with TB antigen
*Dlugovitzky D et Argentina ELISA in serum No cell stimulation
al., 1999 [20]. studies performed.
*Montiel M et al., Venezuela ELISA in serum IL-4 also raised in PPD
2002 [22]. stimulated PBMCs.
*Sanchez FO et al., Columbia ELISA- stimulation n/a.
1994 [23]. with PPD
*Smith SM et al., The Gambia FACS- stimulation ELISA not performed.
2002 [29]. with M tb
*Bhattacharyya S et India FACS- stimulation IL-4 also detected by
al., 1999 [347]. with M tb ELISA in supernatants.
*Sharma SK et al., India ELISA Serum IL-4 raised in
2002 [24]. miliary TB.
*Wang L et al., 2002 China ELISA in serum n/a.
[346].
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Consequently, it has been suggested that vaccines should be screened in helminth- 
infected animals primed with environmental mycobacteria, rather than in 
immunologically naive pathogen-free laboratory mice, which have few mature 
dendritic cells [342]. In such animals, the challenge dose can be adjusted to cause 
progressive disease in only a subset of the animals, so that an increase in the true 
percentage protection can be sought (rather than using bacterial load as a marker of 
vaccine efficacy where 100% of the animals have disease). Using such Thl/ Th2 
primed animals, it might emerge that to provide protection in developing countries, it 
is more important to suppress subversive IL-4 production than to increase an already 
adequate Thl-cell response.
1.8. Conclusion
The data outlined in Chapter 1 provides an overview of the basic immunology 
relevant to TB, the prevailing putative mechanisms that may explain disease 
progression, the biological attributes of IL-4 and IL-452 (effects, source, signalling 
pathways and regulatory mechanisms), the existing literature pertaining to IL-4 and 
TB, and how this pertains to vaccine design and the failure of BCG.
Nevertheless, there are many issues related to the IL-4 hypothesis that require 
clarification. From the data already reviewed, it seems clear that a sensitive and 
reliable quantitative assay is required to clarify the discordant findings of previous 
investigators. Moreover, it remains unclear whether IL-4 represents cause or is a 
consequence of disease in humans. Further information is required regarding IL-4 
regulatory pathways, sources of IL-4 in human TB, compartment specific expression 
of human Thl and Th2 cytokines (lung and blood), and the role of IL-4 and IL-452 in 
HIV-TB co-infection. Before more detailed antigen fractionation, to identify the 
components that drive expression of Th2 cytokines is performed, the observation that 
TB antigen can preferentially drive IL-4 needs to be confirmed in cells from patients 
with TB. Data addressing these questions form the subject matter of this thesis.
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CHAPTER 2. METHODS: OPTIMISATION AND VALIDATION OF A 
REAL-TIME RT-PCR ASSAY TO QUANTIFY IL-4 AND IL-452 GENE 
EXPRESSION.
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2.1. Introduction
Measuring human IL-4 in biological samples is challenging because of the biological 
properties of IL-4 and the insensitivity of existing immunoassays when using
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unstimulated cells (discussed in detail in section 2.1.1. of this chapter). This 
necessitates the use of very sensitive techniques like reverse-transcription polymerase 
chain reaction (RT-PCR) to detect IL-4 in human samples. However, conventional 
RT-PCR has a number of drawbacks particularly if quantification is required (section
2.1.2.). Real-time RT-PCR addresses a number of these drawbacks (section 2.1.3. and
2.2.4.). However, despite these improvements there still certain inherent difficulties 
such as data normalisation, which requires the selection of a reference to control for 
errors during RT-PCR and for the amount of starting material (section 2.1.6). In 
addition to the above-mentioned considerations, this chapter outlines the development 
and performance characteristics of a probe based real-time RT-PCR assay to measure 
IL-4 and IL-452 mRNA levels (section 2.3.1), measures undertaken to minimise 
measurement error, reference validation and the implications of the validation 
exercise (or lack thereof) on inter-group comparisons (2.3.2). The work outlining the 
development and validation of the assay has been published [409, 410].
2.1.1. Why PCR?
With the exception of subjects in tropical countries where IL-4 is markedly raised by 
the likely adjuvant activity of helminth infections, anyone who has worked with 
human biological samples will appreciate the challenge and difficulty of measuring 
IL-4. This is due to a number of technical factors related to the biological properties 
of IL-4; these are outlined in table 2.1. Failure to take many of these factors into 
account may result in discordant data and the generation of results that are sometimes 
of questionable biological significance [410]. For example Doherty and co-workers 
showed recently that detection of IL-4, even by RT-PCR, was substantially reduced 
within 2 hours in freestanding heparinised blood samples from Ethiopian patients; 
moreover, IL-4 was undetectable by ELISA in this study [411].
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Table 2.1. Factors that make the measurement of human IL-4 technically difficult.
i) The short half life of IL-4 mRNA in clinical samples; approximately 60 minutes 
[412]. IL-4 mRNA is no longer detected if heparinised blood samples are not 
processed within a couple of hours, as often occurs under field conditions [411].
ii) The low mRNA copy numbers at which IL-4 is active; ~ a thousand fold below 
that of IFN-y [413, 414]. Some publications fail to find IL-4 in patients or controls 
and so illogically conclude that it is not raised in the patients.
iii) The binding of IL-4 and rapid internalisation to soluble or cellular receptors [415], 
which are widely distributed on cells in whole blood.
iv) Pre-stimulation of cells by mitogens, used in some protocols is Thl biased and 
causes potent induction of IFN-y and rapid reciprocal down regulation of an 
already low copy number cytokine (IL-4) [35]. This effect is routinely studied by 
workers in the field of allergy, and adds further to measurement difficulties and 
misinterpretation of data in tuberculosis work.
v) Immunoassays fail to distinguish between between free IL-4 and that bound to sIL- 
4R [308] or to naturally occurring anti-IL-4 antibodies [311] (bound IL-4 is 
inactive).
vi) Current immunoassays used by investigators, such as conventional ELISA, are not 
sensitive enough to detect biologically active amounts of IL-4, particularly in 
unstimulated cells, and even when blocking antibodies are used [34]. ELISPOT is 
more sensitive but still requires a pre-stimulation protocol [416]. Immunoassays 
using cytometric bead array [417] and flow cytometry are equivalent in sensitivity 
to ELISA [418]. There are no data evaluating the comparative sensitivity of the IL- 
4 cytokine secretion assay (Miltenyi Biotech), however a pre-stimulation protocol 
is usually required.
vi) To overcome these problems investigators have used RT-PCR. However, failure to 
recognise the existence of a second cytokine, IL-452, and use of primers which 
simultaneously amplify cDNA of IL-4 and its slice variant IL-452 confuse most 
existing studies involving RT-PCR.
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2.1.2. Conventional RT-PCR: limitations and drawbacks
In addition to the technical and sensitivity considerations outlined above there are no 
available immunoassays that specifically bind IL-452. It remains unclear whether the 
current immunoassays measure IL-4, IL-452 or both cytokines. Consequently, at the 
current time PCR remains the only alternative that simultaneously addresses the 
issues of assay sensitivity and specificity for IL-452. Indeed, conventional nested RT- 
PCR used in earlier studies, the most appropriate technology available at the time, has 
been used to show that both IL-4 and the splice variant and antagonist, IL-452, are 
upregulated in PBMCs from patients with active tuberculosis [17] and antigen 
stimulated mononuclear cells from healthy control subjects [26]. However, these 
studies suffer from the drawbacks inherent in conventional RT-PCR (table 2.2). 
Before these are discussed a few basic concepts integral to the understanding of PCR 
are discussed.
The early 1990’s saw the widespread use of conventional RT-PCR, which was first 
described in 1987 [419]. Compared to other methods of RNA detection (in situ 
hybridisation, northern blot and RNAase protection assays) the sensitivity of RT-PCR 
was unrivalled. Two enzymatic steps are involved: the first is a retroviral enzyme 
(RNA-dependent DNA polymerase) based reverse transcription of RNA; the second is 
a heat stable DNA-polymerase dependent primer specific exponential amplification of 
cDNA using a thermal cycler, in a buffer containing deoxynucleotides and 
magnesium [420]. The kinetics of the PCR reaction is shown in figure 2.1 [421]. End 
point PCR discriminates poorly between different RNA input amounts because all 
reactions plateau at a similar end point (shown in figure 2.3 A). Moreover, the poor 
resolution of densitometry scanning, 2 logs at most [422], makes meaningful 
quantification challenging to say the least. Therefore, this simple yet sensitive assay 
could only provide qualitative (yes/ no) answers about gene expression.
However, requirements for diagnostic information (viral load, tumour diagnostics and 
study of gene expression in biological systems) demanded quantification of mRNA 
levels. Consequently, tedious and complicated protocols were developed to satisfy 
this need [423]. It was first necessary to undertake measurements at a cycle number in 
the exponential phase of the reaction. Quantification entailed using a single set of
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primers to amplify the target sequence and a synthetic standard whose amplication 
product could be distinguished from the target sequence on an agarose gel [423]. For 
every sample identical aliquots of the template were co-amplified with a ‘spike’ 
(addition into the mixture) of the synthetic standard in different dilutions. Comparison 
of band intensities of the unknown amount of the target against a standard curve of 
the internal standard (competitor RNA or DNA) enabled quantification of the gene of 
interest. Numerous variations of this theme underpin all competitive RT-PCR 
protocols (competitive because reference and target sequences compete for the same 
primers) [39]. The protocol assumes equal amplification efficiencies of the target and 
synthetic standard, that the ratio of the target template and the standard remains 
constant and no hetroduplexes form between the target and the competitor. 
Furthermore, the technique relied on accurate quantification of the RNA reference 
standard by spectrophotometry (the difficulty with this approach is discussed in 
section 3.1.4). After ‘quantification’ the target copy number was normalised to an 
unvalidated reference (also called ‘housekeeping gene’ and discussed later) to control 
for the inter-sample input amount of RNA. However the semi-quantitative protocols 
that investigators were encumbered with in earlier studies, including a nested RT-PCR 
assay used to detect IL-4 in unstimulated cells [17, 26, 349], suffered from a number 
of drawbacks (table 2.2).
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Table 2.2. Technical limitations and drawbacks of conventional RT-PCR quantitative 
protocols.
i) Unreliable quantification and inconsistent results [424] due to the inherent nature of 
the technique and lack of standardisation. False positive rates can be as high as 28% 
[36] with error rates ranging from 10 to 60% [425].
ii) This was compounded by the poor resolution and dynamic range of gel 
densitometry (2 logs at most) [422].
iii) Highly variable reproducibility [425, 426] due to (i) and (ii) above.
iii) Labour, time and reagent intensive thereby limiting the amount of samples that 
can be processed.
iv) Prone to problems of contamination due to the need for post-PCR gel analysis.
v) Almost routine failure to check the quality of RNA transcripts. Inadvertent use of 
poor quality transcripts result in erroneous data generation.
vi) Difficulty in using predetermined amounts of RNA in cDNA reactions due to 
technical difficulty in quantifying RNA mass by spectrophotometry. This has been 
superseded by more accurate methods using micro fluidic technology [427].
vii) Use of unvalidated internal reference genes leading to potentially erroneous 
results [37, 39]. The type of result generated may be influenced by the choice of 
reference gene used [326, 428].
viii) Unequal efficiencies of the template and competitor RNA [429], hetroduplex 
formation between the template and competitor [426] and failure to maintain constant 
ratios between the target and competitor RNA.
ix) Use of nested protocols (using the PCR product of one reaction in a subsequent 
PCR) compounded these problems
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Figure 2.1. Kinetics of PCR amplification. During the first phase, the linear ground phase, 
there is relatively little increase in template. In the 2nd stage, the early exponential phase, the 
amount of amplified target directly proportional to the input amount of target RNA. During 
the 3rd phase the amplification efficiency is log-linear. The final plateau phase is characterised 
by a sharp drop in amplification due to reagent and substrate limitation; here there is little 
relationship between DNA input and amplified target. Consequently conventional RT-PCR 
has to be stopped in the exponential phase if quantification is attempted [421].
2.1.3. Real-time PCR: theory and general considerations
In the 21st century the difficulties that investigators faced, as outlined in the previous 
section, were dramatically circumvented by the advent of real-time RT-PCR. The 
major advantages of this technique are accurate and reliable quantification even at low 
copy numbers, high reproducibility, a wide dynamic range (10 logs), greater 
specificity because of template specific probes, and reduced contamination and 
workload because no post-PCR processing is required. Furthermore there are 
significant cost reductions due to multi-plexing and high throughput is attainable due 
to automation and simplification of the PCR technique [37-39, 430, 431]. 
Improvements in RNA assessment techniques and the recognition that the use of
85
unvalidated references to ‘normalise’ data could impact on study results, further 
improved the resolution and reproducibility of the technique [37, 38, 430]. Real-time 
PCR is now regarded as the gold standard for determination of viral load, residual 
disease in cancer and quantification of mRNA copy numbers in biological systems
In real-time PCR a fluorescent marker bound to the target template is detected in 
‘real-time’ as the reaction progresses (this concept is explained in figure 2.2). The 
acquired data, after analysis by mathematical software, is displayed as a plot of 
fluorescence versus cycle number (figure 2.3 A). This data plot is based on the 
principle that there is a quantitative relationship between the amount of target 
template present at the beginning of the PCR reaction and the amount during the early 
exponential phase [421].
Figure 2.2. Detection chemistry: the hydrolysis probe. A probe (blocked primer that is 
labelled with reporter fluorophore (R) and a quencher (Q)) binds to a site on the target 
sequence downstream of the forward primer (arrowhead). Whilst closely associated, the 
excitation from the fluorophore is transferred to the quencher molecule without emission of a 
photon (this concept is called FRET (fluorescence resonance energy transfer)). During the 
PCR reaction, Taq DNA polymerase (purple semi-circle) digests the probe. As the reporter 
dye is no longer in close proximity to the quencher there is an increase in reporter emission 
intensity (yellow ‘R’), which is easily detected [421]. There are number of detection 
chemistries (hybridisation probes, hairpin probes, scorpions etc) that are variations of the 
same theme. SYBR Green is DNA binding dye that emits fluorescence when generically 
bound to dsDNA; multiplexing is not possible with this dye.
[38].
A
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Figure 2.3 A and B. Standard curve (2.3 A) and calculation of amplification efficiency (2.3 
B). The real-time PCR plot (shown in log scale) shows serial 10 fold dilutions of cDNA (2.3 
A). The Ct (the cycle at which the fluorescence is statistically greater than the background; 
horizontal red line) is calculated in the early exponential phase. A slope is derived by plotting 
the Ct values against copy number (2.3 B). The efficiency (97% is this case) is calculated 
from the gradient of the slope (~ -3.3); implying that for every log increase in initial starting 
template the Ct occurs 3.33 cycles earlier (shown by vertical black lines). If the gradient of 
the slope was greater (- 4.0) then the efficiency would be reduced to 78%; after 30 cycles this 
would result in an 80% reduction in the target copy number! The R2 value reflects the 
accuracy of the dilution series and the pipetting repeatability of each data point [38, 430].
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Consistent efficiencies approaching 100% and including only raw data above a 
reproducible threshold are important when studying low copy number cytokines. This 
is to minimise the effects of statistical uncertainty (at a 100% efficiency, after 1 cycle 
it us assumed that 1 copy doubles to 2; if the efficiency is 80% then there is a 20% 
chance that there is still 1 copy at cycle 2 due to random mispriming events) [432]. 
Consequently, any transcript diluted beyond a certain point will show large variations 
in amplification (Monte Carlo effect) [433].
Generation of any mRNA copy number result entails a number of steps after sample 
acquisition including sample processing and storage, RNA extraction, reverse 
transcription and real-time PCR (these steps are outlined in figure 2.4). Finally, it 
should be borne in mind that real-time PCR measures only steady state mRNA levels 
and nothing more; it does not convey any information about transcription rates, 
mRNA stability, or protein activity or regulation. It is therefore not surprising that 
mRNA levels may [428] or may not correlate with protein levels [434].
Sample Extract ReverseTranscribe
Real time 
PCR Result
‘ Quantification
‘ Normalisation
Figure 2.4. Sequential steps that are required for the generation of mRNA copy numbers. 
Quality control and maintaining RNA integrity has to occur during every step prior to RT. 
Particularly important is the prevention of gene induction or RNA denaturation at step 1 and 
checking RNA quality at step 2; these steps are often neglected and their details omitted, in 
the published literature. Prior to the acquisition of a final result the raw real-time PCR data 
must quantified and then normalised to a reference to control for the amount of starting 
material and errors during steps 1 to 4.
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2.1.4. Sample processing, RNA extraction. RNA quantification
As often stated: ‘garbage in garbage out’! The generation of biologically meaningful 
and accurate gene expression data are heavily dependent on the input quality of the 
mRNA template. This is influenced by sample processing, RNA extraction and 
suitable nucleic acid storage. It is remarkable that most published literature makes no 
mention of whether RNA quality was checked, let alone how it was done. Guidelines, 
which will soon make it mandatory for investigators to report on the method of 
sample stabalisation, RNA quantification and RNA quality assessment, are being 
developed.
Once RNA has been extracted its integrity must be ascertained; denatured templates 
should be discarded. The traditional method was to check the clarity of the 18s and 
28s band intensity on a formaldehyde agarose gel [435]. However the resolution is 
crude and the requirement for large amounts of RNA make it impractical for most 
investigators. This technique has now been superseded by the Agilent 2100 
Bioanalyser using the RNA 6000 Labchip® (see figure 3.2). This benchtop instrument 
uses a combination of microfluidic and capillary electrophoresis technology to 
simultaneously analyse RNA mass and quality over a wide dynamic range [435, 436]. 
The advantages are simultaneous assessment of RNA quality and quantity, and the 
requirements for very small amounts of RNA. DNA size and concentration can also 
be assessed using a different chip. Alternative methods to assess RNA integrity 
include signal strength determination of four preselected mRNA transcripts [435] and 
the ratio of mRNA fragments proximal and distal to the 3' end of a transcript [437].
Precise RNA quantification is important as it allows efficient use of limited amounts 
of RNA, is crucial if normalisation to total RNA is used and facilitates accurate data 
normalisation, irrespective of the method of normalisation used (discussed later).
2.1.5. Reverse transcription
Reverse transcription (RT) entails converting the mRNA transcript to a single 
stranded complementary copy of cDNA using a reverse transcriptase enzyme, which 
is a RNA-dependent DNA polymerase derived from mutagenised avian (AMV) or 
murine (MMLV) tumour viruses [37, 39]. The enzyme adds deoxyribonucleoside
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triphosphates to a growing DNA chain within a buffer containing divalent ions (Mg2+ 
and Mn2+), primers and RNAase inhibitors. Activity of the enzyme requires binding 
of a primer to the RNA molecule to initiate DNA synthesis. This may be a gene 
specific primer, a random hexamer or oligo-dT (poly-T oligonucleotides), which 
anneals to the 3' poly-A tail of mRNA. There is ongoing debate about which primer 
type is most efficient though random hexamers are known to overestimate copy 
numbers by up to 19 fold [438]. RT is one of the most variable steps in the multistage 
RT-PCR process. The variability is related to the type of priming method used and 
carryovers from the RNA extraction step (phenol, alcohol, salts), which can modulate 
RT efficiency [439]. Control for variation during this step is discussed under 
normalisation (section 2.1.6.2).
2.1.6. Real-time PCR data processing
Acquiring the real-time PCR data is probably the most straightforward part of the 
multi-step RT-PCR exercise (figure 2.4). However, the raw data must be quantified 
(relative or absolute) and then normalised to control for varying amounts of starting 
material and errors during the PCR process.
2.1.6.1. Quantification (absolute versus relative)
The copy number in the sample of interest can be expressed in relation to a standard 
curve containing known numbers of nucleic acid copies (absolute quantification) or 
relative to a control sample (also known as a calibrator sample; here results are 
expressed as a ratio of the sample of interest relative to the calibrator). Unlike relative 
quantification where the patient and control samples have to be run on the same plate 
(methods reviewed in [440-442]), absolute quantification is preferable when large 
numbers of samples need to be assayed over time or at different study sites [421]. 
Because the same dilution series is co-amplified on every plate this method also 
facilitates the monitoring of inter-plate efficiency, day-to-day reproducibility and 
exclusion of results below a detection threshold (lowest dilution series).
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2.1.6.2. Normalisation and Data interpretation
To optimally realise the advantages of real-time PCR and produce meaningful results 
good normalisation strategies are required to control for experimental error introduced 
during the multistage process (inter-sample variability of RNA extraction, RT and 
pipetting error; figure 2.4), and to control for differing amounts of starting material 
(input RNA). It is worth mentioning at this point that operator error is an important 
source of variability [37] and precision pipetting, regular pipette calibration and use of 
robotic technology (if resources permit) is crucial. The concept of normalisation is 
outlined in figure 2.5. There are many strategies that can be chosen; these include 
normalisation to sample size, total RNA, an internal reference (also called a 
housekeeping-gene), genomic DNA or an ‘alien’ molecule that is introduced during 
the RNA extraction stage (reviewed in [436]). Combining then first 3 strategies are 
additive in reducing measurement error and will produce the most robust RT-PCR 
data [436].
Normalising to a reference gene is a simple and popular method for internally 
controlling for error in real time RT-PCR. This strategy targets RNAs encoded by 
genes, which have been collectively called house keeping genes and is advantageous 
as all the steps required to obtain the final PCR measurement (figure 2.4) are 
controlled for [436]. Both the gene of interest and the reference gene are measured 
using real time RT-PCR. Commonly used house keeping genes like p-actin, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) and 18S ribosomal RNA were used as references 
for a number of years before the advent of real time RT-PCR. Their use was 
acceptable for non/semi-quantitative techniques like northern blot, RNase protection 
assays and conventional RT-PCR where a qualitative change was being measured. 
However, because of ease and convenience, they continued to be used for quantitative 
real-time PCR. In the last 5 years it became apparent that reference genes like 
GAPDH and P-actin were highly variable under different experimental conditions and 
were unsuitable for use as ‘one size fits all’ reference genes. This consideration is 
discussed in more detail later.
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100,000 copies/ reaction
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Normalised gene of Interest = 
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Sample A Sample B
Figure 2.5. The concept of normalisation. In reality sample A (tissue biopsy) has greater 
quantities of the target gene of interest than sample B. However, the raw PCR data reveals 
that sample A and B have similar amounts of transcripts. After correcting for the amount of 
starting material (sample A had 1/10th of the mass of sample B), it emerges that sample A 
actually has 10 times more transcripts of the target gene than sample B per unit/ mass. The 
use of the internal reference also corrects for pipetting error, and variability in the RNA 
extraction and RT steps. However, in reality there can be considerable variability of the 
reference, and therefore, validation is required.
Some have argued that the above-mentioned factors are irrelevant and the overall 
study conclusions will be unaffected because reference gene variability is likely to be 
equally distributed in the intervention and control group [443]. Of particular note are 
the findings of Bas et al [444] and Tricarico et al [428] demonstrating that use of 
unvalidated reference genes may impact upon study results. Nevertheless, whether the 
use of unvalidated reference genes can alter statistically significant inter-group 
differences remains unproven. The degree of reference gene variation that is 
acceptable also remains contentious. Both these issues are discussed later in relation 
to the data presented in this chapter.
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2.2. Methods: development and validation of a real time RT-PCR assay
Assay development and validation in the methods (section 2.2 of this chapter) is 
presented in two parts. The first part describes methods relevant to the selection of a 
suitable reference gene. The ABI Prism 7000 real-time PCR machine was used for 
these experiments. The second part outlines the impact on study conclusions, of using 
a validated versus unvalidated reference, in real-time PCR experiments. The 
Rotorgene (Corbett Research) real-time PCR system was used for the latter and 
subsequent experiments described in this thesis.
2.2.1. Selection of optimal reference gene
2.2.1.1. Patients and samples
Clinical samples (n = 28) were taken from four patients with smear-positive 
pulmonary TB (PTB), and from four healthy individuals, and the cells harvested from 
PBMC cultures of four additional patients with PTB. In order to maximize inter­
individual variability, we chose subjects of different ages (from 26 to 50 years), sex, 
and ethnicity (Caucasian, Somalian, Indian, Chinese, Filipino, and Black African). 
Informed consent was obtained from patients, and the relevant hospital ethics 
committees approved the study.
Whole blood (20 mL) was taken, and 2.5 mL was immediately transferred into 
PreAnalytiX PAXgene™ blood RNA tubes (Qiagen, Valencia, CA, USA) to fix the 
mRNA expression profile [445]. The remaining blood was transferred to a 
heparinized container and transported in a thermo flask at 37°C. To assess the effect 
of delayed sample processing on the reference, heparinized blood was incubated at 
37°C for a further 4 hours on reaching the laboratory, after which a further 2.5 mL 
sample was transferred to a PAXgene tube.
Blood taken from four of the patients with PTB was layered over a Ficoll-Paque® 
gradient (Amersham Biosciences, Piscataway, NJ, USA) and the PBMCs isolated. 
PBMCs were cultured in triplicate in medium at a cell concentration of 1 x 106 
cells/mL (final volume of 0.5 mL) in 24-well plates. Cells stimulated with TB antigen
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and harvested at baseline and days 2/3. Days 4/5 were used for housekeeping gene 
expression studies. Control wells were challenged with phytohemagglutinin, 
Mycobacterium vaccae sonicate, or no antigen. Cell viability was assessed at each 
harvest with trypan blue, and a proliferation assay was performed on days 4/5 to 
quantify the proliferative response to antigen challenge. Further details of culture 
conditions are described in chapter 3.
2.2.1.2. Selection of house keeping genes
To begin with, the gene expression levels of 10 housekeeping genes (designated 
group 1) were studied using a commercially available assay (TaqMan® human 
endogenous control plate; Applied Biosystems, Foster City, CA, USA) in the blood 
and culture samples [428]. The 10 genes investigated in this assay are shown in table
2.3. Group 2 genes were selected as they were among 47 out of 535 maintenance 
genes, found by microarray data to be relatively stable, in 11 different human tissues 
[446] and since they were found to be invariant in human CD4 T cell cultures from 
cord blood [447]. The aim was to identify a housekeeping gene with minimal 
variability under our different experimental conditions. As some of the genes of 
interest are low-copy number cytokines, it was anticipated that a significant change 
between study groups was likely to be small. Therefore, a standard deviation of less 
than 2-fold from the mean expression level of the gene was chosen as a requirement 
for suitability as a reference gene. Ribosomal subunit RNAs were not used as 
housekeeping genes, as oligo(dT) was used as a primer for cDNA synthesis, and 
compared to specific downstream primers, random hexamer primers have been shown 
to overestimate mRNA copy numbers by up to 19-fold [438].
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Table 23. Housekeeping genes selected for group 1 and group 2 panels.
GROUP 1 HOUSEKEEPING GENES GROUP 2 HOUSEKEEPING GENES
Human acidic ribosomal protein (HuPO) Human acidic ribosomal protein (HuPO)
P-Actin (BA) Elongation Factor-1-alpha (EF-l-a)
Cyclophylin (CYC) MLN51
Glyceraldehyde-3-phosphate Ubiquitin conjugating enzyme
dehydrogenase (GAPDH) (UbcH5B)
Phosphoglycerokinase (PGK)
P0-Microglobulin (B2M)
p-Glucuronidase (GUS)
Hypoxanthine ribosyl transferase
(HPRT)
Transcription factor IID TATA binding
protein (TBP)
Transferrin receptor (TfR).
2.2.1.3. Isolation of RNA extraction and RT
RNA was isolated from whole blood collected in PAXgene tubes using the 
PreAnalytiX PAXgene blood RNA kit (Qiagen) and from harvested PBMCs using the 
RNeasy® Mini kit (Qiagen). All samples were DNase (Qiagen) treated and the 
standard precautions of RNA handling and storage were observed. The RNA template 
was qualitatively assessed and quantified using an Agilent 2100 Bioanalyzer with the 
RNA 6000 Nano Labchip® kit for blood-derived RNA and the RNA 6000 Pico 
Labchip kit for culture-derived RNA (all from Agilent Technologies, Palo Alto, CA, 
USA). For illustrative purposes examples of Bioanalyser tracings are shown in 
chapter 3, figure 3.2. Total RNA extraction varied from approximately 1-5 pg for 
blood and 0.1-0.8 pg from 5 x 105 cells. To study the effect on housekeeping gene 
expression, we used a fixed amount of input RNA for each cDNA reaction. Limited 
RNA quantities dictated input RNA amounts to be 600 ng for PTB patients, 400 ng 
for healthy volunteers, and 3 ng for the PBMC culture reactions. Reverse transcription 
reactions were performed following the manufacturer’s instructions using 
Omniscript® Reverse Transcriptase (Qiagen) for blood-derived RNA and Sensiscript® 
Reverse Transcriptase (Qiagen) for culture-derived RNA in 60-pL reactions.
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2.2.1.4. Real-time PCR
The PCRs for group 1 genes were performed using the ABI Prism® 7700 Sequence 
Detection System (Applied Biosystems). In each reaction, approximately 15 and 0.1 
ng of reverse-transcribed RNA (based on the initial RNA concentration) was used for 
blood and cell culture PCRs, respectively. The TaqMan endogenous control plate 
assay was used according to the manufacturer’s instructions, with the exception of the 
18S ribosomal RNA reaction, which was omitted (initial step of 50°C for 2 min and 
95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min, in a 50- 
pL reaction volume). Using these parameters, the reaction efficiency approaches 
100%. The primer and probe sequences for group 2 were obtained from previously 
published work [447]. These sequences are shown in Table 2.4. Primers and probes 
were synthesized by MWG (Ebensburg, Germany) and Sigma-Genosys Ltd. 
(Cambridgeshire, UK), respectively, with the exception of human acidic ribosomal 
protein (HuPO), which for this particular experiment was purchased from Applied 
Biosystems (Assays-on-Demand™). Primers and probes were used at 500 and 300 
nM, respectively, in a 50-pL reaction. The reactions were performed on the ABI 7700 
Sequence Detection System with the same parameters as the group 1 genes.
Reaction efficiencies for group 2 genes (range of 96%-100%) were derived from 
standard curves using serial dilutions of purified PCR product. Amplification of the 
correct product was confirmed by using the Agilent 2100 Bioanalyzer (with the DNA 
500 Labchip Kit; Agilent Technologies) [448]. All reactions were run in duplicate, 
and cycle threshold (Ct) values for group 1 genes were normalized to the internal 
positive control (IPC) to control for interplate variability. HuPO measurements were 
used to compare the results between groups 1 and 2. Non-template controls were used 
as recommended [39].
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Table 2.4. Primer and probe sequences used to quantify gene expression by real-time PCR. 
All gene abbreviations are defined in table 2.3.
Genes * Probe sequence 5'-(FAM- TAMRA)-3' 
0  primer 1 -5'-3'
□ primer 2 -5'-3'
Produc 
t size
R2
EF-l-a * AGCGCCGGCTATG CCCCTG 
OCTGAACCATCCAGGCCAAAT 
□ GCCGTGTGGCAATCCAAT
59bp 0.992
MLN51 * AGGCCTGTGGAAGCTGGTGGGC 
OCAAGGAAG GTCGTGCTGGTT 
□ ACCAGACCGGCCACCAT
72bp 0.999
UbcH5B * TGATCTGGCACGGGACCC TCCA 
OTG AAGAGAATCCACAAGGAATTGA 
□ CA ACAGGACCTGCTGAACACTG
64bp 0.999
HuPO Applied Biosystems® (Assays-on-demand™) llObp 0.999
Group 1 Taqman Human Endogenous Control Plate, Applied 
Biosystems®
n/a n/a
2.2.2. Effect of reference gene selection on inter-2roup comparisons
This section describes the methods relating to the second set of experiments, which 
outline the effect of using an unvalidated reference gene to normalise real-time PCR 
data.
2.2.2.1. Patients and samples
For this part of the study, 21 patients with proven PTB and 21 matched healthy 
volunteers were recruited. Further details regarding diagnosis and clinical 
characteristics are described in chapter 4.
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Whole blood (2.5ml) was immediately transferred into PAXgene Blood RNA tubes 
(PreAnalytix, Qiagen), and total RNA was extracted and reverse transcribed as 
already described (20 |iL reaction, Omniscript, Qiagen). RNA integrity and quantity 
was assessed using an Agilent Technologies 2100 bioanalyzer. In each cDNA reaction 
150ng of input RNA was used. Levels of mRNAs encoding IL-4 were measured in 
whole blood from all patients at baseline (before or within the first 2 weeks of anti-TB 
treatment) and in 10 patients at approximately 6 months after initiating anti-TB 
treatment. Design and optimisation of HuPO and IL-4 primers and probes are 
described in chapter 3 (General methods).
2 .222 . Real-time PCR & data analysis
The PCR reactions were performed using the Rotorgene (Corbett Research). In each 
reaction, -15 ng of reverse transcribed RNA (based on the initial RNA concentration) 
were used for reactions containing whole blood. Reaction parameters and primer 
sequences for IL-4 mRNA and HuPO are described in detail in chapter 3. All 
reactions were run in duplicate and nontemplate controls were used as recommended
[39].
Cytokine mRNA values from TB samples were normalized to a conventional 
reference gene (GAPDH) or (HuPO), a validated reference gene. The sue of HuPO 
was validated, as outlined in the section 2.2.1 above, by assessing the variability of 13 
reference genes in samples (blood and mononuclear cell cultures) from patients with 
tuberculosis and from healthy volunteers [409].
For the purposes of data analysis, raw data replicates that were nonreproducible and 
below the detection limit of the assay (10 copies) were given an arbitrary value of 1 
copy in the final analysis. Results were analyzed using the Mann-Whitney U test, the 
Wilcoxon matched-pairs test, and the Student’s t test.
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2.3. Results
2.3.1. Reference gene validation
The results presented in section 2.3.1 pertain to finding a suitable reference for 
normalising real-time PCR data in donors with TB and healthy volunteers using 
different biological samples.
2.3.1.1. HK gene expression in whole blood
The median expression level (Ct value) of group 1 and group 2 HK-genes for whole 
blood (n = 16) are shown in figures 2.6 A and B. Also shown are Ct (25th and 75th 
percentile) values, and ranges for each house keeping gene. Figure 2.7 shows the 
standard deviation (SD) expressed as a fold change from the mean and range 
expressed as maximum variability for selected house keeping genes in whole blood.
The most stable HK gene in whole blood was HuPO with an average fold change of < 
2 and a maximal variability of < 5 fold. There was considerably greater variability for 
GAPDH, P-Actin and HPRT (maximum variability of 20-25 fold). When gene 
expression at 4 hours was compared to baseline there was little difference in the 
expression levels of all 13 genes (average FC for all genes over 4 hours = 1.37 ± 
0.33x).
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Figure 2.6 A and B. Real-time PCR cycle threshold values. Expression levels of Group 1 (A) 
and 2 genes (B) are shown as medians (lines), 25th percentile to the 75th percentile (boxes) 
and ranges (whiskers) for 16 human blood samples (4 normal and 4 tuberculosis patients at 
two time points 4 hours apart). All gene abbreviations are defined in table 2.3.
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Figure 2.7. Fold change in gene expression. Variability of selected group 1 and 2 genes in 
human whole blood shown as an average fold change from the mean (columns) and 
maximum fold change (error bars). All gene abbreviations are defined in table 2.3.
2.3.1.2. HK gene expression in PBMC culture
The median expression levels (Ct value) of group 1 and group 2 HK-genes for PBMC 
culture (n = 12) are shown in figures 2.8 A and B. Figure 2.9 shows the Ct values 
expressed as fold changes. The most stable HK genes in PBMC culture were HuPO 
and HPRT with an average fold change of < 2 and a maximal variability of ~5 fold 
each. The most variable genes were GAPDH, P2 microglobulin, p Actin and EF-l-a 
with an average fold of >2 and a maximum variability of 20-35 fold.
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Figure 2 .8  A and B. Real-time PCR cycle threshold values. Expression levels of Group 1 (A) 
and 2 genes (B) are shown as medians (lines), 25th percentile to the 75th percentile (boxes) 
and ranges (whiskers) for 12 human PBMC culture samples (4 tuberculosis patients at 3 time 
points). All gene abbreviations are defined in table 2.3.
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Figure 2.9. Fold change in gene expression. Variability of selected group 1 and 2 genes in 
human PBMC culture shown as an average fold change from the mean (columns) and 
maximum fold change (error bars). AH gene abbreviations are defined in table 2.3.
2.3.2. Effect of reference genes on inter-group comparisons
The data presented above demonstrate that many conventionally used reference genes 
vary widely in mRNA expression and only one gene (HuPO) was found to be suitable 
as a reference. The data presented in the following section demonstrate the effects of 
using a validated (HuPO) versus un-validated reference (GAPDH) on the target gene 
expression.
2.3.2.1. Normalisation of data with HuPO vs GAPDH in whole blood.
An increase in expression of IL-4 in tuberculosis patients can be masked when real 
time RT-PCR is used with an inappropriate reference gene (figure 2.10 A and B). 
Data normalised to HuPO resulted in a highly significant, p = <0.0001, ~ 7 fold 
increase in IL-4 mRNA expression in TB, which was abrogated when the data were 
normalised using GAPDH.
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Figure 2.10 A and B. Differences in IL-4 mRNA expression in patients with pulmonary 
tuberculosis and healthy controls. Inter-group gene expression differences were statistically 
significant when data was normalized to HuPO but not GAPDH. Raw data is normalised to 
-106 copies of HuPO (A) or -106 copies GAPDH (B).
2.3.2.2. Comparison of data between time-points using different reference genes.
Normalisation of IL-4 gene expression with HuPO suggests that anti-TB treatment 
results in a non-significant decrease in IL-4 mRNA expression. However, if GAPDH 
is used a -5  fold significant increase is observed (figure 2.11 A and B).
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Figure 2.11 A and B. Differences in IL-4 mRNA expression in untreated patients with 
pulmonary tuberculosis and patients treated for 6 months. Inter-group gene expression 
differences were statistically significant when data was normalized to GAPDH but not HuPO. 
Raw data is normalised to ~106 copies of HuPO (A) or ~106 copies GAPDH (B).
2.4. Discussion
2.4.1. Reference gene validation
Though a number of previous studies [413, 449, 450] have assessed the experiment- 
specific suitability of reference genes, none have screened genes suitable for 
normalisation when using human biological samples derived from patients with active
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tuberculosis. A study of the expression levels of 13 HK genes in patients with 
tuberculosis revealed only one gene suitable for normalisation of RNA levels. 
According to the selection criteria of less than two fold, HuPO was the most suitable 
gene overall (blood and PBMC culture). GAPDH and p-Actin did not satisfy the 
suitability criteria and had an unacceptably high maximal variability. Moreover, genes 
found to be invariant in mitogen stimulated human T cell cultures [447], were found 
to be unsuitable when studied in human PBMC cultures stimulated with TB antigen. 
Other genes like HPRT were more variable in whole blood than in proliferating 
PBMC cultures. These data show that HK genes are highly specific for a particular 
experimental model and validation for each situation, on an individual basis is a 
crucial requirement.
2.4.1.1. Reference genes and choice of a suitable normalisation strategy
Logically, if the reference or ‘house-keeping gene' is to be used to compensate for 
errors and the amount of starting material it should not theoretically vary between 
individuals, different tissues and under different experimental conditions. However, in 
reality there is considerable inter-individual and inter-tissue variability in reference 
gene expression [37, 421, 430, 436]. Considerable changes in levels were noted with 
viral infection (18s RNA), tissue type (HPRT) and cell type (P-actin) [436]. More 
recently there have been a number of reports that demonstrate that the classic 
reference genes can vary considerably and are unsuitable for normalisation purposes 
due to large measurement error [37, 39, 409, 421, 428, 430, 431, 436]. Using rRNA 
(28S and 18S) are also problematic as they can remain intact despite mRNA 
degradation, they are transcribed with a different polymerase compared to mRNA, 
and they are not reverse transcribed by oligo-dT or gene specific primers [421]. 
Consequently, validation has to be performed to measure the variability of reference 
genes. If this is not done small but significant differences between study and control 
groups may be masked. Even worse, it is possible for artificial inter-group differences 
to be created if the reference gene is induced in one direction and the target gene is 
induced in the opposite direction (directional shift). It is extraordinary that despite 
these observations there are countless examples of published work that have used 
reference genes without any mention of a validation process.
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An alternative is normalisation to total RNA. However, this method does not control 
for the RT and other steps, requires significant amounts of RNA, and there must be an 
accurate and reliable method of RNA quantification. This can be problematic when a 
spectrophotometer is used because of instrument insensitivity, signal contribution by 
contaminants (phenol in particular), residual DNA despite DNAase treatment and 
unreliability at concentrations below lOOng/uL [37, 39, 435]. In the current study, the 
Bioanalyser was found to give consistent results between group 1 and 2 genes and it is 
generally considered to be more reliable than a spectrophotometer [37, 39, 435]. 
However, the analyser is expensive and may not be widely available, especially to 
laboratories in developing countries where the burden of tuberculosis is the highest 
and there is an urgent need to build research capacity. The RiboGreen assay is widely 
regarded as the gold standard for RNA quantification. A non fluorescent dye binds to 
RNA and is quantified against a rRNA reference standard using a fluorimeter [451]. 
Results obtained using the RiboGreen assay and the Agilent Bioanalyser showed good 
correlation except at very low RNA concentrations (Prof. S.A. Bustin, personal 
communication).
For the proposed model of TB-specific cytokine study presented in this thesis, it was 
decided to choose the housekeeping gene method for normalisation as it is simple, 
least costly and measures the composite error of all the steps involved in the real-time 
PCR process. Finding a suitable HK (HuPO) created a convenient way to normalise 
for intra-experimental error and differing input amounts of RNA, yet concurrently 
avoids the variability associated with GAPDH and P-Actin. The disadvantage of HK 
gene validation is that considerable effort and cost is expended to perform an exercise 
like the one presented here. This may not be feasible in small studies or those with 
limited budgets. Similar constraints apply to normalisation with an average of 3 
housekeeping genes [452], which is advocated by some investigators. Indeed, there 
are a number of programs (Gnorm, BestKeeper, Norm-Finder) based on the excel 
platform that allow the assessment of multiple reference genes by using the geometric 
mean of the candidate gene expression levels [452, 453]. Whilst this is a robust 
method for providing accurate normalisation it is severely limited by sample 
availability, labour intensity and cost. Consequently, the findings presented here will 
facilitate the use of the HK gene method in small laboratories or those from resource 
poor settings when studying TB host gene expression in blood and PBMC culture.
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2.4.1.2. Choice o f study participants and experimental design
In order to create maximum variability subjects of different ages, sex and ethnic 
backgrounds were used. Furthermore, different tissues or cell types sampled at 
different time points, which included cells challenged with TB antigen were used. The 
selection of subjects and time-points mirrored experimental protocols that will be 
used (described in chapter 3) to study IL-4. The HK gene variability in blood was 
largely due to inter-individual differences. There was surprisingly little difference in 
gene expression levels at four hours in the samples of both normal and tuberculosis 
patients, considering that these samples had been subjected to in vitro storage 
conditions for several hours. It is possible that the expression of highly regulated 
genes e.g. COX 2 would have shown a large variability between time points. 
Compared to blood, the variability in culture was due to both inter-individual 
differences and differences between different culture time points; these differences 
were not patient specific.
2.4.1.3. Screening of HK genes and selection of cut-offs
Using the ABI commercial plate was a convenient way to do the initial screen because 
these genes vary in expression levels and cover a wide range of biological functions. 
Group 2 genes were selected to increase the number of genes considered in the 
validation exercise.
A variability of two fold was chosen as some cytokines (e.g. IL-4) are both expressed 
and biologically functional at low levels; a one log difference being significant in 
human models of TB [17]. A HK gene with wider variability would increase the assay 
noise, hence limiting sensitivity. Consequently, defining the limits of the HuPO 
gene’s variability is helpful for data interpretation of low copy number cytokines like 
IL-4 (for example a 5 fold difference between study groups may be statistically 
significant but not meaningful when the reference itself varies by 5 fold or more). It 
should be borne in mind that the resolution of the real-time PCR technique is 
dependent of the margin of error occurring during the multi-step process (variability
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of the operator, the RT step and the reference). Consequently, when a change of < 2 
fold is detected, it may be may be statistically valid but is it meaningful? Without 
reference gene validation and other controls (standardisation of sample size or mass, 
using the same amount of input RNA in all reactions, robotic technology to minimise 
operator error) the resolution of the technique is unlikely to meaningfully detect small 
differences in gene expression (2 to 5 fold) [38, 435]. What constitutes an acceptable 
reference in relation to inter-group comparisons are discussed in the next section.
2.3.1.4. Conclusion: Reference gene validation
In conclusion HuPO is suitable for use as a house keeping gene in models of human 
pulmonary tuberculosis when gene expression is studied in whole blood and PBMC 
cultures. GAPDH and p-Actin are unsuitable for this purpose. Whatever strategy is 
used to control for differences in input RNA it must be validated for a particular 
experimental model on an individual basis. This is to avoid significant inaccuracies 
when quantifying target gene expression.
2.4.2. Effect of reference gene selection on inter-group comparisons
The former section outlined the selection of a suitable reference for normalising data 
pertaining to biological samples obtained from healthy volunteers and patients with 
TB. This section discusses how using this validated reference (HuPO), compared to 
an unvalidated one (GAPDH), impacts upon inter-group experimental comparisons 
and conclusions.
2.4.2.1. Change in target gene expression is reference dependent
The data already presented in section 2.4.1 demonstrate that many conventionally 
used reference genes vary widely in mRNA expression. What is discussed here is the 
effect of using a validated versus un-validated reference on the target gene expression. 
The error or ‘noise’ of an unvalidated reference may mask a significant inter-group 
difference or falsely create a difference where one is not present. The latter may occur 
when the target gene is induced in one direction and the reference is induced in the 
opposite direction. Indeed, figure 2.9 and 2.10 demonstrate that a significant increase
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in IL-4 expression can be masked whilst a non-significant decrease in expression can 
be converted to a significant increase with an inappropriate reference gene. This may 
partly explain previous conflicting results when looking at IL-4 mRNA expression in 
TB [17, 27, 353]. Therefore, inappropriate normalisation can generate results that may 
be erroneous and not biologically meaningful.
Although it has been suggested that normalising to ribosomal RNA is a favourable 
strategy [37], the assumption that the rRNA:mRNA ratio is always constant is likely 
to be incorrect. This has been demonstrated in situations were there are proliferating 
cells and situations of stress (reviewed in [436]); it is therefore also possible in an 
infectious disease like tuberculosis. Consequently, normalization to rRNA will also 
require validation.
2.4.2.2. What constitutes an acceptable reference?
What is apparent from this study is that validated reference genes can be used to 
define the whole experimental error (error of all sequential steps of PCR including 
reverse transcription); however, this cannot distinguish between the experimental 
error and the inherent variability of the reference gene itself. Nevertheless, this does 
not matter as long as the cumulative error is less than the inter-group difference to be 
measured i.e. a reference gene that has a log variation is sufficient to measure a 2 log 
change in a gene of interest. Consequently, what constitutes acceptable variability of a 
reference is dependent on the inter-group difference being studied. Furthermore, it is 
crucial that both the directional shift and noise are defined for a particular reference 
gene prior to measuring the gene of interest.
2.4.2.3. Conclusion: Effect of reference gene selection on inter-group comparisons
In conclusion, this part of the study demonstrates that when a carefully validated 
reference is used to normalise data, biologically meaningful results can be measured. 
However, use of an unvalidated reference can lead to the generation of erroneous 
inter-group differences. Furthermore, in validating the reference gene the whole 
experimental noise can be assessed, thus defining the experiments sensitivity. 
Consequently, demonstrating the variation in expression of a reference gene and/or
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the extent by which it may be affected by the experimental conditions is essential if 
robust and biologically meaningful conclusions are to be drawn.
2.5. Overall conclusions
The data presented in this chapter show that a ‘one size fits all’ approach (e.g. 
GAPDH and p-actin) to reference gene selection is inappropriate for data 
normalisation. If this approach is used then erroneous data are generated and the 
conclusions derived from inter-group study comparisons is misleading. Therefore, 
investigators must be able to demonstrate that the reference gene has been validated 
for the experiment in question. When whole blood and antigen driven PBMCs are 
used in samples acquired from index cases and healthy controls HuPO is a suitable 
reference as it has a average fold change of less than 2 fold.
The methods presented here have facilitated the development of a sensitive and 
specific assay to measure IL-4 and IL-452 mRNA levels over a wide dynamic range 
(reproducible minimal detection limit of 10 copies and distinguishing an average 2 
fold difference in target gene quantity between study groups). Furthermore, it ensures 
generation of data that can be interpreted with confidence and relevance. The specific 
reaction kinetics, detection limits, reproducibility, and primer and probe sequences of 
the real-time assay are outlined in chapter 3.
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3.1. Patient selection and sample acquisition
3.1.1. Patients (details for HIV+ donors are outlined in chapter 8)
Twenty-nine patients with pulmonary tuberculosis (PTB), 15 of whom underwent 
lung bronchoalveolar lavage (BAL), were recruited at the Royal Free and Middlesex 
Hospitals, London, UK. All patients yielded positive cultures from sputum or alveolar 
lavage fluid, were negative for antibodies to HIV (3 ELISAs on 2 samples) and 
responded clinically to anti-TB treatment. All patients with PTB had pan-sensitive 
isolates, received standard short course chemotherapy (6 to 9 months) and responded 
clinically and radiologicaily to anti-TB treatment.
3.1.2. Control subjects. TB exposure and excluding LTBI
Control donors (n=21) were healthy volunteers matched to the first 21 sequentially 
recruited TB patients for age (within 4 years), sex and ethnicity. They were 
asymptomatic, had no risk factors for HIV infection (but were not formally tested), 
had normal chest x-rays and did not have LTBI despite risk of exposure to M. 
tuberculosis (TB health care workers and contacts of PTB patients with variable risk 
exposure; subjects with LTBI were excluded). Six of these volunteers underwent 
(BAL). Effector T-cell IFN-y responses to TB specific antigens were used to confirm
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absence of latent infection in the control subjects [41, 454]. Participants with a history 
of atopy or helminth infection, another inflammatory disorder, pregnancy or on 
immunosuppressive medication were excluded from the study. Informed consent was 
obtained from all patients and the Royal Free and UCLH ethical review committees 
approved the study.
3.1.3. Processing of whole blood samples
Whole blood (2.5 to 20 ml) was taken within the First 2 weeks of anti-TB treatment 
(baseline) and 2.5 ml was immediately transferred from the patient into PAXgene 
Blood RNA tubes (PreAnalytix, Qiagen, Cologne, Germany) to fix the mRNA profile 
[445]. The remaining blood was used for further experiments (cell sub-population 
studies, IFN-y and IL-4 ELISPOT assays, mononuclear cell culture). Ten donors with 
PTB were bled after 3 months and then again within 4 weeks of stopping 
chemotherapy. Samples not immediately fixed in RNA buffer, were transported in a 
thermo flask at 37°C in accordance with regulations governing the transport of bio 
hazardous materials. A safety and hazards assessment was conducted far all 
experiments and the relevant good laboratory practice and category 3 laboratory 
training courses were undertaken. Methods relating to the processing of blood for 
half-life experiments and HIV+ subjects are described in chapter 4 and chapter 8, 
respectively.
3.1.4. Bronchoalveolar lavage
BAL was undertaken under local anaesthetic and midazolam sedation. To obtain BAL 
fluid 0.99f saline was instilled into a radiologically involved lung segment, using 180 
ml saline in 60ml aliquots. In control donors the right middle lobe was lavaged. BAL 
fluid was transported on ice to a laboratory adjacent to the bronchoscopy suite, 
filtered through a 100pm Partec filter (CellTrics®, Munster, Germany) and 
centrifuged at 900 g for 3 minutes. A buffer containing chaotropic salts (RLT buffer, 
Qiagen) was added to the cell pellet to fix the RNA profile and the sample 
homogenised to disrupt cell structure (QIA shredder, Qiagen). The supernatant was 
frozen at -80°C and concentrated ~ 10 fold before analysis (Centriprep YM-3
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Centrifugal Filter Unit, Millipore, Watford, England). An aliquot of fresh lavage fluid 
was used to determine BAL lymphocyte sub-populations by flow cytometry (section
3.5.).
3.2. Radiological scoring system for tuberculosis
To assess the extent of pulmonary disease a composite chest radiograph scoring 
system was developed, in collaboration with Dr J Haddock at the Royal Free Hospital, 
which divided the lung into 6 zones. The extent of airspace consolidation (0 to 3 
based on the amount of shadowing in each zone), number of cavities (no cavities, <3 
and > 3 in both lung Fields) and extent of fibrosis (0 to 3 based on the amount of 
reticular shadowing) was assessed and scored (minimum score 0, maximum score 32) 
for each patient (appendix 1.1). Two radiologists blinded to the patient identities 
independently scored the X-rays; there was good inter-observer correlation (p= 
0.0001). To validate the x-ray scores post-treatment spirometry data (percent 
predicted forced vital capacity and forced expiratory volume in the 1st second; FVC 
and FEV1/FVC ratio) is being collected in an extended cohort of patients. These 
Findings will be analysed when the cohort is large enough and the results will be 
published later. Although thoracic computer tomographic (CT) scans would be a 
better measure of disease extent and cavitation, they are not used in routine clinical 
practice, and their availability for this study was limited because of ethical and cost 
considerations. There are currently no validated scoring systems available for 
quantifying the radio-pathogical changes seen in pulmonary tuberculosis.
3.3. Density centrifugation to obtain mononuclear cells
For cell separation and mononuclear cell culture experiments PBMCs were separated 
from fresh whole blood by density gradient centrifugation. Whole blood, after 
separation and removal of an aliquot of plasma, was layered (diluted 1:1 with Roswell 
Park Memorial Institute medium (RPMI)) over Ficoll-Paque Plus (sodium 
metrizoate/polysaccharide solution; Amersham Biosciences, Buckinghamshire, UK), 
and centrifuged at 900 g for 15 minutes (no brake); the PBMC layer was harvested 
with a Pasteur pipette. Red cells were lysed by incubation with ammonium chloride 
solution for 10 minutes on ice (StemCell Technologies, Vancouver, Canada). PBMCs
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were washed twice in RPMI and then counted using a Neubauer counting chamber 
(depth 0.1 mm).
3.4. Cell separation to acquire whole blood cell sub-populations
Peripheral blood mononuclear cells (PBMC) from 10 patients with PTB and their 
healthy matched controls were used for cell sub-population studies. Enrichment of 
CD3+, CD3+CD4+ and CD3+CD8+ and depletion of T cells was performed using 
antibody based density centrifugation reagents, added to whole blood, according to 
the manufacturer’s directions (RosetteSep, StemCell Technologies, Vancouver, 
Canada). The RosetteSep antibody cell separation cocktail consists of monoclonal 
antibodies to CD surface molecules and a tetrameric glycophorin antibody that 
agglutinates red blood cells and antibody bound leucocytes. The antibody bound cells 
are removed by density centrifugation over Ficoll-Paque Plus (Amersham 
Biosciences, Buckinghamshire, UK). The negative selection T cell cocktail contains 
glycophoran A, anti-CD 16, anti-CD 19, anti-CD56 and anti-CD36 antibodies; the CD 
4 cocktail in addition contains anti-CD8 antibody; the CD8 cocktail has in addition 
anti-CD4 antibody; total non T cells are acquired by depleting all CD3+ T cells. Cell 
viability was checked using trypan blue.
3.5. Flow cytometry
Cell sub-population purity and lymphocyte counts in BAL (total CD3+, CD4+ and 
CD8+) were confirmed by flow cytometry (104 gated events). Cells (~ 7.5 x 105) were 
stained with anti CD4-FITC, anti CD8-PE and anti CD3-PercP antibodies (BD 
TritestTM, BD Biosciences, Oxford, UK) and incubation on ice for 15 minutes. 
Excess antibody was removed by washing in FACS buffer (appendix 2) and cells 
were fixed in 1% formaldehyde. Mean cell purities of the relative whole blood 
fractions were > 95%, 99%, 93% and 90% for T, total non-T, CD4+ and CD8+ 
fractions, respectively and were determined by FACS using the Cell Quest 3.3 
(FACScan; Becton Dickinson, San Jose, CA) and Ortho Cytoron absolute flow 
cytometer (Ortho Diagnostic Systems, Raritan, NJ). Dot plots of the cell fractions are 
shown in chapter 6.
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3.6. Immunoassays.
3.6.1. ELISPOT assay for IL-4 and IFN-y
To determine whether healthy volunteers had latent TB infection, T cell IFN-y 
responses to ESAT-6 and CFP-10 peptide pools were measured after -16 hour 
incubation in serum-free medium using the T SPOT-TB kit (Oxford Immunotec, 
Oxford, UK) according to the manufacturer’s instructions. PBMCs (2 x 106 cells/ml, 
150 |il Final volume, 2 x 105 cells per well) were seeded into the wells containing pre­
coated IFN-y antibody. Responses, the number of IFN-y spot forming T cells (SFC) 
per million PBMC was enumerated by a ‘blinded’ operator using an Oxford 
Immunotec ELISPOT reader. The assay contains an internal positive control (figure
3.1) defined, according to manufacturer’s instructions, as < 20 spots in the 
phytohaemagglutinin (PHA) positive control wells (~ 100 spots/ 106 PBMC). Initially 
an in-house ELISPOT IFN-y assay was developed using ESAT-6 protein, however, 
this assay was abandoned due to inconsistent results and poor reproducibility.
Duplicate IL-4 ELISPOT assays (significant if greater than 2 SD above the mean of 
unstimulated wells) were performed on -  2 x 105 PBMCs, non-T, T-cell, CD4+ T cell 
and CD8+ T cell fractions after -  48 hours incubation, in RPMI 1640 medium 
(supplemented with 57c human AB serum, glutamine and penicillin/streptomycin). 
Cells in positive control wells were stimulated with a combination of 
Phytohemaglutinin, Phorbol 12-Myristate 13-Acetate and calcium ionophore (final 
concentrations of 10, 0.5 and 0.5 jig/ ml, respectively). Cell viability was assessed 
with trypan blue. IL-4 production was detected using 96 well ELISPOT plates 
(MultiScreenHTs Filter Plates for Elispot, Millipore Corp.) coated overnight with 
lOOpl anti human-IL-4 mAh (Mabtech, Stockholm, Sweden; 5 |ig/ml) and then 
blocked with RPMI containing 107c human AB. After 48 hours incubation the plate 
was incubated with lOOpl biotin labelled anti-IL-4 antibody (1 pg/ml, Mabtech) for 1 
hour. Finally steptavidin alkaline phosphatase 1:10 000 (Caltag Laboratories, CA, 
USA), 100 pi per well was added for 1 hour, followed by substrate solution (BCIP- 
NBT [5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium] conjugated to 
alkaline phosphatase, BioRad, CA, USA) for 15 minutes. The plate washed 5 times
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between all steps using PBS (appendix 3). Spot counts expressed per million cells 
were analysed using the AID Elispot Reader System and software (AID, Strassberg, 
Germany).
ESAT-6 CFP-10 PHA -control
A
B
Figure 3.1. IFN-y ELISPOT (T SPOT TB) reading o f an individual with (row B) and without 
LTBI (row A). PBM Cs are incubated with antigen (column 1 and 2 from  the left), PHA (+ 
control in column 3) or no antigen (negative control, column 4). Detection o f IL-4 by 
ELISPOT followed the same principle but wells were coated with anti-IL-4 antibody and the 
positive control was a com bination o f PHA, PM A and calcium  ionophore.
3.6.2. Enzyme linked immunosorbent assays for IFN-y. IL-4 and sCD30
Soluble CD30 (sCD30, Bender MedSystems, Vienna, Austria), IL-4 and IFN-y ( 
Pelikine CompactTM, Sanquin reagents, Amsterdam, The Netherlands) plasma and 
BAL levels were measured by ELISA in PTB and controls according to the respective 
manufacturers’ instructions. The sensitivity of the assays were 0.33U/ml (sCD30), 
0.5 pg/ml (IL-4) and 5 pg/ml (IFN-y). Plates were read using an ELISA-plate reader
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(MR5000, Dynatech, Guernsey). Standard curves were plotted and sample protein 
concentrations were calculated using Graphpad Prism.
3.7. Culture of peripheral blood mononuclear cells
Fresh PBMCs from 8 patients with PTB were cultured in filter sterilised RPMI 
(supplemented with 5% human AB serum, glutamine and penicillin/streptomycin) at a 
final concentration of 5 x lOVml, over 6 days in 24 well plates incubated at 37°C in a 
humid 5% CO: incubator; non adherent cells were harvested every 2 days. Cell 
viability was determined with 0.4% trypan blue (> 80% viability) and proliferative 
responses to antigen challenge (Cell Proliferation ELISA, BrDU, Roche, UK) 
undertaken on day 5 to 6 and expressed as a stimulation index relative to the 
unstimulated wells. BrDU is a thymidine analogue that is bound to the cellular DNA 
of dividing cells and detected by ELISA to a monoclonal antibody to BrDU. 
Reactions were stopped after 15 minutes using 1M sulphuric acid. Lack of appropriate 
facilities precluded the use of a radioactive 3-H thymidine proliferation assay. 
Experiments conducted with an aqueous calorimetric tetrazolium/formazan cell
viability assay (CellTitre® 96 AQueous Non radioactive Cell Proliferation assay) was
found it too be too insensitive for relatively low level of proliferation e.g. 
lymphocytes.
Cells were treated with crude whole cell sonicates of H37RV M. tuberculosis 
(50|ig/ml final concentration), phytohaemaglutinin (5pg/ml), an environmental 
mycobacterium (sonicated M. vaccae NCTC 11659, 50pg/ml to determine if findings 
were TB specific) or medium alone. Antigens were prepared by sonicating (100-watt 
ultrasonic disintegrator with the wave peak distance set at 9 pm) harvested 
mycobacteria (grown on Sautons’ slopes and centrifuged at 20,000 g for 15 min) for 
15 min. The suspensions were centrifuged to remove cellular debris and the 
supernatants filter-sterilised (0.22 pm-pore size). The protein concentration was 
quantified by the Lowry method [455]. A single batch of sonicates was used for all 
reactions. Optimum antigen concentrations were dictated by performing preliminary 
experiments that included assessment of cell viability and proliferative responses. The
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use of frozen PBMCs was abandoned after optimisation experiments revealed poor 
recovery of viable cells.
3.8. Real-time RT-PCR
RNA was isolated from whole blood using the Paxgene Blood RNA Kit (PreAnalytix, 
Qiagen) and from purified or cultured cells using the RNeasy® Mini Kit (Qiagen). All 
samples were treated with DNase (Qiagen). The RNA template was qualitatively 
assessed and quantified using an Agilent Technologies 2100 Bioanalyser (RNA 6000 
Nano and Pico Labchip® [448]; the latter was used to quantify RNA amounts less than 
5 ng; figure 3.2). Reverse transcription was performed using a fixed amount of input 
RNA (Omniscript™ for RNA derived from blood and mononuclear cell cultures and 
Sensiscript™, Qiagen for RNA derived from cell sub-population studies) and 
incubated at 37 °C for 1 hour, followed by 93°C for 5 minutes to denature the 
enzyme.
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Figure 3.2. Assessm ent o f  RNA 
integrity using the Agilent 2100 
Bioanalyser. The bottom  tracing 
(fluorescence against time) 
shows good quality RNA whilst 
the top tracing shows poor 
quality RNA as reflected by the 
overall decrease in RNA signal, 
decreased ratio o f 18s and 28s 
rRNA peaks and an abnormal 
baseline. An electronic capillary 
electrophoretic tracing shows the 
the 18s and 28s bands against a 
reference RNA standard (gel 
strip on the left).
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Real time RT-PCR reactions were performed using a Rotogene real-time PCR system 
and Robot (Corrbet Research, Australia). Amplified templates were quantified using a 
standard curve prepared from 10 fold serial dilutions of purified PCR product 
(Qiagen). Measures taken to ensure robust and reproducible PCR data are shown in 
table 3.1 and figure 3.3. Reaction kinetics are outlined in table 3.2 and figure 3.4 and
3.5. Cytokine mRNA values were normalised to a validated housekeeping gene, 
human acidic ribosomal protein (HuPO) [409]. Raw data replicates that were non- 
reproducible and below the detection limit of the assay (10 copies) were given an 
arbitrary value of 1 copy in the final analysis. Primer and probe sequences are shown 
in table 3.3.
Table 3.1. M easures taken to ensure robust and reproducible real-tim e PCR data.
• A quantitative standard curve was run on every plate to monitor efficiency, 
reproducibility, inter-plate variability and exclusion of templates below a 
detectable threshold.
• Normalisation to a validated reference gene (HuPO) (chapter 2).
• Use of a robot (Corbett Research) for preparation of real-time PCR plates to 
reduce operator variability [37, 421 ].
• Immediate stabalisation of samples in RNA buffer to fix in vivo profiles.
• Assessment of RNA integrity to exclude unsuitable templates.
• RNA quantification and use of fixed amounts in each reaction to reduce 
reference gene variability.
• Confirmation of linearity of cDNA synthesis when using different initial RNA 
amounts (figure 3.3).
• Use of good laboratory practice relevant to the handling of RNA preparations 
including the use of RNAzap® (Ambion) on surfaces and plasticware to digest 
RNAases. All reagents were stored in aliquots according to the manufacturer’s 
instructions.
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6RNA mass (pg)
Figure 3 3 .  Linearity o f the RT reaction for different input amounts of RNA. The copy 
num ber detected by real-time PCR shaded bars) corresponded well with the RT input amount 
o f RNA (copy num ber derived from the RNA mass; non-shaded bars) when using 
O m niscript1 M (OS) down to 10000 pg but not below 1000 pg. This problem is resolved when 
Sensiscript™  (SS) is used instead; the 1000 and 100 pg [RNA] correlates well with the actual 
starting concentration.
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Table 3.2. Reaction kinetics, prim er concentrations and perform ance outcom es o f real-time 
PCR.
• All reactions were run in duplicate (12.5pl volume) with 8 serial dilutions of 
PCR product (standard curve, figure 3.4), non-template controls, and 
containing 2ng and 15ng of reverse transcribed RNA for mononuclear cell and 
blood samples, respectively. Quantitect Probe PCR Mastermix (HotStarTaq™ 
DNA Polymerase, Quantitect PCR buffer, dNTPs, ROX reference dye and 
5mM MgCL; Qiagen) was used in all reactions.
• Each run comprised an initial step of 95°C for 15 minutes followed by 40 
cycles at 95°C for 5s, 56°C for 10 seconds and 72°C for 20 seconds for IL-4 
and IL-462 (for HuPO and IFN-y the annealing step occurred at 55°C).
• Primers were intron spanning to avoid amplification of genomic DNA and 
designed according to recommended guidelines. Primers distinguished 
between IL-4 and IL-462 (figure 3.5) and were synthesized by MWG Biotech 
(Germany). The coding regions chosen for amplification are not known to be 
associated with IL-4 gene polymorphisms [456].
• Primer and probe concentrations were optimised to achieve efficiencies 
approaching 100% for all amplicons (final primer concentrations were 500 nM 
for IL-4 and IL-452 and 250 nM for IFN-y and HuPO; all probes had a final 
concentration of 500 nM). All amplicons were run on an agarose gel 
(appendix 4) to exclude primer dimers. Reaction specificity (amplification of 
the correct product) was confirmed using Agilent 2100 Bioanalyser; in 
addition PCR products for IL-4, IL-462 and HuPO were sequenced.
•  Reproducibility (inter-experim ent variability) was < 20% (co-efficient o f variation) 
for IL-4, IL-462, IFN-y and HuPO (CV calculated using raw copy num bers o f 5 
reactions done over a 6 month period and using the same tem plate; data for IL-4 is 
shown in figure 3.6).
•  The m inim um  reproducible detectable threshold was 10 copies for IL-4, IL-462 and 
IFN-y. Copy num bers were regarded as valid if replicates were within 30%: o f each 
other.
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copie;
Background
Norm Fluoro
10M
1CT-2
Unknown 
sample ‘X ’
Name Type Ct Given Cone (Copies) C % Var
IL-4 Standard 11.64 100,000,000.00 104,946,255.19 4.95
IL-4 Standard 11.68 100,000,000.00 102,123,758.13 2.12
IL-4 Standard 15.15 10,000,000.00 9,265,994.04 7.34
IL-4 Standard 14.74 10,000,000.00 11,091,739.15 10.92
IL-4 Standard 17.82 1,000,000.00 1,089,529.70 8.95
IL-4 Standard 18.14 1,000,000.00 948,087.16 5.19
IL-4 Standard 21.22 100,000.00 101,282.04 1.28
IL-4 Standard 21.11 100,000.00 109,700.15 9.70
IL-4 Standard 24.32 10,000.00 10,673.25 6.73
IL-4 Standard 24.62 10,000.00 8,573.39 14.27
IL-4 Standard 28.29 1,000.00 900.23 9.98
IL-4 Standard 27.47 1,000.00 1,092.38 9.24
IL-4 Standard 30.77 100 99.76 0.24
IL-4 Standard 30.59 100 113.45 13.45
IL-4 Standard 34.18 10 8.38 16.2
IL-4 Standard 33.45 10 11.32 13.2
Sample 'X‘ Unknown 26.04 3,078.23
Unknown 25.84 3,558.83
NTC
NTC
Figure 3.4. IL-4 dilution series and quantification o f unknowns. A 10 fold serial dilution of 
standards were co-amplified with unknown samples (sample ‘x’ in this example) on every 
plate. The minimal reproducible detectable num ber was 10 copies for both IL-4 and IL-462; 
detection o f 1 copy of IL-4 was stochastic. The adjoining table (in Rotorgene result format) 
shows the calculated copy numbers (Calc Cone) derived from the standard curve (99.1% 
efficiency); the calculated copy numbers for sample ‘x’ are shown in blue and negative 
controls in red text.
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Figure 3.5. Specificity o f primers for IL-4 and IL-452. The 
IL-4 transcript consists o f 4 exons (numbers indicate 
nucleotide positions); the sense prim er (arrowheads) spans 
the exon 2/3 boundary, generating a 71 bp amplicon. Splicing 
mediated deletion of exon 2 in the IL-482 transcript results in 
the loss o f amino-acid residues 22 to 37, which encode an a -  
helix, a short (3-strand and a disulphide bridge. This alters the 
3-D crystalline structure o f IL-452 [22]. The IL-452 sense 
prim er spans the exon 1/3 boundary and generates a 76 bp 
am plicon. The IL-4 and IL-452 amplicons can be 
distinguished by microfluidic capillary electrophoresis 
(A gilent 2100 DNA Labchip). Specificity was also confirmed 
by sequencing reactions (ABI v3.1 BigDye® Term inator 
using the same prim ers shown in table 5).
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1.0x1012-|-o
o
1 . 0 x 1 0 “ -
10000 -
8 7 6 5 4 3 2 1 effic
Log actual copy numbers generated by PCR
F ig u re  3.6. Serial 10 fold dilutions o f IL-4 cD N A  (duplicates) run on 5 separate occasions 
over a 6 month period. The x-axis show s actual copy num bers generated by real-time PCR. 
C o-efficients o f variation were less than 20*T for each dilution shown. Effic = reaction 
efficiency (m edian; range = 99; 98-103).
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Table 33. Prim er and probe sequences used to quantify gene expression by real-tim e PCR. 
Prim ers and probes for each gene were designed with the assistance o f prim er 3 
(http://frodo.w i.m it.edu/cgi-bin/prim er3/prim er3_w w w .cgi ). A m plicon size was kept to ~ 
100 bp for maximal am plification efficiency.
Genes
* Probe sequence 5'-(FAM- TAMRA)-3' 
0  primer I -5'-3'
□ primer 2 -5'-3'
Product
size
R2
IL-4 * AAACCTTCTGCAGGGCTGCGAC 
CGCTGCCTCCAAGAACACAAC 
□CTGT AG AACTGCCGG AGC AC
71 bp 0.998
IL-452 * AAACCTTCTGCAGGGCTGCGAC 
OGCCTCACAGAGCAGAAGAACAC 
□ CTGT AG AACTGCCGG AGC AC
76bp 0.999
HuPO *TGCCAGTGTCTGTCTGCAGATTGG
<3GCTTCCTGGAGGGTGTCC
□GGACTCGTTTGTACCCGTTG
105bp 0.999
IFN-y * TGGCTGTTACTGCCAGG ACCCA 
OTTCAGCTCTGCATCGTTTTG 
□ TCCGCT ACATCTGAATG ACCT
112bp 0.998
3.9. Data analysis
The study was designed (prospective cross sectional) to detect an inter-group (12 
patients per group) IL-4 copy number difference of -1.5 logs (standard deviation 1.5) 
with a power of 809£ at the 5% significance level. Statistical methods and sample 
sizes were determined Dr Morris and Dr F Lampe of the Department of Primary Care 
and Population Sciences, Royal Free Hospital, London.
TB patient and control groups were compared using the Mann-Whitney U test. 
Wilcoxon matched pairs test was used to assess changes within groups over time. 
Spearman rank-sum correlation was used to assess associations between variables. To
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compare TB patients and controls with respect to T-cell IL-4 production, while 
controlling for non-T cell IL-4 production, linear regression was used on logged data. 
Cytokine ratios were expressed as log differences between respective cytokine pairs. 
Analysis was conducted using GraphPad prism and SPSS v 11.5.
127
CHAPTER 4: HALF LIFE OF IL-4 AND IL-462
4.1. Introduction 128
4.2. Methods
4.2.1. Patients and samples 130
4.2.2. Inhibition of mRNA transcription 130
4.2.3. Inhibition of p38 MAP kinase pathway and THP1 cell line 131
4.2.4. RNA extraction, RT and real-time RT-PCR 132
4.2.5. Data analysis 132
4.3. Results
4.3.1. IL-4 mRNA half-life in whole blood 133
4.3.2. Th2/Thl ratio in whole blood 133
4.3.3. p 38 MAPK inhibitor and IL-4 mRNA levels in THP1 cells 133
4.4. Discussion
4.4.1. IL-4 and IL-462 mRNA half life 136
4.4.2. p38 MAPK inhibitors and mRNA half-life 137
4.4.3. Validity of results 138
4.5. Conclusion 139
4.1. Introduction
Th2 cytokines enhance disease susceptibility and progression by subverting 
macrophage protective mechanisms, and exacerbate immunopathology by enhancing 
the toxicity of TNF (reviewed in detail in chapter 1 and in [31]). Whilst real-time PCR 
allows reliable quantification of steady state IL-4 mRNA levels it tells the investigator 
nothing about transcription rates or mRNA degradation (mRNA stability or half-life). 
Regulatory mechanisms like soluble IL-4 receptor [308] and natural antibodies [311, 
313] may modulate the biological effects of IL-4 (discussed in chapter 1, section
1.6.4.1). An additional putative mechanism of regulation, about which little is known, 
is enhancement or inhibition of IL-4 mRNA stability. Logically, enhancement of 
stability would be expected to facilitate the immunopathologic effects of IL-4. 
Indeed, even if mRNA half life is modestly prolonged (~ four fold) this can result in 
large increases in mRNA (-1.5 logs) and sustained cellular effects [457]. However 
studies of IL-4 mRNA stability in human biological samples are sparse [297, 412, 
458, 459] and there are no data on whether mRNA stability is modulated in subjects 
with pulmonary tuberculosis compared to healthy volunteers.
A number of factors (sequences within the mRNA molecule, proteins, enzymes etc) 
either alone or in combination may modulate the stability of human mRNA (these 
factors are summarised in table 4.1).
128
Table 4.1. Factors and motifs that determ ine m RNA stability. One or more motifs may 
interact in a com partm ent and cell specific m anner to regulate mRNA stability.
• Sequences in different parts of the mRNA molecule (sequence 
determinants)
- poly (A)
3' untranslated region (heavily influences half-life [457])
* AU-rich elements (AURE; translocation of AURE from one mRNA to 
another dramatically increases instability [457])
* Iron responsive elements (sequences in the 3' end determining 
transferrin mRNA stability)
* stem loops (IGF I and histone mRNA)
5' untranslated region and mRNA cap 
coding region
• mRNAases (poorly studied and incompletely characterized)
• RNA binding proteins 
to AU rich regions
poly (A) binding proteins
Others (Iron regulatory protein, c-fos and c-myc coding region 
determinant-binding proteins, ribonucleotide reductase m-RNA binding 
proteins)
• Non-RNA binding proteins
(3 tubulin, histones, HSP, p27rex, factors affected by translational 
inhibitors etc
• Hormones. GF. ions
Estrogen, phorbol esters, cytokines, growth factors, kinases
• Association with ribosomes and translation inhibitors
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One important determinant of stability is the presence of AU (adenylate-uridylate) 
rich elements in the 3' untranslated region of the mRNA molecule. Recently a new 
class of therapeutic agents, p38 mitogen activated-kinase (MAPK) inhibitors 
belonging to the pyridinyl imidazole class of compounds, were discovered. They have 
anti-inflammatory effects in murine models of rheumatoid arthritis [460] and ischemia 
reperfusion injury [461], and exert their effects by phosphorylating mRNA AU 
binding proteins, thereby reducing the mRNA stability of cytokines like IL-3, IL-6, 
IL-8 and TNF (reviewed in [298]). This may conceivably have beneficial outcomes 
on the immunopathology of tuberculosis by effects on multiple cytokines including 
IL-4. However, there are no studies examining whether the stability of human IL-4 
induced by TB antigen is MAP kinase dependent.
To address these questions the half-life of IL-4 mRNA, and of the antagonist, IL-462, 
was evaluated in the blood of patients with active TB compared to healthy volunteers, 
and in TB antigen driven THP1 cells treated with an inhibitor of p38 MAP kinase.
4.2. Methods
4.2.1. Patients and samples
Eight patients with pulmonary tuberculosis (sputum culture positive, negative for 
antibodies to HIV, mean age 33 years, 5 males, mixed ethnicity- 4 Black Africans, 2 
Somalians and 2 whites) and 5 healthy volunteers (mean age 34 years, 3 males, mixed 
ethnicity- 1 Indian, 1 Korean, 1 Chinese, 2 White) were recruited at the Royal Free 
and Middlesex Hospitals, London, UK. Control subjects had previous exposure to M. 
tuberculosis but no LTBI, which was excluded by determining TB antigen-specific 
(ESAT-6 and CFP-10 peptide pools) IFN-y ELISPOT responses in PBMCs as 
outlined in chapter 3.
Samples (20 ml whole blood) was acquired before or within the 1st 2 weeks of anti- 
TB treatment. After phlebotomy 2.5ml was immediately transferred into a into a 
PAXgene Blood RNA tube (PreAnalytix, Qiagen, Cologne, Germany) to fix the 
baseline mRNA profile [445]. Actinomycin-D was added to a 12ml aliquot of
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heparanised blood and transported, in a thermoflask at 37°C, to the laboratory where 
2.5ml aliquots were transferred to a PAX tube at different time points. The blood was 
stored in a humid 59c C02 incubator during all experiments.
4.2.2. Inhibition of mRNA transcription
All blood samples were treated with 5 pg/ml Actinomycin D (ActD, Sigma-Aldrich, 
Dorset) and samples harvested at 0, 60, 120 and 240 minutes. These time-points 
proved unsatisfactory for the measurement of the half-life of IL-462 mRNA, which in 
control subjects was found to be les than 1 hour. Consequently, in 5 control subjects 
blood samples were also harvested at 15, 30, 45, 60 and 120 minutes. Optimisation 
experiments conducted using different ActD concentrations (5, 10 and 20 fig/ml) 
revealed no significant differential effect on IL-4 and IL-482 and mRNA half-life. To 
verify that ActD effectively inhibits cellular transcription preliminary experiments 
were performed using naturally unstable mRNA (c-myc) as a positive control.
4.2.3. THP1 cell line and p38 MAP kinase inhibitor
The human myelomonocytic cell line THP1 (American Type Culture Collection, 
Manassas, Va.) was cultured (2 x 106/ml final concentration) in filter sterilised 
medium (RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 
fig/ml streptomycin [Gibco BRL, Paisley, UK] and 10 9c fetal bovine serum) at 37°C 
using a 5 9c CO: incubator. For the induction of macrophage cell differentiation 2x 
lOVml cells were initially propagated in 250 ml flasks (Nunc) for 2 days and then 
treated with 1.29c of dimethyl sulphoxide (DMSO, Sigma-Aldrich, Dorset) for 24 
hours and then washed twice in medium. After viability assessment using trypan blue 
cells were incubated with 90 (ig/ml sonicated M. tuberculosis for 6 hours (designated 
baseline). The concentration of TB antigen was determined in optimisation 
experiments that allowed induction of immunological markers without cell toxicity. 
For the measurement of total RNA half life (T Vi), stimulated cells were treated at 
baseline with 10 pg/ml ActD and with or without SB202190 (Calbiochem; a potent 
and cell-permeable inhibitor of p38 MAP kinase). Cells were harvested at baseline, 
30, 60, 120, 240 and 480 minutes. Osteogenic differentiation factor (SOX 9) gene
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expression was used as a positive control as its half-life is known to be p38 regulated 
in THP1 cells [297].
4.2.4. RNA extraction. RT and real-time RT-PCR
RNA was isolated from whole blood using the Paxgene Blood RNA Kit (PreAnalytix, 
Qiagen) and from cultured cells using the RNeasy® Mini Kit (Qiagen). Quality 
assessment of RNA, DNAase treatment, RT and real-time PCR was performed as 
outlined in chapter 3. The 5' 3' forward and reverse primer and probe sequences for 
SOX-9 were AAGCTCTGGAGACTTCTGAACG, GTAATCCGGGTGGTCCTTCT 
and CTCCTCCACGAAGGGCCGCT, respectively.
4.2.5. Data analysis
Depending on the shape of the decay curve conventional linear regression may over 
or under-estimate the half-life. Consequently, one phase exponential phase decay 
nonlinear regression (healthy controls and THP1 cells) or half life cut points from the 
actual curves (TB patients) was employed to measure the half life of IL-4 and IL-482. 
TB patient and control groups were compared using the statistical methods outlined in 
chapter 3.
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4.3. Results
4.3.1. IL-4 mRNA half-life in whole blood
The median (range minutes) half-life of IL-4 mRNA was significantly prolonged in 
patients with tuberculosis compared with control subjects [210 (145- 288) vs 49 (39- 
66), ~ 5 fold increase, p= 0.0016; figure 4.1 A and 4.2]. By contrast, in donors with 
tuberculosis compared to healthy volunteers the half-life of IL-482 mRNA was not 
prolonged [(43 (30-72) vs 33 (20-62); p= 0.7; IL-482 was detected in only 4 patients 
and 5 controls; figure 4.1 B and 4.2]. Consequently, the median (range) IL-4/ IL-482 
half-life ratio in 8 TB patients was significantly greater than in the 5 control subjects 
[1.6 (0.5-2.4) vs 0.09 (-0.04 -0.5), p= 0.003, figure 4.3]. There was no correlation 
between IL-4 mRNA half-life and disease extent on chest x-ray or presence of 
radiological cavitation.
4.3.2. Th2/Thl ratio in whole blood
In unstimulated cells in whole blood the baseline Th2/Thl (IL-4/IFN-y) ratio was 
significantly higher in TB patients compared to controls [2.5 (-0.4- 2.8) vs 0.3 (-0.3-
1.1), p= 0.03, figure 4.4].
4.3.3. p38 MAPK inhibitor and IL-4 mRNA levels in THP1 cells
The mRNA stability of SOX-9 (mean of duplicate wells), but not that of IL-4, was 
p38 MAPK dependent in THP1 cells incubated with ActD and TB antigen in vitro 
(median mRNA half-life in p38 treated vs untreated wells was 36 vs 28 minutes for 
IL-4 and 10 vs 134 minutes for SOX 9, respectively).
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Figure 4.1. mRNA stability over 240 minutes of IL-4 ( 1 A) and IL-482 (IB) in donors with 
pulmonary tuberculosis (n=8) and healthy volunteers (n=5). IL-4 mRNA decay was 
significantly slower in patients (Tl/2= 210 minutes, triangles) compared to controls (Tl/2= 
49 minutes, squares), p= 0.0016 (1A). By contrast, the IL-482 mRNA stability was similar in 
both groups (IB). Error bars represent SEM.
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Figure 4.2. Scatter plot showing the whole blood mRNA half life of individual patients with 
pulmonary tuberculosis and healthy volunteers. The half-lives show relatively little spread in 
patients and controls. Horizontal lines represent medians.
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Figure 4.3. Whole blood IL-4/IL-482 ratios in donors with tuberculosis and healthy controls.
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Figure 4.4. Th2/Thl (IL-4/IFN-y) ratio of unstimulated cells in whole blood from donors 
with pulmonary tuberculosis and healthy volunteers.
4.4. Discussion
A study of human mRNA stability showed significant half-life prolongation (~ 5 fold) 
of the prototype Th2 agonist, IL-4, but not of the antagonist, IL-462, in donors with 
pulmonary tuberculosis compared to healthy controls. Consequently, the IL-4/IL-452 
half-life ratio was significantly higher in TB compared to healthy volunteers. This is 
the first study to show enhanced stability of a gene of interest compared to its splice 
variant. Furthermore, enhancesd stability of IL-4 in whole blood, ex vivo, has not 
previously been described in a specific human disease.
4 .4 .1. IL-4 and IL-462 mRNA half life
With respect to human TB these data suggest a hitherto undescribed post- 
transcriptional regulatory mechanism that may potentiate the biological effect of IL-4. 
Alternative splicing of mRNA encoded by a single gene is a recognised regulatory 
mechanism that controls gene expression and functional diversity of proteins [319,
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325]. However, the increased IL-4/ IL-462 half-life ratio in TB illustrates that 
differential stability of mRNA variants of a single gene may further modulate gene 
expression. IL-4 may subvert protective mycobactericidal mechanisms by down 
regulating protective innate responses (reviewed in chapter 1 and [236]). The 
association between IL-4 and immunopathology has been shown in murine models 
[14, 16, 364] and human studies (discussed further in relation to data presented in 
chapter 5). These deleterious effects are likely enhanced because the half-life of the 
antagonist, IL-462, remains unchanged.
The interaction between IL-4 and IL-462 is likely to have significant applicability to 
tuberculosis as contacts of index cases who remain healthy have high levels of the 
antagonist, IL-462, but not of the agonist, IL-4 [360, 361]. Furthermore, it is 
demonstrated that unlike IL-4, IL-462 mRNA levels increase with clinical 
improvement (chapter 5) and TB antigen preferentially drives IL-4 but not IL-462 
mRNA expression in mononuclear cell cultures from TB patients (chapter 7).
It remains unclear whether the enhanced IL-4 mRNA stability is TB-specific 
compared to other diseases where Th2 cytokines are prominent and associated with 
immunopathology or fibrosis. There are no data on cytokine mRNA stability in Th2- 
biased conditions such as idiopathic pulmonary fibrosis or leprosy. However, in a 
murine model of hypersensitivity pneumonitis, Th2 rather than Thl biased mice had 
enhanced IL-5 mRNA stability [42]. The data presented here do not show a direct 
association between enhanced IL-4 mRNA stability and immunopathology 
(radiological disease scores) but it is possible that such a relationship would have 
been demonstrated in a larger cohort of patients. Nevertheless, similar to the murine 
pneumonitis model [42], patients with TB who had a Th2 biased profile, unlike 
healthy volunteers who did not, showed enhanced IL-4 mRNA stability.
4.4.2. p38 MAPK inhibitors and mRNA half-life
The mechanism by which this differential alteration in mRNA stability occurs in TB 
remains unclear. Certain mRNAs have AU rich motifs (contain AU proteins) in the 3' 
region. In some cases (e.g. IL-6 mRNA) p38 MAP kinases phosphorylate AU
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binding-proteins, thereby impeding translation and reducing mRNA stability [298, 
457]. Approximately 900 AU-motif-containing genes have been described but only a 
minority (-50) are p38 MAPK regulated [298, 457]. The anti-inflammatory potential 
of p38 MAPK inhibitors, the only known therapeutic modulator of mRNA stability, 
has recently been explored in human phase 1 studies [462] and disease models of 
rheumatoid arthritis [460]. It is intriguing to speculate that reducing the stability of IL- 
4, which is a key facilitator of immunopathology in tuberculosis (reviewed in [12, 
236]), may impact on morbidity and disease progression, as it does in models of 
unrelated inflammatory diseases [460, 461].
However our data show that, unlike SOX-9, IL-4 mRNA stability does not appear to 
be p38 MAP kinase dependent in TB antigen stimulated THP1 cells, or for that matter 
in LPS stimulated THP1 cells [297]. Discordant data have been reported when TNF 
mRNA stability was studied in models using inhibitors of p38 MAPK [297]. 
Collectively, these data suggest that stability may depend on a number of factors 
including cell type (human versus murine), inducing antigen (LPS versus other) and 
interaction with other mRNA stability determinants (described in table 4.1 and 
reviewed in [457]). Consequently, it remains unclear whether IL-4 mRNA stability is 
p38 MAPK independent in specific cells types, which show increased IL-4 mRNA 
expression in TB (chapter 6). p38 MAPK has been shown to interact with NF-kappa 
B and modulate the levels of a number of inflammatory molecules [297, 298] and it is 
therefore still possible that it may have a modulatory effect in TB.
4.4.3. Validity of results
Are the observed 2 to 3 fold changes over the course of individual mRNA half-life 
decay curves and the five fold inter-group changes in mRNA stability, technically 
valid when using real-time PCR? Although real-time PCR is the most sensitive and 
reliable means to quantify gene expression the measurement resolution of this 
technique remains contentious. To keep measurement error to a minimum we used a 
reference validated for our experimental conditions (including use of blood from 
index cases and volunteers and TB antigen stimulated cells) [409], quality assessed all 
RNA templates, used a set amount of RNA in all reactions, immediately fixed mRNA 
profiles ex vivo, and employed a robot to minimise operator error. Furthermore, the
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pattern of mRNA decay curves were consistent in each group of participants (TB or 
controls). Consequently, we feel that our results are reliable. Indeed, when 
measurement error is carefully controlled for, reliable detection of as little as 2 fold 
have been reported with real-time PCR [421]. Our data also indicate that the reference 
gene (HuPO) has a relatively long half-life and remained stable over the first 240 
minutes. Analysis of transcripts with a longer half-lives requiring the use of later time 
points would necessitate an alternative normalisation strategy (e.g. total RNA [37]).
A limitation of the study is that control subjects were incompletely matched to 
patients with respect to ethnicity. However, the variable ethnicity of the study subjects 
makes these results more generalisable to an ethnically diverse population that is 
encountered in many large cities in both developed and developing countries. 
Nevertheless, it is possible that the results may have been different in a single ethnic 
group or in a developing country setting.
4.5. Conclusion
The half life of IL-4 mRNA, but not that of the natural antagonist IL-452, is 
prolonged in pulmonary tuberculosis. This may represent an additional post- 
transcriptional regulatory mechanism by which M. tuberculosis may subvert host 
immune responses. Further studies are required in TB and other infectious diseases to 
determine whether pathways that modulate mRNA stability may offer future 
therapeutic potential.
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5.1. Introduction
Immunity to human mycobacterial disease is known to require TNF-a and a Thl 
response because genetic defects in signalling by IFN-y or IL-12 lead to susceptibility 
[343, 344] and neutralisation of TNF-a reactivates latent infection [153]. Although 
these data suggest a minimum requirement for Thl cytokines and TNF-a, it is 
becoming evident that is not the complete answer. There are strong IFN-y responses at 
the site of disease and observations about the protective efficacy of vaccines, and 
pathological changes in TB lesions, suggest that augmenting Thl responses are 
unlikely to improve protective efficacy but will nonetheless enhance 
immunopathology (discussed later in this chapter). Indeed immunopathology is 
essential to the pathogenesis of M. tuberculosis because cavities opening into bronchi 
allow the dissemination of bacilli by coughing.
These and other considerations have led several authors to postulate that something 
else is involved, in addition to the production of IL-12, IFN-y, and TNF-a. There are
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two logical possibilities. Either immunity requires some additional Thl-associated 
activity, such as an unidentified macrophage function with variable inter-individual 
efficacy [463], or immunity mediated by the Thl response is only effective in the 
absence of another corrupting influence. Many authors have suggested that this 
corrupting influence might be a form of Th2-like response (reviewed in [236]), 
because IL-4 downregulates iNOS [276], drives an inappropriate alternative form of 
macrophage activation [274] and in animal models [14, 16] can contribute to tissue 
damage and fibrosis. Moreover, recent human data suggest that those with pre­
existing lymphocyte IL-4 responses have a high rate of progression to active TB [15].
However our tenuous understanding of the role of IL-4 production in human 
tuberculosis is confounded by the fact that earlier studies produced discordant results 
(discussed later in this chapter) due to technical difficulties in measuring IL-4 (these 
are outlined in chapter 2, table 2.1). Furthermore, these studies did not distinguish 
between the agonist IL-4 and its splice variant [33] and antagonist [314], IL-452, 
resulting in data that is difficult to interpret. The two forms can easily be
distinguished by RT-PCR. However, even when discriminative nested conventional 
PCR is used [328] there are a number of drawbacks (outlined in chapter 2 table 2.2) 
the most important being uncertain validity due to unreliable mRNA quantification. 
Finally, there are no studies that have examined the compartment-specific (lung 
versus blood) disparities in IL-4/ IL-452 expression in human tuberculosis.
This chapter outlines IL-4 and IL-452 gene expression in lung lavage and whole 
blood, and correlation with clinical parameters, using a validated (chapter 2 ), 
reproducible and sensitive real-time PCR assay (chapter 3).
5.2. Methods
Twenty-nine patients with culture positive pulmonary tuberculosis (PTB), 15 of 
whom underwent lung bronchoalveolar lavage (BAL), were recruited. Control donors 
(n=21) were healthy volunteers matched to the first 21 sequentially recruited TB 
patients for age, sex and ethnicity. They were asymptomatic had normal chest 
radiographs and were selected because of the absence of LTBI despite exposure to M. 
tuberculosis (health care workers and contacts of PTB patients). Six of these
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volunteers underwent BAL.
Whole blood (2.5 ml) was taken within the first 2 weeks of anti-TB treatment and 
immediately transferred from the patient into PAXgene-RNA tubes to fix the mRNA 
profile. Ten donors with PTB were bled again after 3 months or within 4 weeks of 
stopping chemotherapy. More detailed participant and experimental details including 
acquisition of BAL, method of radiographic scoring, TB antigen-specific ELISPOT to 
exclude LTBI, ELISA for sCD30, details of RT and real-time PCR, and methods 
relevant to data analysis are outlined in chapter 2  (general methods).
5.3. Results
5.3.1. Clinical and baseline parameters
Demographic details of matched patients and controls (n=21) and BAL cell counts are
shown in table 5.1. When all TB patients (n=29) were compared to controls there
were no differences in baseline characteristics. None of the study subjects had
*
elevated eosinophil counts and all control patients had normal chest radiographs and 
were not latently infected with M. tuberculosis by antigen specific IFN-y assay.
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Table 5.1. Demographic details and lavage cell counts at recruitment. Demographic details 
and radiographic scores are of 2 1  patients with pulmonary tuberculosis and their matched 
controls; the lavage cell counts are those of 1 0  patients and 6  controls.
Numbers in parenthesis = % TB Control
Age (median; range in years) 30; 18-81 31; 21-80
Sex (male) 14(67) 13(62)
Ethnicity
Black African 12(57) 11(52)
White 4 (19) 4 (19)
Other 5 (24) 6  (29)
X-ray features
Cavitation 12 (57) 0
>50% airspace shadowing 5 (24) 0
of total lung field
BAL (mean ± SE)
Total leucocytes (x 104 /ml) 28 ± 19 12.8 ±4.2
lymphocyte count (x 1 0 4 /ml) 308± 106 81 ±25
CD4/CD8 ratio 3.58 ± 0.99 2.55 ±0.94
5.3.2. Th2 markers in whole blood and BAL at baseline
Both IL-4 and IL-452 mRNA levels (mRNA copies per 106  copies HuPO) were 
significantly elevated in whole blood and lung lavage of PTB vs controls (p<0.005 for 
IL-4 and IL-452, Figure 5.1 A and 5 .IB); all median and 25th-75th percentiles are 
shown in table 5.2. Levels of IL-4 and IL-452 were not significantly different when 
whole blood and BAL were compared in paired samples (median mRNA levels 317 
vs 118 and 60 vs 45, respectively). The 2 subjects in whom IL-4 was undetectable in 
alveolar lavage cells had no cavitation and minimal parenchymal lung changes, 
however, the subjects in whom IL-452 was undetectable could not be characterised by 
disease phenotype. In contrast to IL-4 and IL-452, IFN-y was massively upregulated 
in BAL (p= 0.0007) but not in whole blood (figure 5.1C) of TB donors compared to 
controls. Furthermore sCD30 was elevated in the plasma (p=0.0025) and BAL fluid 
(p=0.01, figure 5.2) of PTB vs controls.
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In whole blood there was a significant correlation between the PTB total radiographic 
score and the IL-4/IFN-y. ratio (p= 0.0034, Figure 5.3A) and a negative correlation 
with IFN-y, p= 0.005. In BAL there was a significant correlation between the PTB 
total radiographic score and sCD30 levels (p= 0.0001, Figure 5.3B). Furthermore, TB 
patients with high levels of cellular inflammation (high BAL total leucocyte count) 
had high IL-4/IFN-y ratios (p= 0.02 for the correlation).
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Figure 5.1 A, B and C. IL-4 (A), IL-482 (B) and IFN-y (C) mRNA levels in whole blood and 
alveolar lavage (BAL) at the start o f treatm ent. Expression o f IL-4 and IL-452 were 
significantly increased in patients with tuberculosis com pared to controls. IFN-y was elevated 
in the lung lavage o f PTB vs controls. C ytokine m RNA copy num bers are expressed per 
m illion copies o f HuPO.
145
Table 5.2. IL-4, IL-452 and IFN-y values (median; 25th-75th percentiles) in whole blood (n= 
21 TB and matched controls), alveolar lavage (n=15 TB and 6  controls) and cell sub­
populations of peripheral blood (n=10 TB and matched controls). Also shown are values pre 
and post anti-TB treatment matched to controls (n=10). All values are expressed as mRNA 
levels per million copies of HuPO.
TB Matched Control P value
IL-4:
Whole blood 
BAL
344; 107-544 
262; 104-551
52; 7-129 
21; 6-36
P= 0.0004 
P= 0.0024
IL-452:
Whole blood 
BAL
37; 10-46 
51; 1-166
1 ; 1 - 1  
2; 1-4
P= 0.0002 
P= 0.08
IFN-y:
Whole blood 
BAL
6 ; 1-148 
2858; 627-7458
6 ; 1-38 
13; 4-113
P= 0.4 
P= 0.0007
sCD30 (U/ml): 
Plasma 
BAL
14.2; 7-22 
20.3; 0.2-30.4
4.4; 2-6
0 .6 ; 0 . 1 -0 . 2
P=0.003 
P= 0.01
Response to Rx: 
IL-4 baseline 
IL-4 post Rx 
IL-452 baseline 
IL-452 post Rx
348;25-566 
177;59-234 
23; 5-43 
52; 28-75
37; 1-143 
1 ; 1 - 1
P= 0.4*
P= 0.03** 
P= 0.02*
P= 0.0002**
* comparison between values at baseline and values after treatment 
** comparison between values after treatment and values in matched controls
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Figure 5.2. Soluble CD30 levels. Soluble CD30 was elevated in plasma (n=13) and alveolar 
lavage fluid (n=15, alveolar lavage) when patients with tuberculosis were compared to 
controls (dashed line indicates the detection limit of the assay).
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Figure 53 A and B. Radiological scores and Th2 markers. There was a significant 
correlation between the total radiographic score and the whole blood IL-4/IFN-y ratio (5.3 A, 
expressed as differences between logged data), and the alveolar lavage sCD30 (5.3 B) in 
patients with pulmonary tuberculosis.
5.3.3 Cavitary versus non-cavitarv disease
When patients with and without cavitation were compared there was no significant 
difference in the median (25,h-75th percentiles) IL-4 mRNA levels in whole blood 
[310 (158-804) and 354 (211-625), respectively] or BAL [190 (45-438) and 90 (1- 
219)]. Similarly, IL-462 mRNA levels, the Th2/Thl (IL-4/IFN-y) ratio and the IL- 
4/IL-452 ratio were similar in both whole blood and BAL.
5.3.4. Comparison of IL-4 relative to IL-462 in whole blood and BAL
Although both IL-4 and IL-462 mRNA levels were substantially higher in TB 
compared to control subjects (figure 5.1), the ratio of IL-4/IL-462 was not 
significantly different in the 2 groups (TB and controls) for both whole blood and
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BAL.
When only TB subjects were considered and the blood and BAL compartments 
compared the IL-4/IL-462 ratio was not significantly different in 15 paired blood and 
BAL samples [median (25th- 75th percentiles) ratio of 0.17 (0.0-1.16) and 0.45 (0.06- 
2.46), respectively].
5.3.3. IL-4 and IL-452 in response to anti-TB treatment
After the intensive phase of short course chemotherapy (month 3, n=5) there was no 
significant change in IL-4 or IL-462 mRNA levels (data not shown). However > 6  
months after initiation of short course chemotherapy (n= 1 0 ) there was a non­
significant decrease in IL-4 mRNA expression which was still higher than in matched 
controls (p=0.03, figure 5.4 A and table 5.2). By contrast there was a significant 
increase in IL-462 (p= 0.02, Figure 5.4 B and table 5.2) and IFN-y mRNA levels (p< 
0.0001, table 5.2) after treatment. Furthermore the median IL-4/IL-462 ratio and the 
IL-4/IFN-y ratio (expressed as log differences between cytokine pairs) significantly 
decreased > 6  months after initiation of chemotherapy (1 vs 0.4 for the former, p=0.04 
and 2.3 vs 0.3 for the latter, p<0.0002).
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Figure 5.4 A and B. Comparison between IL-4 (5.4 A) and IL-452 (5.4 B) mRNA levels at 
baseline, after 6  months of chemotherapy (TB 6-10) and in matched controls (n=10). At 6  
months IL-4 mRNA was non-significantly changed from baseline but significantly higher 
than matched controls. IL-452 at 6  months was significantly higher than at baseline.
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5.3.4. ELISPOT assays
PBMC from control donors cultured with ESAT- 6  and CFP-10 yielded median 
(range) IFN-y spot counts (per million PBMCs) that did not differ significantly from 
negative control wells (0; 0-52 vs 0; 0-65 spots) suggesting that they were not latently 
infected.
5.3.5. ELISA for IL-4 and IFN-y
IL-4 was elevated in the BAL of PTB vs controls (median 12.2 vs 6.9 pg/ml, p= 0.5) 
and detectable in 11 of 15 PTB patients and 4 of 6  controls. In plasma, IL-4 levels 
were not different in PTB vs controls but in most cases levels were around the 
detection limit of the assay. IFN-y protein was largely undetectable in BAL or plasma 
(2 of 15 TB BAL samples and 3 of 13 TB plasma samples).
5.4. Discussion
It has been recognised since the days of Koch that stimulating the acquired immune 
response may exacerbate the clinical manifestations of TB. However, the pathways 
that underpin disease progression remain unclear. One hypothesis (others have been 
discussed in chapter 1, section 1.5) is that a small but significant IL-4 component may 
subvert the protective Thl response, while IL-452 might be protective (reviewed in 
detail in 13;30). However, whether IL-4 cytokine levels are raised in TB has been 
contentious and the data discordant with some studies finding IL-4 [18, 19, 29, 349] 
and others failing to do so [27, 28, 30, 355]. Furthermore, IL-452 mRNA levels and 
sCD30 have not previously been investigated in BAL fluid of donors with active TB.
In the present study, the first to investigate IL-4 and IL-452 mRNA levels using a 
real-time quantitative assay, found that patients with PTB have significantly greater 
expression of mRNA encoding both IL-4 and IL-452 in whole blood (~ 7 fold and 
-37 fold respectively) and lung lavage (-12 fold and -  26 fold, respectively). 
Furthermore, pre-treatment radiographic scores correlated with the IL-4/IFN-y ratio. 
After short course chemotherapy IL-4 mRNA levels did not decline significantly
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whilst IL-482 mRNA significantly increased. The implication of these findings and 
their relationship to other studies is further discussed.
5.4.1. Discordant IL-4 data and findings in relation to other studies
On the one hand, subjects with TB close to the equator may have levels of IL-4 high 
enough to be detected in the serum by ELISA (discussed later). On the other hand, 
studies conducted in temperate latitudes require stimulation protocols or PCR to 
detect IL-4 in donors with active TB [17-19, 186, 345]. Indeed, IL-4 is undetectable 
by ELISA in Dutch patients with TB [32]. Nevertheless, study results have been 
discordant due to technical factors related to IL-4 (summarised earlier in table 2.1) 
and failure to distinguish between IL-4 and IL-452, which make most studies relating 
to IL-4 in TB un-interpretable. Only one study examined IL-452 mRNA levels in 
active TB [17] but interpretation is constrained by the technical limitations of earlier 
PCR techniques (summarised earlier in table 2.2). To address these problems a probe 
specific real-time PCR assay was designed (chapter 2) to measure mRNA levels in 
index cases of tuberculosis. The assay is able to distinguish between IL-4 and IL-482 
mRNA and circumvents the problems of imprecise quantification, poor 
reproducibility, low dynamic range of earlier PCR assays. Furthermore, to ensure the 
detection of small inter-group differences whilst avoiding artefactual changes a 
validated reference was used to normalise mRNA levels (44) and only quality 
controlled RNA templates were used. Indeed, probe specific assays have been shown 
to give better resolution when low copy number genes of interest are studied (46). As 
IL-4 is expressed at low levels that approach the detection limit of the assay, it is 
essential that the above considerations are adhered to if meaningful results are to be 
obtained. This is particularly relevant to the detection of IL-4 in unstimulated cells, a 
strategy used in this study as pre-stimulation protocols are Thl biased and rapidly 
turns off IL-4 [35].
The considerations, discussed in the previous paragraph, explain the failure of earlier 
studies to detect IL-4 [27, 28, 30, 355]. However more recent studies show that IL-4 
is detected in antigen-stimulated cells by ELISPOT [18] and flow cytometry [19] and
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in unstimulated cells by RT-PCR [17]. Nevertheless, 2 studies from the USA [27, 28] 
and 2 from developing countries (Mexico and China) [30, 355] failed to detect IL-4 
using RT-PCR. The failure to detect IL-4 may be due to delays in fixing the RNA 
profiles. Indeed, Doherty and co-workers showed that delays of as little as 2 hours 
may substantially reduce IL-4 detection by ELISPOT and RT-PCR [411]. This may 
be particularly relevant in Thl biased in vitro cultures where IL-4 is rapidly down- 
regulated by IFN-y [27, 28] and the inevitable delays experienced when attempting to 
fix the mRNA profiles in excised lymph nodes [27]. In contrast to the findings of Lin 
and colleagues [27], another study detected IL-4 mRNA in tuberculous lymph nodes 
[464]. Furthermore, in the studies that failed to detect IL-4 details about RNA 
template quality is not provided and the use of an unvalidated reference (p-actin or 
GAPDH in all the studies) could have easily obscured significant inter-group 
differences (proven and discussed in chapter 2). Finally, none of these studies 
discriminated between the agonist, IL-4, and the antagonist, IL-452.
In contrast to studies conducted in temperate countries, those performed within 30 
degrees of the equator (except in alpine climates e.g. Addis Ababa) find IL-4 levels 
that are high enough to be detected in the serum by immunoassays (these studies are 
listed in table 1.6). This phenomenon may be related to the adjuvant activity of 
environmental saprophytes or helminths; this is reflected in Th2 responses to BCG in 
children whose mothers are exposed to parasites [405]. That this effect is purely 
helminth related is unlikely as matched control subjects from the same areas do not 
have raised IL-4 levels and upregulated IL-4 responses in TB patients are seen in both 
Africa and Europe. Nevertheless, epidemiological evidence showing an association 
between helminth infection and TB is sparse. Elias and co-workers showed an 
association between active TB and helminth infection in Ethiopia [465] but there were 
confounding variables that predisposed to both infections and it is uncertain whether 
helminth infestation was cause or effect. A prospective study of otherwise healthy 
HIV+ subjects in Africa indicates that eosinophilia, presumably helminth induced, is 
predictive for progression to active TB [466]. On the other hand, rates of TB are not 
dissimilar in different parts of Ethiopia where helminth infection is endemic or 
uncommon, respectively (Dr TM Doherty, SSI, personal communication). Taken 
together, these data suggest that the high IL-4 levels seen in developing countries are
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TB-specific but helminthiasis may simultaneously potentiate Th2 responses by their 
adjuvant activity. The high background cytokine responses primed by environmental 
mycobacteria and helminths may also explain the failure of BCG in developing 
countries and has implications for laboratory testing of vaccine candidates in murine 
models (discussed in detail in chapter 1, section 1.7.5.2).
5.4.2. IL-4 findings in BAL
In the present study there was a significant ~ 1.5 log increase in IL-4 mRNA 
expression in TB compared to control donors but IL-4 was largely undetectable in 
BAL fluid when ELISA was used. There are limited data on IL-4 levels in the BAL 
fluid of TB patients. Three reports documented raised IL-4 levels [24, 265, 356] 
whilst IL-4 was undetectable in four studies [264, 357-359]. The latter studies used 
either immunocytochemistry or in situ hybridisation (relatively insensitive for IL-4) 
[358, 359], or ELISPOT in PPD stimulated cells [264], or ELISA of lavage fluid 
[357]. In fact, ELISA was also unhelpful in the present study because of the 
substantial dilutional effect in BAL (even with 10 fold concentration) and the lack of 
a satisfactory normalisation strategy. BAL produces a 150 to 300-fold dilution of 
cytokines [44, 467], resulting in stochastic detection in body fluids. Further 
concentration of BAL fluid is constrained by technical factors and the very small 
volumes generated by concentration (< 300pl). The dilutional effect has been 
documented in other studies using ELISA to measure cytokine levels in BAL fluid 
[24, 44, 264, 468]. In pulmonary sarcoidosis [469] and systemic sclerosis [44] IFN-y 
is undetectable by ELISA but found to be substantially elevated when RT-PCR is 
used. Consequently, real-time PCR is useful to study IL-4 and IFN-y cytokine profiles 
in BAL fluid. ELISPOT is at least one log more sensitive than ELISA [470, 471] but 
may still fail to detect IL-4, which is physiologically active at concentrations 3 logs 
below IFN-y [413, 414]. Finally, cytokine detection is influenced by the 
characteristics of the segment that is lavaged (presence and degree of inflammation 
and immunopathology) [468].
In this study there were no detectable differences in the BAL or whole blood IL-4 
mRNA levels in subjects with cavitary versus non-cavitary TB. By contrast,
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Mazzarella and co-workers, using FACs and ICCS after PMA stimulation, 
demonstrated that BAL CD4+ T cell IL-4 expression was raised in cavitary compared 
to non-cavitary disease [356]. The use of unstimulated cells in the current study, 
different degrees of lung involvement, and detection methods used may account for 
the different Findings. Nevertheless, both the current study and two previous reports 
[17, 19] showed that IL-4 expression in peripheral mononuclear cells correlates with 
cavitation or the degree of radiographic pulmonary involvement. The data presented 
in this chapter show that the Th2/ Thl (IL-4/ IFN-y) ratio in peripheral blood 
correlated with radiological disease extent (a composite score of consolidation, 
reticular infiltrates and cavitation). Furthermore, another surrogate marker of severity, 
the total BAL leucocyte count (highest in those with greater radiological disease 
extent), correlated with the IL-4/IFN-y ratio. Collectively, these data support the 
contention that IL-4 facilitates human tissue necrosis and immunopathology, as it 
does in murine models of TB [14, 16].
5.4.3. Comparison of IL-4 vs IL-462 expression in BAL and blood
The findings of this study indicate differential cytokine balance in the different body 
compartments. In subjects with TB the median IFN-y mRNA level was more than 200 
fold higher in alveolar lavage cells than in whole blood. By contrast, the median IL-4 
and IL-462 mRNA levels were similar in both the body compartments. However, the 
relationship of IL-4 and IL-462 mRNA levels to each other (discussed later) and to 
the different body compartments was heterogeneous. This may reflect the degree of 
lung inflammation or disease chronicity in different individuals. When there is 
inflammation of the alveolus or pulmonary interstitial tissue it is logical to expect 
some spill over of inflammatory cells and cytokines into the blood compartment. 
However, the cytokine-specific expression in one body compartment relative to 
another is poorly understood. It is not size dependent because large molecules like 
insulin rapidly translocate from the lung into the blood [472]. Furthermore, 
chemokines like MIP 1-a, but not IL-6 , when they are readily detected in the lung of 
septic patients are poorly detectable in serum [473]. Consequently, cytokine and 
compartment-specific disparity has to be taken into account to avoid misinterpretation 
of TB-specific immunological data.
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IL-452 mRNA levels have not previously been reported in alveolar lavage cells in TB. 
Atamas and colleagues found that CD8 + alveolar lavage T cells of scleroderma 
patients, with pulmonary fibrosis and rapidly declining lung function, expressed a 
mixed IFN-y / IL-4/ IL-452 profile [44]. Furthermore, whilst IL-452 is antagonistic to 
IL-4 in lymphocytes cultures [314], it is an agonist like IL-4, able to stimulate 
collagen production in human lung fibroblasts [44]. Although IL-452 was upregulated 
in BAL cells in the current study there was no correlation with pre-treatment 
radiological disease extent (a composite score of lung fibrosis, cavitation and 
consolidation). Nevertheless, in the early stage of TB there maybe little fibrosis and it 
would be enlightening to examine the relationship between 6  month radiological 
scores and the initial IL-452 mRNA levels. These data are currently being 
accumulated as part of a separate study.
5.4.4. The IL-4/ IL-452 ratio
The precise function of IL-452 remains unknown. However, the available evidence 
indicates that it serves a regulatory mRNA function (discussed in chapter 4), it acts as 
a natural antagonist in T cells, B cells and monocytes [314], but is an agonist on 
fibroblasts [44]. Interestingly, preliminary studies indicate that IL-452 mRNA levels 
are elevated in African subjects with LTBI (as defined by ESAT- 6  responses) who 
remained healthy in the short term [360, 361]. Furthermore, a study of healthcare 
workers in Portugal has revealed that individuals whose peripheral blood 
mononuclear cells synthesised IL-4 (IL-452 expression was not assessed) in response 
to M. tuberculosis in vitro went on to develop overt TB within 2-^  years [15]. 
Collectively these data raise the question of whether the ratio between the agonist (IL- 
4) and the antagonist (IL-452) is a correlate of protective immunity. Indeed, the 
significantly decreased IL-4/ IL-452 ratio with anti-TB treatment lends support to this 
hypothesis. However, against this hypothesis, both IL-4 and IL-452 mRNA levels 
were upregulated in TB, and the ratio of the agonist to the antagonist (IL-4/IL-452) 
was similar in patients and controls and in the different body compartments. 
Nevertheless, it is possible that in the crucial early stages of disease the ratio will be 
different and favour the agonist, IL-4, thereby facilitating disease progression. Indeed, 
in BALB/c mice the ratio of IL-4/IL-452 changed during the different phases (early
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and late progressive infection) of disease (R Hemado-Pandez, personal 
communication, study in progress). Longitudinal studies will be required to address 
whether the balance of the agonist (IL-4) and potential antagonist (IL-452) might be 
relevant to disease progression. Crucial unanswered questions are whether IL-452 is 
present only as mRNA or also as active protein, and whether the ratio portends 
disease progression.
5.4.5. High IFN-y mRNA levels in BAL compared to whole blood
Over the last decade many reports, using peripheral blood because of the difficulty in 
obtaining lung specimens, indicated that TB patients compared to healthy volunteers 
have relatively poor IFN-y or proliferative responses in peripheral blood [29, 203] and 
recovery of the IFN-y response with treatment [77, 474]. This created the notion that 
vaccines augmenting antigen specific IFN-y responses therapeutically or 
prophylactically could prevent or inhibit disease progression. However, our data 
demonstrate that at the site of disease, the lungs, there are very high IFN-y mRNA 
levels (~ 2.5 log increase in IFN-y mRNA in alveolar lavage cells of TB patients 
compared to controls but no difference in whole blood). There are only a handful of 
studies that have used lung cells but their findings are similar. High IFN-y levels are 
also found in induced sputum [7], BAL [356] and by RT-PCR in alveolar cells from 
subjects with active TB [475]. In one of the few studies that compared peripheral 
blood and lung profiles simultaneously, Schwander and colleagues found that 
mycobacterial antigen-induced proliferative responses and IFN-y producing cells were 
reduced in PBMCs but enhanced in the lung [264].
Collectively, our data and those of other investigators suggest that the idea of a sub- 
optimal Thl response in TB is probably incorrect. Of course, a certain minimum 
requirement for IFN-y, IL-12 and TNF-a are crucial for protection [114, 153, 343] but 
further enhancement of Thl responses are unlikely to be helpful. In addition to the 
prominence of Thl cytokines demonstrated here, three other lines of evidence support 
this view. Firstly, close examination of the tissues in pathological studies of LTBI 
show minimal cellular infiltration suggesting that little immunological activity is 
required to maintain this control [51, 137]. Secondly, studies of genetically modified
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strains of TB with mutations within transcription factors or associated components 
(SigH, rpoV and WhiB3) show that relatively few Thl cells are sufficient to control 
proliferation, and that the remaining 90% facilitate immunopathology [145, 146]. 
Thirdly, BCG, a predominantly Thl-inducing vaccine, has poor protective efficacy in 
countries close to the equator [342]. Enhancing the Thl response of BCG or sub-unit 
vaccines does not provide any additional protective efficacy [476-478], in fact, it may 
exacerbate immunopathology [149]. This was demonstrated a century ago by Robert 
Koch who showed that tuberculous animals [50] and humans [479] mount a necrotic 
reaction to components of M. tuberculosis. Moreover, animals in which the “The 
Koch Phenomenon” could be elicited were more susceptible to subsequent challenge 
than were un-immunised controls [480]. Taken together these data suggest that M. 
tuberculosis, rather than down regulating IFN-y, actually enhances the Thl response 
but at the same time corrupts it, so that it is inefficient at killing bacteria. This is 
logical as it promotes immunopathology and the continued propagation of M. 
tuberculosis.
The presence of significantly elevated IL-4 mRNA levels in BAL fluid in the 
presence of high IFN-y mRNA levels indicates a mixed Thl/Th2 profile. At this 
point, it is appropriate to clarify that the Th2 hypothesis (IL-4 is deleterious in TB) 
does not imply a dominant Th2 mediated down-regulation of the Thl response, but its 
subversion so that there is disease progression and immunopathology. Indeed, IL-4- 
mediated immunopathology in mixed T hl/ Th2 lesions have been demonstrated in 
murine models of TB [14] and in other infectious disease models [369, 391, 481]. 
These murine data suggest that TNF-a is toxic in Thl-dominant lesions when there is 
a superimposed Th2 profile. The Th2/Thl profiles observed in the current study and 
the correlation of the IL-4/IFN-y ratio with radiological disease severity suggests that 
a similar mechanism could be operating in humans. Nevertheless, other murine 
models (IL-4 or STAT- 6  knock-outs) do not support this notion [366, 367]. The latter 
studies showed a lack of susceptibility to M. tuberculosis in IL-4 gene knockout 
strains C57B1 x 129SvJ [366] and C57B1 [367] mice, in which IL-4 secretion is not 
characteristic of the infection. In other words these strains of mice, unlike the more 
relevant BALB/c model, are poor producers of IL-4 to begin with and do not mimic 
the human situation. Consequently, IL-4 gene disruption may not have had
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appreciable effects on measures of susceptibility. Indeed, Huygen and co-workers 
showed that the type of immune response (Thl vs mixed Thl / Th2) to mycobacterial 
antigens is dependent of the strain of mice (C57BL vs BALB/c) [482].
5.4.6. Changes in IFN-y and IL-4 mRNA levels with anti-TB treatment
This study found that whole blood IFN-y mRNA levels were similar to control 
subjects at diagnosis and increased significantly after 6  months of anti-TB treatment. 
Relatively few studies have analysed cytokine levels or responses during the course of 
anti-TB treatment. However, similar to the findings presented in this study, Torres 
and co-workers found that PBMC IFN-y mRNA levels (and antigen induced 
proliferation) were enhanced by the end of treatment [30]. By contrast, at the site of 
disease, IFN-y levels in induced sputum decrease with progressive treatment [7]. 
Collectively, these data suggest that cytokine levels during the course of treatment are 
also compartment-specific. In the current study it would have been interesting to 
investigate BAL IFN-y mRNA levels post-treatment but this was not possible due to 
ethical constraints. A few studies have also investigated antigen-specific IFN-y 
responses of PBMCs during the course of anti-TB treatment. IFN-y responses to the 
30kDa antigen [30], PPD [474] and other specific antigens [483] were enhanced after 
treatment. Similarly, four studies found that ESAT - 6  specific IFN-y responses 
increased during the course of treatment. By contrast, Pathan and Carrara [484, 485] 
and my own unpublished observations have indicated that ESAT-6 -specific responses 
declined during treatment. Two conclusions are evident from these discordant 
findings. Firstly, responses (increase or decline) during the course of treatment may 
be antigen specific. Secondly, for a particular antigen the results may depend on the 
formulation used (protein vs peptides), the detection method (ELISA vs ELISPOT) 
and the incubation time (probably reflects effector vs memory responses; discussed in 
detail in chapter 1, section 1.3).
After short course chemotherapy the median IL-4 mRNA level, though lower, was not 
significantly different compared to pre-treatment levels (in five patients the levels 
remained the same or increased and in 5 patients the levels declined) but significantly 
higher than in control subjects. This is similar to the findings of Seah et al, who found 
that IL-4 mRNA levels were not significantly different in whole blood after 3 months
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of anti-TB treatment [349]. The failure of IL-4 to decline substantially despite 
clinical, radiological, and immunological improvement (LFN-y levels increased 
significantly in all patients) argues against IL-4 being a non-specific inflammatory 
bystander response. Rather, if IL-4 antagonises mycobactericidal macrophage activity 
it may explain why even after several months of treatment, when bacterial load is 
extremely low, the immune response still cannot contain the disease, and treatment 
must continue. Alternatively, IL-4 mRNA levels may take considerably longer to 
decline; it is unclear if they do.
Nevertheless, IL-452 levels, not previously studied in response to chemotherapy, 
increased significantly during the course of treatment. Given the pattern of IL-4 
treatment-associated change, this increase in IL-452 is unlikely to be due to a reversal 
of the peripheral immuno-suppressive effect of TB. These findings are relevant to the 
study of surrogate immunological and serological markers denoting successful 
treatment and cure of TB [486] and are a priority for the evaluation of new therapeutic 
vaccines and anti-TB drugs. There were two patients in whom IL-452 levels did not 
increase at the time of assay; both had disseminated disease, and it is possible that the 
rise in IL-452 was delayed in those patients. Further studies are required to clarify the 
role of IL-452 in TB infection, longitudinal changes during active disease and 
whether IL-452 is a correlate of protective immunity. IL-452 illustrates the underlying 
complexity of the Th2 response in TB and this may explain the difficulty in 
categorising TB into the classical Thl/Th2 paradigm.
5.4.7. IL-4 mRNA levels and biological relevance
The real-time PCR data in this study reflect steady state mRNA levels only. They 
convey no information about mRNA transcription rates, mRNA stability, or protein 
levels. Nevertheless, PCR was chosen as it is the only technique able to discriminate 
between IL-4 and IL-462, and that is sensitive enough to detect IL-4 in unstimulated 
cells (these considerations and comparison with other techniques have been discussed 
in detail in chapter 2, section 2.1.1). Measurement of IL-4 protein levels by ELISA 
were attempted in plasma, BAL fluid, culture supernatants (chapter 7) and by 
ELISPOT in cell sub-populations (outlined in chapter 6 ). However, detection of IL-4
160
was limited by the poor assay sensitivity, rapid cellular uptake, binding to sIL-4R and 
the dilutional effect in BAL fluid. Moreover, in samples where IL-4 was detected it 
remains unclear whether the antibodies used bind IL-4, IL-452, or both proteins. 
Despite these limitations the correlation of the IL-4/IFN-y ratio with radiological 
disease extent suggest that these results are biologically meaningful. Other 
investigators have also shown a correlation between IL-4 and radiological patterns 
[17, 19]. The raised IL-4 mRNA levels are also validated by the significantly elevated 
levels of plasma and BAL sCD30, which also correlated with radiological disease 
extent (despite the very high IFN-y level in the lungs). Although expression of 
sCD30 is not confined to Th2 cells there are quantitative differences in cellular 
expression such that sCD30 correlates well with Th2-based markers in asthma, 
seasonal allergy and atopic dermatitis (reviewed in [333]). The functional relationship 
between sCD30 and membrane CD30 is uncertain. A putative mechanism by which 
IL-4 mediated expression of CD30 modulates immune responses is by promoting 
TNF mediated lymphocyte apoptosis. which may facilitate immunopathology [26]. 
Recent work has suggested that CD30 is expressed on CD25+ regulatory T cells that 
can suppress the activity of CD8 + T cells by causing them to undergo apoptosis [487]. 
A regulatory role that decreases T cell function is compatible with the data presented 
here.
5.4.8. Selection of patients and controls
As immunological profiles may vary with the disease site only patients with culture 
positive pulmonary tuberculosis were recruited. To avoid treatment related effects, 
whilst at the same time allowing practical collection of samples, all specimens were 
taken before or within the first 2 weeks of anti-TB treatment. Nevertheless, it is 
difficult to control for inter-individual variations in disease chronicity at the time of 
diagnosis and differing bacterial loads.
To determine the significance of biological markers in active TB (correlate of 
susceptibility or epiphenomenon) the ideal comparator group is one, which is 
‘immune’ to M. tuberculosis and free of infection (it is now clear that LTBI is not 
immunologically silent [75]). Until recently, the TST provided the only way to select 
out those who had been exposed but remained healthy. However, this TST based
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distinction was ‘muddy’ because it could not discriminate between subjects with false 
positive reactions due to BCG and environmental mycobacteria, and those with LTBI, 
some of whom may progress to TB over the short term. Ideally, it would have been 
instructive to study a control group with LTBI simultaneously with one that was 
exposed but not latently infected. However, in the present study subjects with LTBI 
were excluded due to resource constraints and as they were already being studied as a 
cohort in a related study (VACSIS/ VACSEL). Furthermore, we viewed exposed but 
not latently infected controls as a group ‘resistenf to TB infection, and as such 
constituted an appropriate control group compared to ‘susceptible’ subjects that 
developed progressive disease. Samples from subjects with LTBI and donors with 
other respiratory diseases (including sarcoidosis) have been stored for future analysis.
5.5. Conclusion
The data presented here, using an accurate real-time quantitative assay, indicate that 
IL-4 and IL-482 mRNA levels are significantly elevated in donors with TB, compared 
to healthy controls, both in whole blood and the site of disease. These data add to the 
accumulating evidence that a small but significant Th2-like response is indeed present 
in tuberculosis. The biological significance of these results is supported by the 
analogous expression of sCD30 and correlation with immunopathology (radiological 
scores). These findings are compatible with a hypothesis that IL-4 may subvert 
protective host mechanisms. The patterns of Th2 cytokine gene expression with anti- 
TB treatment suggest that IL-4 is not an inflammatory epiphenomenon; the cause- 
effect relationship is explored further in chapter 7. The usefulness of IL-482 or the IL- 
482/IL-4 ratio as longitudinal markers of disease activity deserve further 
investigation. The differential expression of IFN-y in blood and BAL indicate that 
cytokine profiles may be compartment-specific and that tuberculosis progresses 
despite the prominence of a supposedly protective Thl response.
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6.1. Introduction
The previous chapter outlined that IL-4 and IL-462 mRNA levels are significantly 
elevated in active pulmonary tuberculosis and the IL-4/IFN-y ratio correlates with 
pre-treatment radiological disease scores (chapter 5). However, there are few data 
about the cell sub-populations in whole blood expressing IL-4. Moreover, there are no 
data regarding the T cell sub-types that express IL-462 in human tuberculosis.
There are few data on the contribution of cell types other than lymphocytes to TB- 
associated immunopathology. Murine and human pathological studies indicate that 
neutrophils may be important for granuloma formation and tissue necrosis [111, 123]. 
BAL neutrophil counts are significantly higher when obtained from lung segments 
affected by cavitation [356, 357] and IL-4 is associated with immunopathology in 
human [17, 19, 356] and animal models of TB [14, 16]. However, there are no human 
data on the contribution of non-T cells to IL-4 production in TB.
To gain further insight into the nature of the IL-4 response in human tuberculosis IL-4 
and IL-462 mRNA expression was investigated by real-time RT-PCR and ELISPOT 
in sub-populations of peripheral blood (PBMCs, total T cells, CD4 and CD 8 + T cells 
and a population depleted of T cells) in ten patients with PTB and ten controls that 
were not latently infected. The relevant laboratory and experimental methods have 
been outlined in chapter 3.
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6.2. Results
6.2.1. Purity of separated cell fractions
Mean cell purities of the relative whole blood fractions were > 95%, 99%, 93% and 
90% for T, total non-T, CD4+ and CD 8 + fractions, respectively. Flow cytometry dot 
plots of the CD3+ T-cells and non-T cell fractions are shown in figure 6.1.
6.2.2. T and total non-T sub-populations making mRNA encoding IL-4 and IL-462
The IL-4 and IL-462 mRNA levels in CD3+ T cell fractions were significantly higher 
in PTB than in controls (p=0.01 for IL-4 and p= 0.02 for IL-462, figure 6.2 A and B, 
respectively; median and 25th-75th percentile mRNA levels for all cytokines are 
shown in table 6.1). Patients with PTB had higher absolute levels of IL-4 and IL-462 
mRNA in both T cells (IL-4 ~ 25 fold and IL-462 ~ 100 fold greater) and non-T cells 
(IL-4 ~ 6  fold and IL-462 -100 fold greater). For a given production by non-T cells, 
the T cells of TB patients produced significantly more IL-4 than controls (p= 0.02, 
figure 6.3); T cells contained 25% of the IL-4 mRNA in TB.
By contrast, in healthy exposed volunteers both IL-4 and IL-462 were produced 
mainly by non-T cells compared to T cells (p<0.05, figure 6.2 A and B); 93% of IL-4 
mRNA in control patients was made by non T cells. Furthermore, as the T-cell 
fraction was ~ 95% pure it is possible that the expression of IL-4 by T-cells of 
controls is even lower.
6.2.3. CD4 and CD8  sub-populations making mRNA encoding IL-4 and IL-462
The increase in IL-4 mRNA in T cells from patients with PTB was present both in 
CD4+ T cells (IL-4 mRNA ~ 7 fold greater in TB) and CD8 + T cells (IL-4 mRNA ~ 
10 fold greater in TB). However, the increase in IL-462 mRNA in T cells from TB 
patients was confined to CD4 T cells (~ 500 fold more than in controls). There was no 
difference in IL-462 expression in the CD 8 + T cells from PTB patients and controls.
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6.2.4. The T h2/T hl and IL-4/IL-452 ratio
The Th2/Thl (IL-4/IFN-y) ratio was significantly higher in the T cells of TB patients 
compared to control subjects (-0.7 vs -10.1; p = 0.02). Furthermore, in TB there was a 
trend in patients with a higher IL-4/IFN-y ratio having greater radiological disease 
extent scores (p = 0.06; figure 6.4). In TB and control subjects the ratio of IL-4 to 
IL-452 was not significantly different in the various cell sub-populations.
6.2.5. ELISPOT assays
ELISPOT assays were performed to confirm the production of IL-4 and/or IL-452 
protein. It is not known whether the ELISPOT assay detects one or both of these 
cytokines. Significant numbers of IL-4/IL-452 spots were detected in 90% of PBMC, 
60% of non-T cells, 92% of T-cells, 92% of CD4+ T cells and 92% of CD8 + T cells 
where either cytokine was detectable by PCR. In the PBMC fraction of one TB 
patient IL-4 was detected by ELISPOT but not by RT-PCR. However all other cell 
fractions of this patient had IL-4/ IL-452 detectable by both methods. There was no 
correlation between the magnitudes of IL-4/IL-452 responses between the two 
methods, but these findings confirm that IL-4 mRNA correlates with production of 
active protein.
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Figure 6.1 A and B. Flow cytometry dot plots of the CD3+ T-cells (6.1 A) and non-T cell 
fractions (6.1 B) indicating purities of 97% and 99%, respectively (cells were stained with 
anti CD8 -PE and anti CD3-PercP antibodies, respectively)
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Table 6.1. Cell sub-populations of whole blood and expression of mRNA for IL-4, IL-452 
and IFN-y. All values represent comparisons (median; 25th-75th percentiles) between TB and 
controls.
Cytokine Sub­
population
TB vs control median; interquartile 
range mRNA copy number
P value
IL-4 mRNA PBMC 480; 162-4867 vs 7; 1-56 P< 0.05
T cell 280; 17-1484 vs 11; 1-26 P= 0.01
total non- T 875; 336-4016 vs 140; 4-314 P= 0.005
CD4 616; 37-6299 vs 11; 1-248 P= 0.04
CD8 146; 6-1372 vs 14; 1-79 P< 0.05
IL-452 T cell 115; 1-629 vs 1; 1-2 P= 0.02
total non- T 874; 360-1340 vs 9; 1-82 P= 0.06
CD4 523; 1-848 vs 1;1-18 P= 0.06
IFN-y PBMC 1260; 1123-13970 vs 285; 108-1361 P= 0.04
T cell 1402; 893-3912 vs 315; 85-380 P= 0.002
total non- T 1670; 1049-5108 vs 241; 100-811 P= 0.04
CD4 1121 ;326-3212 vs 194; 118-286 P= 0.002
CD8 1271; 643-9291 vs 430; 130-1067 P= 0.04
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Figure 6.2 A and B. IL-4 (6.2 A) and IL-452 (6.2 B) mRNA levels in CD3+ T cell and total 
non-T cell fractions. IL-4 and IL-452 levels were significantly higher in the T  cells and non-T 
cells o f PTB vs controls.
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6.3. Discussion
6.3.1. IL-4 mRNA levels and their significance
As already outlined in chapter 1 and chapter 5, Th2 cytokines are causally associated 
with disease progression and immunopathology in animal models [14, 16]. However, 
this relationship is more difficult to prove in humans. In chapter 5, the change in 
mRNA levels with chemotherapy implying that IL-4 is less likely to be a 
inflammatory bystander effect, was discussed. The data presented here demonstrate 
that the production of IL-4 and IL-452 is predominantly T cell mediated (~ 25-fold 
increase) suggesting that this is a true antigen driven response. Previously described 
phenomena, like TB-specific IgE [351] and antigen driven T cell clones producing IL- 
4, support this contention [348]. Furthermore, evidence suggests that activation of 
CD8 + T cells during polyclonal activation is antigen specific with minimal bystander 
activation of T cells [488]. The biological relevance of these results and association 
between pathology and IL-4 expression is supported by the correlation of the T cell 
Th2/Thl (IL-4/IFN-y) ratio with the extent of radiological disease.
Our findings concur with those of van Crevel, who found that CD8 + T cells make IL- 
4 in TB and this correlates with cavitation [19]. Other investigators using flow 
cytometry and ICCS in TB antigen stimulated lymphocytes also found raised IL-4 in 
CD 8 + [29] and CD4+ T cells [21, 347]. However, two older studies (1995 and 1997) 
failed to find raised IL-4 mRNA in stimulated CD4 T cells [28, 355]. The likely 
reasons and limitation of these studies have already been discussed (chapter 5, section
5.4.1). Nonetheless, the reagents used in these studies do not distinguish between 
agonist and the antagonist raising the likelihood that the cells making IL-4 in these 
reports might be really making IL-452.
Although T cells produce significant amounts of IL-4 and IL-452 in PTB, it is 
unclear whether these are from effector or Th2 derived regulatory T cells or both. 
Although not conclusive, the increasing whole blood and T cell IL-4 response seen 
with more extensive pulmonary involvement in this study and others (22;33) argues
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against regulatory T-cells being the primary source of IL-4.
6.3.2. IL-452 mRNA levels
Whilst IL-4 gene expression has been demonstrated in CD4+ and CD8 + T-cells, the 
production of IL-482 has not previously been taken into account. Moreover, the 
antibodies used for flow cytometric studies do not distinguish between the agonist and 
the antagonist. The current data show that, compared to controls, IL-482 mRNA 
levels are significantly increased in the T cells of patient with TB. However, in both 
patients and controls there was no difference in the IL-4/IL-482 ratio in CD4+ or 
CD8 + T cells. Does this imply, unlike the data generated in latently infected contacts, 
that the balance between the agonist (IL-4) and antagonist (IL-482) is irrelevant to 
disease progression and immunopathology? The IL-4/IL-482 ratio only reflects an ex- 
vivo ‘snapshot’ and does not reflect profiles in the earliest stages of disease. Indeed, 
Ordway and colleagues found that asymptomatic subjects with pre-existing IL-4 
responses had a high rate of progression to active disease [15]. Nevertheless, how 
much of this ‘IL-4’ was IL-482 is unclear [15]. It is intriguing to speculate that the IL- 
4/IL-482 ratio changes with disease progression and may represent a potential 
correlate of susceptibility and progression. Although it was not logistically possible, it 
would have been instructive to repeat the cell subpopulation experiments at the end of 
anti-TB treatment.
When TB and control patients were compared the IL-482 mRNA levels were 
upregulated in CD4+ T cells (~ 500 fold) but not significantly different in CD8 + T 
cells. By contrast, Atamas and colleagues found that CD8 + alveolar lavage cells were 
the dominant cell type expressing IL-4 in scleroderma patients with rapidly 
progressive pulmonary fibrosis [44]. Interestingly, in several patients CD8 + T cells 
expressed both IL-4 and IL-482 mRNA, though the latter did not correlate with lung 
function or the degree of alveolitis. IL-482 is antagonistic to IL-4 with regard to 
lymphocyte function [314, 324], but it is an agonist on fibroblasts and drives collagen 
production [44]. Whether IL-482 antagonises IL-4 and reduces inflammation, or 
agonises with IL-4 to drive lung immunopathology, remains unclear and needs further 
investigation.
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6.3.3. Expression o f Th2 cytokines in the total non-T cell fraction
Notably, in TB patients the total non-T cell fraction (granulocytes and NK cells) also 
produced significantly more IL-4 than control subjects (here > 90 % of IL-4 mRNA 
was produced by the non-T cell fraction). To what extent granulocytes facilitate 
disease progression and Th2 production in TB is unclear. It was recently 
demonstrated that eosinophil infiltration and degranulation occurs in the earliest 
necrotic lesions of guinea pig tuberculosis (about 5 to 10 days) [489] and eosinophils 
have also been demonstrated in human tuberculosis lesions [490, 491]. Eosinophils 
facilitate antibody-dependent cellular cytotoxicity, chemokine receptor expression, 
cellular influx into the respiratory tract, and interact closely with Th2 CD4+ T cells in 
mediating cytokine production [492]. Similarly, neutrophils may also facilitate tissue 
necrosis [111, 123, 124] challenging the traditional dogma that CMI-mediated 
macrophage destruction underpins caseous necrosis (discussed in detail in section
1.4.2). Neutrophils have also been implicated in early protective immunity to 
tuberculosis [493]. Other cell sub-types like tissue mast cells, which produce IL-4, 
can induce immunological responses by directly interacting with M. tuberculosis 
[494]. Nevertheless, the significance of mast cells and granulocytes, their role in Th2 
cytokine production, and how they interact with T cells remains unclear, and requires 
further investigation.
6.3.4. IL-4 detection by ELISPOT compared to real-time PCR
The lack of correlation between the magnitude of IL-4 detected by ELISPOT and 
real-time PCR is consistent with other reports [34] and may reflect the different 
sensitivities of the assays, the fact that the ELISPOT may have measured both IL-4 
and IL-462 simultaneously, and dichotomy between mRNA and protein levels. 
Furthermore, ELISPOT detects the number of cells secreting the cytokine, not the 
total quantity of cytokine produced. Although ELISPOT may detect as little a one cell 
per million PBMCs pre-stimulation is usually required (discussed in chapter 5) and it 
may not be as sensitive as real-time PCR where mRNA is amplified ~ a million fold. 
Nevertheless, it has been demonstrated in this study that IL-4 (and/ or possibly IL- 
452) is produced at protein level. Moreover, the demonstrated association between the
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T cell cytokine profile and radiologically detected pathology suggests that the results 
are biologically meaningful.
6.4. Conclusion
IL-4 and IL-462 mRNA levels have not previously been investigated in T compared 
to non-T cell sub-populations in whole blood of donors with tuberculosis. 
Furthermore, the type of ‘TL-4” expressed in these cells required clarification. The 
predominant T cell production of IL-4 suggests that it is a true antigen driven 
response rather than bystander production by other cell types. Nevertheless, the role 
of other effector cell types (Treg, NK T cells, y6  T cells) in producing IL-4 require 
further clarification. The production of IL-4 by non-T cells requires further 
investigation particularly in relation to immunopathology. Finally, the role of IL-462 
and the significance of the IL-4/IL-462 ratio in tipping the balance in favour of 
disease progression needs further investigation.
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CHAPTER 7: IL-4 AND IL-462 mRNA LEVELS IN TB ANTIGEN DRIVEN 
CULTURES.
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7.1. Introduction
Studies investigating cytokine profiles, including IL-4, generated by antigen driven 
cultures from TB patients are limited and are discussed later in relation to the data 
presented in this chapter. In TB both IL-4 and IL-462 increase in parallel (chapter 5) 
compared to bronchial asthma where IL-4 is the dominant form, being expressed at 
1000 fold greater than IL-462 [331]. Findings in contacts with LTBI and the fact that 
IL-4 and IL-462 are physiologically antagonistic raises the possibility that the balance 
between the two may determine susceptibility and progression in TB. If this 
hypothesis is correct then it would have implications for vaccine design and 
developing surrogate markers for protective immunity. However, the relationship 
between IL-4 and IL-462 in antigen driven cultures from TB patients has not 
previously been investigated. To study this question, the PBMCs of eight patients 
with PTB (median age 45 years; 5 Black Africans and 3 Caucasians) and four healthy 
volunteers (median age 32; 1 Afro-Caribbean and 3 Caucasians) were incubated with 
sonicated TB antigen for several days. IL-4 and IL-462 mRNA levels were measured 
by real-time PCR; more detailed methods relevant to this chapter are outlined in 
chapter 3.
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7.2. Results
7.2.1. IL-4 and IL-452 expression in PBMC culture
Sonicated TB antigen preferentially induced the expression of IL-4 rather than IL-482 
when PBMCs from 8  TB patients were stimulated over 7 days (Figure 7.1 A and B). 
When cells stimulated with TB sonicate were harvested on days 1 or 2, expression of 
IL-4 was increased compared to baseline (p= 0.02), and compared to unstimulated 
wells (p= 0.0006), and to wells stimulated with M. vaccae sonicate (p= 0.03).
When harvested on days 3 or 4 expression of IL-4 was increased compared to 
unstimulated wells (p= 0.02). Median (range) mRNA levels are shown in table 7.1. A 
similar pattern was observed using cells from 4 healthy normal volunteers though the 
median IL-4 mRNA levels were 5 fold lower than in the TB patients’ cells and not 
significantly increased compared to unstimulated wells (figure 7.2).
IL-4 was largely undetectable by ELISA in culture supernatants. At all time points 
IFN-y expression was not significantly different in TB patients compared to control 
donors.
7.3.2. Proliferative responses
In TB patients proliferative responses (expressed as a stimulation index relative to the 
negative control) to both TB sonicate and M. vaccae sonicate were variable and not 
significantly greater than in unstimulated wells but significantly lower than in PHA 
stimulated wells (p< 0.0002; table 7.2).
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Figure 7.1 A and B. Cultures of blood mononuclear cells from 8  TB patients. Sonicated TB 
antigen drives the expression of IL-4 (7.1 A) relative to IL-452 (7.1 B, ratio of log!0 IL-4 to 
logioIL-482 normalised to HuPO). When stimulated cells were harvested on days 1 or 2 (D 1 
or 2), expression of IL-4 was increased compared to baseline [p< 0.05 (•)], and compared to 
unstimulated wells [p< 0.005 (**)], and to wells stimulated with M. vaccae sonicate [p< 
0.05(x)]. When harvested on days 3 or 4 expression of IL-4 was increased compared to 
unstimulated wells [p<0.05(*)]. BL= baseline, TB= TB sonicate, MVS= M. vaccae sonicate, 
cont= unstimulated control wells and error bars represent range.
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Table 7.1. IL-4 mRNA levels in PBMCs stimulated with M .tuberculosis sonicate.
Cytokine Time-point TB vs (negative control) or [MVS] 
median; range mRNA copy number
P value
IL-4 mRNA Dl/2 vs BL 460; 40-7673 vs (BL 12; 1-63) P= 0.02
Dl/2 460; 40-7673 vs (5; 1-141) P= 0006
Dl/2 460; 40-7673 vs [19; 10-261] P= 0.03
D3/4 145; 1-4451 v s ( l;  1-31) P= 0.02
IL-4/IL-452 Dl/2 0.44 vs (-0.01) NS
ratio* (expressed as D3/4 0.85 vs (-0.21) NS
a log difference D5/6 0.65 vs (0) NS
between cytokines)
*only median values shown for IL-4/IL-482 ratio. MVS = M. vaccae sonicate. D = 
day. NS= non significant.
Table 7.2. Antigen-specific proliferative responses (overnight BrdU incorporation) in 8  
patients with pulmonary tuberculosis.
Antigen Median (range)
Stimulation Index
TBS 1.3 (0.6-3.5)
MVS 1.1 (0.5-3.5)
PHA 6.2 (4-26)
Negative control l.O(l.O-l.O)
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Figure 7.2. Cultures of blood mononuclear cells from 4 healthy control subjects (A shown 
as a bar graph and B shown as a scatter plot). IL-4 mRNA expression was higher in TB 
antigen stimulated wells than unstimulated wells (non-significant). BL= baseline, TB= TB 
sonicate, cont= unstimulated control wells, error bars represent range and horizontal lines 
represent medians.
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7.3. Discussion
7.3.1. IL-4: exploring the cause effect relationship
Is the IL-4 response in TB an irrelevant consequence of infection and general 
immunological activation, or is it significantly involved in reducing protection and 
increasing immunopathology? Simple experiments where mice were pre-immunised, 
so that they had small Th2 responses to one or several components of M. tuberculosis 
before infection, have shown that pre-existing Th2 activity leads to increased severity 
of infection and to death [495, 496]. Wangoo et al. demonstrated that even a single 
epitope inducing a Th2 response can undermine the immune response [16]. In this 
transgenic mouse model polarised Thl, ThO or Th2 cells, specific for a single 16 
amino acid ovalbumin epitope, were transferred to recipient animals that were 
challenged with recombinant M. tuberculosis expressing the ovalbumin epitope, or 
with a control strain expressing an irrelevant epitope. Mice receiving Thl cells before 
challenge were unaffected, while Th2 recipients showed enhanced weight loss and 
lung fibrosis and increased lung weight during acute high-dose infection with M. 
tuberculosis. Further studies in BALB/c IL-4 knockout mice proved that the absence 
of IL-4 led to diminished bacterial growth, and confirmed that IL-4 is directly 
involved in TNF-a-mediated immunopathology and fibrosis in this strain [14]. 
Interestingly, although other authors have not studied IL-4 knockout BALB/c mice, it 
was found that STAT6  (signal transducer and activator of transcription 6 ) knockout 
BALB/c mice respond normally to aerosol infection with M. tuberculosis [497]. This 
implies that the relevant functions of IL-4 (fibrosis and enhanced toxicity of TNF-a) 
might be signalled through 4PS/IRS-2 or IRS-1 rather than via STAT6  [498]. There is 
accumulating data that a DNA vaccine expressing hsp65 reduces pathology, enhances 
cure, shortens the duration of treatment and is effective against multidrug-resistant 
bacilli (MDR-TB) in infected mice [403, 499]. These beneficial effects are 
accompanied by the down regulation of IL-4 responses. Moreover, IL-4 neutralizing 
antibody showed enhanced bacterial elimination and therapeutic benefit in mice 
[500]. Collectively, these murine data suggest that the Th2 response in TB is unlikely 
to be an irrelevant bystander one.
179
This clear cause effect relationship in murine models has been more difficult to prove 
in humans. Collectively, published literature (reviewed in chapter 5) and the data 
presented in this thesis (chapter 5 and 6 ) demonstrate that both in BAL and peripheral 
whole blood, and their cell sub-populations, there is a mixed Thl/Th2 cytokine 
profile. However, this in itself does not imply a causal association between M. 
tuberculosis and IL-4. Demonstrating a relationship between IL-4 and the extent of 
disease (chapter 4 and 5) may also be insufficient (whether IL-4 is causal or an 
inflammation-related epiphenomenon, a greater degree of pathology would portend 
higher IL-4 levels). However, in addition to showing an association between IL-4 
(whole blood and T cells) and radiological disease extent, demonstrating that TB 
antigen actually drives IL-4 in PBMCs from donors with active disease, supports the 
contention that IL-4 is not simply a bystander effect. Recently published human data 
showing that health care workers with pre-existing IL-4 responses have an increased 
rate of progression to active TB compared to those who do not [15] and that IL-4 gene 
polymorphisms may modulate disease severity and presentation [228], further 
supports this notion.
7.3.2. Sonicated TB antigen preferentially drives IL-4
Although data are limited, studies have shown that PBMCs or peripheral T cells 
stimulated with TB antigen (heat killed or sonicated or specific antigens or PPD), 
express IL-4 detected by RT-PCR [186], ELISPOT [18], or flow cytometry [21, 29, 
347, 348]. Furthermore, hypervirulent Beijing M. tuberculosis strains cause human 
monocytes to express IL-4 [290]. By contrast, 3 earlier studies (before 1998) using 
RT-PCR failed to find IL-4 in TB antigen stimulated PBMCs or peripheral T cells 
[28, 30, 355]. The technical and other reasons for the failure to find IL-4 in these 
studies [28, 30, 355] have already been discussed in chapter 5, section 5.4.1). 
Collectively, however, the data suggest that more sensitive methods such as RT-PCR 
and ELISPOT are required for the detection of IL-4 in subjects from developed 
countries [18, 186] compared to FACS in subjects from developing countries [21, 29, 
347, 348] (already discussed in chapter 1, section 1.7.5.2). The findings presented in 
this chapter confirm the findings of previous investigators that TB antigen can drive 
IL-4 in subjects with active disease.
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However, the expression of IL-452 has not previously been investigated. As already 
mentioned in chapter 1, 5 and 6 , the expression of IL-452 mRNA is increased in 
unstimulated PBMCs from healthy donors who have LTBI, but not household 
contacts or those without LTBI, in The Gambia and Ethiopia [360, 361]. This 
suggests the possibility that blocking the effects of IL-4 through increased production 
of IL-452 might have a protective function. The observation that TB antigen 
preferentially drives IL-4 rather than the antagonist IL-452 may fit with this 
hypothesis. However, further experiments are required to confirm or refute this 
contention. The toxicity of TNF-a in an IL-4 knockout mouse infected with M. 
tuberculosis has been shown by the addition of recombinant IL-4 [14]. Similar 
experiments conducted with IL-452 and follow-up of the Gambian and Ethiopian 
cohort for disease progression would help to clarify the role of IL-452 in tuberculosis. 
Murine experiments are already underway in Mexico to answer some of these 
questions and preliminary data indicate that some of the previously found ‘IL-4’ is, in 
fact, IL-452 (Rogelio Hernandez Pando, personal communication).
7.3.3. Are there specific antigens that preferentially drive IL-4 or IL-452?
Having demonstrated that TB antigen, and not an environmental mycobacterium, 
drives IL-4 the next step will be to determine which specific antigenic components do 
this. Such antigens can be excluded from vaccine preparations (e.g. recombinant 
BCG), or, administered together with adjuvants that can drive Th2 suppressing 
regulatory cells [257, 402] or induce a Thl response rather than one driving IL-4. 
Alternatively, an intriguing possibility is to find adjuvants or antigens that drive IL- 
452, thereby tipping the balance in favour of the IL-4 antagonist. Putative strategies to 
identify such antigens (IL-4 and IL-452-specific) include the screening of TB antigen- 
specific IgE responses or E. coli DNA libraries expressing M. tuberculosis antigens. It 
has been shown that certain antigens can drive IL-4 and function as promoters of Th2- 
cell responses. The 16kDa heat-shock protein (a-crystallin) of M. tuberculosis 
contains epitopes that are preferentially recognised by Th2 cells from patients with 
TB [501]. In some individuals the 30kDa and 19kDa may induce IL-4 [18] and whilst 
IL-4 responses to antigen 85B may be detected 2 months after anti-TB treatment but 
not at diagnosis [502]. Consequently, if the hypothesis that IL-4 subverts protective
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host responses is correct, vaccines that boost antigen 85 responses are likely to be 
ineffective in their current format.
Most known vaccine candidates that are effective as prophylactic vaccines in mice, 
including BCG and preparations of M. tuberculosis itself, are ineffective as 
therapeutic vaccines [148, 149]. The history of this observation goes back to Robert 
Koch, who observed necrosis (the Koch Phenomenon) in guinea-pigs and humans 
given injections of 'Old Tuberculin' (reviewed in [503]). However, there are two 
preparations which downregulate IL-4, that are active therapeutically in murine TB. 
One, discussed in section 7.3.1 above, is a DNA vaccine based on heat-shock protein 
65 (hsp65) of Mycobacterium leprae, which reduces bacterial numbers in chronically 
infected mice and concomitantly reduces IL-4 ELISPOT+ T-cell numbers [499]. The 
other exception, heat killed Mycobacterium vaccae, markedly reduces IL-4 expression 
when administered after intrapulmonary infection [365]. Indeed, in the current study 
TB sonicate drove significantly greater IL-4 mRNA expression compared with M. 
vaccae, whose major mode of action is suppression of Th2 responses by driving 
CD4+CD45RBlow regulatory T cells [402]. Multiple doses of M. vaccae, in contrast 
to a single dose that does not enhance sputum conversion rates [504, 505], are being 
used therapeutically by the Chinese on a large scale. In a large RCT M. vaccae enabled 
successful shortening of the standard anti-TB regime to 4 months [506] and improved 
6  month culture conversion rates in MDR-TB [507]. A multiple dose M. vaccae trial 
in HIV+ subjects is currently in progress in Tanzania.
7.3.4. Choice of experimental protocol
Initial experiments suggested that 24 to 48 hours was the peak time-point at which IL- 
4 responses could be elicited in antigen driven PBMC cultures. Nevertheless, a seven 
day culture period was chosen to evaluate proliferative responses and protein 
measurements by ELISA, which may lag behind mRNA expression. The optimal 
antigen dose was selected by measuring cell proliferation, assessing cell viability with 
trypan blue and microscopic inspection of cultures (a final concentration of TB 
sonicate exceeding 50 |ig/ml was found to be toxic).
We viewed exposed but not latently infected controls as a group ‘resistant’ to TB
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infection, and considered this group as an appropriate control group relative to 
‘susceptible’ subjects that developed progressive disease. Given the raised IL-452/ IL- 
4 ratio recently described in latently infected contacts [360, 361], it would have 
desirable to simultaneously study a control group with LTBI in addition to the chosen 
one (exposed but not latently infected). However, resource constraints and related 
studies in Africa (VACSIS/ VACSEL) precluded the inclusion of this group. Further 
limitations of the antigen driven culture study include the small number of patients ( 8  
TB patients and 4 controls) and groups that were incompletely matched with respect 
to ethnicity. However, the addition of each patient (with the relevant control) would 
have added 144 additional samples (3 wells in triplicate, for 4 timepoints, in 2 donors 
for 3 genes) for processing (RT-PCR and ELISA). This was not logistically possible 
given the resourses committed to this study.
7.3.5. Detection of IL-4 and IFN-y by RT-PCR vs ELISA
IL-4 was largely undetectable by ELISA in culture supernatants. This was not 
surprising given the poor sensitivity of ELISA for IL-4, which is undetectable even 
when blocking antibodies are used [34] because of in vitro consumption by widely 
distributed cellular (and soluble) receptors [415]. This failure to detect IL-4 in culture 
supernatants, whilst confirming expression by RT-PCR in antigen driven PBMCs, has 
been confirmed by other investigators [26, 186]. In TB patients antigen driven IFN-y 
mRNA expression was not significantly different compared to control subjects 
(similar to findings in whole blood outlined in chapter 5) and TB-specific proliferative 
responses were unremarkable. Poor antigen-driven proliferative and IFN-y responses 
in peripheral blood or PBMCs of donors with TB has been well documented by other 
investigators [28-30, 78]. This is likely to be due to translocation of antigen-specific 
IFN-y producing cells to the lungs where there are high IFN-y levels (demonstrated in 
chapter 5) and strong proliferative responses [264]. Though not possible due to 
logistical and budgetary constraints, it would have been enlightening to compare 
antigen driven responses in PBMCs and alveolar lavage cells where IL-4 mRNA 
levels are increased by almost 2 logs (chapter 5). Cytokine production may also be TB 
strain-dependent with some strains driving little or no IFN-y production compared to 
others, even in healthy volunteers [508].
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7.4. Conclusion
The data presented in this chapter indicate that, in patients with active disease, TB 
antigen, preferentially drives IL-4 rather than the antagonist IL-452. This together 
with the association between IL-4 mRNA levels and radiological disease extent 
(chapter 5 and 6 ) supports the contention that IL-4 is not simply a bystander effect. 
These data, together with those latently infected contacts that remain healthy [360, 
361], support the hypothesis that IL-452 expression may determine the balance 
between infection and disease. The implications for vaccine design will be to screen 
for antigenic components (that drive IL-4, or perhaps IL-452), which can then be 
manipulated to downregulate the subversive Th2 component but at the same time 
augmenting the Thl response.
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8.1. Introduction
Tuberculosis and HIV are closely interactive pandemics that continue to flourish 
despite the availability of effective chemotherapy. Accordingly, immunotherapy in 
the form of widely available vaccines or immune modifiers would be crucial adjuncts 
for disease containment [509]. However, developing a successful HIV or TB vaccine 
has been more challenging than expected. The mechanisms underlying HIV related 
CD4+ T cell dysfunction and progression to AIDS remain unclear. Furthermore, the 
mechanisms governing disease progression and correlates of protective immunity are 
poorly understood.
It has been suggested that a subversive Th2 component, which undermines the 
dominant Thl response, is associated with the pathogenesis of TB [236], HIV [510, 
511] and progression to AIDS [512]. However, the presence and significance of Th2 
cytokines in HIV is controversial [513]; moreover, Th2 related data in HIV [510, 514- 
517] and HIV-TB co-infection [350, 353, 408, 518] is sparse and discordant. More 
importantly, the available literature fails to take into account the presence of IL-452, 
which confounds the interpretation of existing Th2 data. However, IL-452 expression 
has not previously been studied in HIV or HIV-TB co-infection. Understanding the
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relevant contribution of IL-4/IL-452 in TB and HIV may be important for intervention 
strategies, which modulate the Thl/Th2 balance in both diseases.
The expression of IL-452 in whole blood and lung lavage, of donors with TB-HIV co- 
infection, HIV alone and non-HIV infected healthy volunteers, is outlined in this 
chapter.
8.2. Methods
8.2.1. Patients and samples
Twenty patients with clinical and radiological features of pulmonary TB (sputum or 
lavage fluid positive by nucleic amplification test or culture for M. tuberculosis [6 ]) 
and HIV co-infection, 13 of whom underwent bronchoscopy and bronchoalveolar 
lavage (BAL), were recruited. Control donors were 20 otherwise healthy HIV-positive 
volunteers who were matched to the index cases for age (within 4 years), sex, and 
CD4 count (<200, 200 to 350 or > 350 cells/ml); and 20 HIV-negative healthy 
volunteers. Six volunteers from each control group (HIV positive and negative) 
underwent BAL. Thus, whole blood was obtained from 20 HIV-TB co-infected 
subjects, 20 HIV+ volunteers without opportunistic infection (OI) and 20 healthy 
controls; BAL was obtained from 13 HIV-TB co-infected patients, 6  HIV+ volunteers 
and 6  HIV negative healthy controls.
In all HIV+ donors other concomitant viral (hepatitis, CMV, EBV), bacterial 
(syphilis, bacterial culture of BAL fluid in appropriate donors), fungal 
(cryptococcosus, histoplasmosis) and parasitic infections (toxoplasmosis and screen 
for stool parasites if indicated) were excluded by PCR, serology, cytology and culture 
of relevant biological samples (blood or BAL). Plasma HIV viral load (LCx HIV 
RNA Quantitative assay; Abbott Laboratories, North Chicago, USA), total peripheral 
blood and BAL CD3+, CD4+ and CD8 + counts (TruCOUNT™, BD Biosciences, San 
Jose, CA) were performed in all HIV positive participants (performed by technicians 
in the Dept. Virology, Royal Free Hospital). Whole blood, obtained from all 
participants before or within 10 days of initiating anti-TB treatment and also from 10
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TB-HIV co-infected patients after anti-TB treatment, was immediately transferred to 
Paxgene tubes (Qiagen, Germany) to fix the RNA profile. BAL and radiographic 
scoring was performed as outlined in the general methods (chapter 3).
8.2.2. ELISPOT. ELISA and RT-PCR
Latent TB infection was excluded in HIV+ and HIV- control subjects by overnight T- 
cell IFN-y responses to TB-specific antigens (T-SPOT TB, Oxford Immunotec, 
England). In addition ELISA for sCD30, IL-4 and IFN-y was performed on ~10 fold 
concentrated lavage supernatants as described in chapter 3. RNA extraction, reverse 
transcription and real-time quantitative RT-PCR for IL-4, IL-452 and IFN-y were 
performed on all blood and BAL samples as previously described after quantification 
and quality control of RNA templates (chapter 3). Data was analysed according to the 
methods described in chapter 3.
8.3. Results
8.3.1. Demographic and laboratory characteristics
The baseline demographic and laboratory characteristics were not significantly 
different in the 3 patient groups (table 8.1). However HIV-TB co-infected patients had 
higher viral load (median copies/ml plasma) than HIV+ controls (77760 vs 50, 
p=0 .0 0 0 1 ).
Table 8.1. Demographic and laboratory characteristics of study participants. Figures 
accompanied by parentheses are means (SD).
Characteristic TB+HIV+ HIV+ HIV -
Age (years) 37.1 (8 .6 ) 36.2 (5.7) 34.9(14.7)
CD4 count (cells/mms) 223(201) 279(198) n/a
% male 50 42 57
% Black African 79 74 50
% using HAART 15 40 n/a
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8.3.2. HIV positive and HIV negative healthy controls
In HIV+ controls without OI vs non-HIV controls IL-4, IL-452 and IFN-y were 
similar in whole blood and lung lavage fluid (figure 8.1 A, B and C), even when 
paired samples from both compartments were compared. mRNA levels did not differ 
significantly in those taking HAART compared to those who were not.
8.3.3. HIV-TB co-infected patients and HIV positive controls
By contrast mRNAs for IL-4 and IFN-y were increased in both compartments of TB- 
HIV co-infected donors, compared to the HIV+ controls [p< 0.003 for IL-4 (~5 fold 
increase in blood and -17 fold increase in lavage) and p< 0.02 for IFN-y (>350 fold 
increase for blood and >1300 fold increase for lavage); figures 8.1 A and C)]. 
However, IL-452 mRNA levels were similar in the blood whether the HIV+ 
individuals were TB co-infected or not, whereas levels were much higher in lung 
lavage from co-infected donors (p< 0.005, -100 fold increase, figure 8.1 B). 
Consequently, in co-infected patients the IL-4/ IL-452 ratio was significantly higher 
in whole blood than in lung lavage (p= 0.0006), where the dominant form of “IL-4" 
was in fact the antagonist, IL-452 (figure 8.2).
sCD30 and IL-4 were undetectable by ELISA in BAL from most HIV+ donors, 
whether TB-coinfected or not. By ELISA, IFN-y was increased in BAL from some 
co-infected patients, but undetectable in 509L Thus, ELISA results were unhelpful.
188
IL
-45
2 
co
pi
es
/10
 
Hu
PO
 
IL-
4 
co
pi
es
/10
 
Hu
PO
r
p = 0.02
p = 0.0029 p = 0.0025
10000-1
1000 -
• • •
• • •100 -
■■
10 -
vv
J L
Whole blood BAL
B
10000-1
1000 -
100 -
10 -
p = 0.0045
A A
1
p = 0.0042
I 1
J  J _
Whole blood BAL
189
2
X
co
c/>Q)
Q.OO
?*-
c
10000 -
1000 -
100 -
10 -
p = 0.01
I 1
p = 0.0012
I 1
Vy
Whole blood BAL
Figure 8.1. A, B and C. IL-4 (A), IL-452 (B) and IFN-y (C) mRNA levels (expressed per 
million copies of mRNA encoding Human acidic ribosomal protein) in whole blood and 
alveolar lavage at the start of anti-TB treatment. Expression of IL-4 and IFN-y were 
significantly increased in patients with tuberculosis compared to controls. IL-452 was 
elevated in the lung lavage but not in whole blood of co-infected patients compared to 
controls.
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Figure 8.2. IL-4/IL-462 ratio (expressed as a log difference between cytokines) in whole 
blood (WB) and alveolar lavage cells (BAL). The IL-4/IL-462 ratio was significantly higher 
in BAL compared to whole blood in subjects with TB-HIV infection.
8.3.4. Relationship to clinical, laboratory and treatment parameters
In HIV-TB co-infected patients the IL-4/IFN-y mRNA ratio was similar in whole 
blood and lung lavage and the latter correlated with pre-treatment radiological disease 
extent (p= 0.02, figure 8.3). It was not feasible to evaluate the relationship between 
cytokine mRNA levels and cavitory disease as there were only 2 patients with 
cav itation discernable on chest x-ray.
IL-4 and IL-452 mRNA levels were independent of blood and lavage CD4 and CDS 
counts, blood viral load, the presence of disseminated tuberculosis and use of 
HAART. There was no relationship between the CD4 count and immunological 
parameters (IL-4, IL-452 and IFN-y mRNA levels, and the Th2/Thl ratio were not 
significantly different in subjects with CD4 counts < 200 vs > 200).
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Following short course anti-TB treatment IL-4 and IFN-y mRNA levels did not 
significantly change whilst IL-452 levels significantly increased (p=0.01, -85 fold 
increase, figure 8.4 A-C).
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Figure 83. Correlation between radiological disease extent and the Th2/Thl (IL-4/IFN-y) 
ratio in BAL.
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Figure 8.4 A-C. Comparison between IL-4 (A), IL-452 (B) and IFN-y (C) mRNA levels at 
baseline and after anti-TB treatment (n= 10). At -  6  months post treatment IL-4 and IFN-y 
mRNA levels were non-significantly changed from baseline but IL-452 levels significantly 
increased (p=0.01, -85 fold increase).
8.4. Discussion
8.4.1. IL-4 in asymptomatic HIV infection
The T h l to Th2 switch' hypothesis proposes that immune dysregulation facilitating 
infection and progression to AIDS is dependent on the balance between Thl and Th2 
responses to HIV [512]. There is also evidence that Th2 cells are more permissive to 
HIV infection [519]. However, published studies regarding IL-4 are conflicting with 
some studies supporting [510, 515, 516, 520] and some opposing [514, 517] the T h l 
to Th2 shift' hypothesis. In asymptomatic HIV+ subjects there was a progressive 
decline in IL-2 and IFN-y responses and increased IL-4 responses, detected by 
conventional RT-PCR [510] or flow cytometry [515, 520], in mitogen stimulated 
PBMCs. Similar findings were noted in primary HIV infection but not in chronic 
asymptomatic infection [516]. By contrast, IL-4 was largely undetectable by RT-PCR 
in unstimulated PBMCs in primary HIV infection [514], or by flow cytometry in
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chronic asymptomatic HIV infection, even at CD4 counts less than 200 cells/mm 3 
[517]. Serum IL-4 levels were not elevated in the serum of patients with chronic 
asymptomatic infection [521]. Consequently, the issue of whether a switch to Th2 
responses facilitates the progression of HIV remained controversial.
Why are the data discordant? Collectively, these studies did not distinguish between 
the agonist, IL-4, and antagonist, IL-462. Moreover, stimulation protocols, which are 
Thl biased may have down regulated IL-4 responses in in vitro cultures. 
Interpretation is further complicated by heterogeneity in the stage of HIV studied 
(primary infection, stable HIV or AIDS), the site of sample acquisition (peripheral 
blood vs disease site), geographical location (Europe and USA vs Africa) and the type 
of assay used to measure IL-4 (conventional RT-PCR, ELISA, flow cytometry). The 
drawbacks of immunoassays and unreliability of conventional RT-PCR protocols 
have been summarised (chapter 2, table 2.2). In the current study mRNA levels of IL- 
4 and IL-462 were measured in unstimulated cells from both blood and lung lavage, 
using a validated probe based real-time quantitative assay (chapter 2 ), in 
asymptomatic HIV+ subjects over a wide range of CD4 counts. The Th2 profiles were 
similar in HIV infected and non-infected healthy volunteers and this was independent 
of disease stage (CD4 count), viral load or use of HAART. The data presented here 
argue against the implication of Th2 cytokines in the pathogenesis of HIV in the 
absence of other opportunistic infections. This implies that immunotherapeutic 
interventions based on the Thl/Th2 shift are unlikely to be useful in asymptomatic 
HIV+ subjects. Nevertheless, it remains possible that cells from HIV-infected donors 
release more IL-4 (or IL-462; the assays used would have measured both together) 
when stimulated in vitro with mitogens [515, 516]. Moreover, whether the findings 
presented here apply to primary HIV infection remain unclear.
8.4.2. IL-4 expression in HIV-TB co-infected subjects
Considering that TB is the commonest OI in HIV and that in some parts of the world 
more than 609c of TB patients are co-infected with HIV, it is remarkable that there are 
few published data about T hl/ Th2 cytokine profiles in co-infected patients. 
Analogous to asymptomatic and primary HIV infection the data are conflicting. Two 
studies reported a shift to a type 2 cytokine profile [518, 522] whilst three others
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found reduced type 1 responses but no enhancement in IL-4 responses [353, 408, 
523]. These studies used ELISA to detect IL-4 in in vitro cultures and conventional 
RT-PCR protocols; the same drawbacks discussed in the previous section are 
applicable here. The current study found that HIV-TB co-infected patients, but not 
HIV+ controls, had significantly higher levels of IL-4 mRNA in blood and alveolar 
lavage cells. That these observations are biologically meaningful is corroborated by 
the correlation of the lung Thl/ Th2 (IL-4/ IFN-y) ratio with pre-treatment 
radiological scores. Nevertheless, the association of IL-4 mRNA levels with disease 
extent does not necessarily imply a cause-effect relationship and further studies will 
be required to clarify this issue. Whether these observations apply only to TB or also 
to other opportunistic infections remain unclear. Published reports investigating 
Thl/Th2 cytokine profiles in other OI such as PCP, cryptococcosis and toxoplasmosis 
are too sparse to draw any meaningful conclusions.
The mechanisms that underpin increased viral replication during TB co-infection are 
poorly understood. The data presented here confirm that in HIV+ hosts, TB induces 
IL-4 as it does in HIV sero-negative TB (chapter 5), and the profile of IL-4 and IL- 
452 in HIV-TB co-infection is similar to that found in sero-negative TB (chapter 5). 
IL-4 may facilitate HIV progression by up-regulating HIV co-receptors, encouraging 
syncytium-inducing strains [524], inhibiting anti-viral a-defensins [525, 526] and 
activating viral transcription [524, 527]. Furthermore, in HIV-TB, as in any co- 
infection, there is enhanced viral cellular entry due to cellular activation and increased 
viral transcription mediated by transcription factors like NF-kB [513]. The high IFN-y 
levels found in co-infected patients may also facilitate HIV progression by up 
regulating HIV co-receptors [528] though there was no correlation between plasma 
viral load and IFN-y mRNA levels. However, plasma viral load is only a surrogate 
marker of total viral burden and viral load was not measured at the main site of 
disease, the lung.
Not surprisingly, ELISA for IL-4 was unhelpful in the current study. Immunoassays 
have poor sensitivity in detecting protein in BAL due to the considerable dilutional 
effect in lavage fluid (this point has been discussed in chapter 5, section 5.4.2).
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8.4.3. IL-452 mRNA expression
In contrast, to IL-4 mRNA expression, IL-462, the antagonist, was increased 
predominantly in the lungs but not in the blood. Consequently, co-infected patients 
had a significantly higher IL-4/ IL-462 ratio in whole blood compared to lung lavage. 
As IL-4 enhances immunopathology in animal models [14, 16, 364] and human 
disease [19, 356], it is not unreasonable to speculate that the paucity of 
immunopathology (necrosis and cavitation) seen in HIV may be relate to the high IL- 
462 levels in the lungs. However, it is recognised that the genesis of 
immunopathology is complex and may be modulated by different cell types (T cells 
and granulocytes), cytokines (IL-4, TNF and TGF-J3), protease dysregulation and 
other factors (toxicity of mycobacteria, Koch phenomenon and Schwartzman 
reaction) (reviewed in chapter 1 ). Nevertheless the relationship between IL-462 and 
immunopathology in HIV merits further investigation. In the current study it was not 
feasible to determine the relationship between IL-462 and cavitation as there were 
only 2 individuals in whom cavitary lesions were visible on CXR. However, it is 
possible that a larger cohort and use of more sensitive methods such as CT scans may 
have detected an association. BAL samples from the current study have been banked 
for future experiments, which will seek to determine the relationship between Th2 
cytokines and markers of lung remodelling (TGF-p, MMPs, procollagen peptide III).
8.4.4. Response to anti-TB treatment
Analogous to the changes seen in HIV negative subjects (chapter 5), completion of 
chemotherapy was accompanied by a significant increase in IL-462 mRNA levels and 
a reduced IL-4/ IL-462 ratio. Further studies are warranted to evaluate the utility of 
this ratio as a marker of disease activity or successful treatment. If this is borne out it 
may be of value for future trials of new therapeutic interventions. The observation 
together with those in latently infected contacts that remain healthy [360, 361], raises 
questions about whether IL-4/IL-62 ratio could be used as a correlate of protective 
immunity. This point has been discussed in relation to HIV negative subjects in 
chapter 5.
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8.4.5. IFN-y levels in blood and BAL
The notion that there are sufficient Thl responses in TB and further enhancement is 
unlikely to increase protection, was discussed in detail in chapter 5. In HIV-TB co- 
infection, compared to HIV+ controls, IFN-y mRNA levels were significantly higher 
in peripheral whole blood and the lungs. Furthermore, co-infected subjects with CD4 
counts < 200 cells/mm3 did not have significantly lower IFN-y mRNA levels than 
those having counts > 200 cells/mm3. Antigen specific IFN-y responses are also 
robust in the lungs, even at low CD4 counts (RAM Breen, personal communication). 
In contrast to the data presented here, the only other study to evaluate expression in 
BAL fluid [468] found that IFN-y mRNA levels were reduced in 4 co-infected 
subjects compared to HIV negative controls. However, a semi-quantitative protocol 
and the small number of patients were limitations of this study. Collectively, the 
findings presented here and in chapter 5 suggest that Thl cytokines like IFN-y are 
unlikely to be the limiting factor in protective immunity in both HIV negative and 
HIV+ subjects with tuberculosis.
8.5. Conclusion
The data presented in this chapter suggest a role for Th2 cytokines in the pathogenesis 
of HIV-TB co-infection but not in otherwise stable HIV infection. Further studies are 
required to determine if this applies to other HIV related opportunistic infections, and 
whether the selective increase in IL-4 expression in the periphery of co-infected 
patients contributes to increased HIV replication. The relationship between the IL- 
4/IL-462 ratio and immunopathology, disease activity and protective immunity 
warrants further investigation. Collectively, the findings presented here have 
implications for the design of immunotherapeutic interventions that seek to slow 
disease progression by modulating the Thl/Th2 balance in HIV and HIV-TB co- 
infection.
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9.1. Introduction
The studies related to pulmonary tuberculosis, performed in fulfilment of this thesis, 
aimed to further the understanding of those Thl and Th2-specific responses and 
regulatory pathways, about which little or no previous human data existed.
9.1. Discordant IL-4 data in relation to TB
There are many technical difficulties when measuring and interpreting data in relation 
to low copy number cytokines like human IL-4 (summarised in table 2.1). 
Furthermore, published literature is characterised by unreliable mRNA quantification 
using conventional RT-PCR protocols (drawbacks are listed in table 2.2), variability 
in sample acquisition (periphery rather than the disease site) and geographical 
location (implications discussed in chapter 1, section 1.7.5.2), and a general failure to 
distinguish between IL-4 and IL-462. Accordingly, it is not surprising that IL-4- 
related data are discordant. The first step in addressing this problem was to design an 
accurate and reproducible assay that would circumvent these problems (chapter 2  and 
3). Real-time RT-PCR was the obvious choice as it addressed most of these 
drawbacks and could simultaneously distinguish between IL-4 and IL-462, for which 
there are no available discriminatory immunoassays. As IL-4 is active at 
concentrations ~ 300 fold below that of IFN-y [413], the technique had to be precise 
enough to detect even small inter-group differences yet concurrently not create 
artefactual ones (a possible effect of data normalisation when using PCR). However, 
as there was no previously established reference for standardising data generated from 
tuberculosis samples, it was first necessary to validate a suitable reference gene
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(chapter 2, part 1). It was also demonstrated, for the first time, that use of an 
unselected conventional reference (GAPDH) could obscure significant inter-group 
differences or artefactually generate them (chapter 2, part 2) when measuring IL-4 
mRNA levels. To generate interpretable data, in the current study, samples were 
simultaneously acquired from peripheral blood and the lung. Furthermore, 
unstimulated cells were immediately ‘fixed’ to ensure a reliable reflection of in vivo 
expression profiles (chapter 3). A number of other technical measures were taken 
(table 3.1), some often ignored in published studies, to ensure the generation of 
accurate, reproducible and biologically meaningful data. Using this carefully 
validated protocol it was unequivocally shown that subjects with pulmonary 
tuberculosis, in the periphery and in the lung, have a mixed Thl/ Th2 profile 
compared to healthy volunteers. The methods developed here, including the use of a 
validated reference, could be applied to study other biological markers (e.g. 
transcription factors, signalling molecules and cytokines) in tuberculosis. It would 
also be useful for study of BAL where dilution of cytokines hampers their detection 
(discussed in detail in chapter 5, section 5.4.2).
9.2. What is the significance of IL-4 seen in TB?
The difficulty with immunological studies in TB, and this also applies to other 
inflammatory conditions, is to determine whether a biological marker of interest is 
causative or an epiphenomenon (bystander effect due to widespread pathology or 
inflammation). The same caveat applies when demonstrating an association between 
IL-4 and disease extent, as shown in the current study. Furthermore, murine data 
which show a direct cause-effect relationship for IL-4 (discussed in detail in chapter
7, section 7.3.1), may not be entirely relevant to human tuberculosis. In vitro studies
using human cells often have discordant findings because of variable culture
conditions and antigen preparations (reviewed in chapter 5). Finally, demonstrating a 
strong cause-effect association in human studies does not necessarily ensure
therapeutic utility. For example human anti-IL-5 antibody, initially validated in 
knock-out mice, effectively abrogated human airway eosinophilia but showed little 
clinical benefit in trials for bronchial asthma [529]. Collectively, these precepts
indicate that proving a direct cause-effect relationship between IL-4 and human TB
can be tricky.
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Nevertheless, a recent study showed that individuals with pre-existing TB antigen- 
specific IL-4 responses had a high rate of progression to active TB [15]. In the current 
study, the association of the Th2 / Thl ratio and sCD30 with radiological disease 
extent (chapter 5) supports the biological relevance of IL-4 mRNA levels. The failure 
of IL-4 mRNA to decrease in parallel with clinical and immuno-pathological 
improvement (radiology and concurrent increase in IFN-y levels) argues against a 
bystander effect (chapter 5). Furthermore, the predominant T cell expression of IL-4 
(chapter 6 ) and the induction of IL-4 by TB antigen (chapter 7) suggest a true antigen 
driven response. Collectively, these data support, but does not prove, the hypothesis 
that TB drives IL-4, within the context of a dominant Thl response, to subvert 
protective host immunity. The hypothesis is summarised in figure 9.1 and if correct 
may help clarify a number of paradoxes and hitherto potentially unexplained 
phenomena in TB (summarised in table 9.1). Further studies are required to assess the 
contribution of regulatory responses (Thl or Th2) in determining T cell profiles in 
active and latent TB (discussed in chapter 1, section 1.5). Moreover, studies are 
required to clarify the role of soluble IL-4R and natural antibodies to IL-4 in 
tuberculosis. It is possible that sIL-4R may represent a major pathway for regulating 
IL-4 protein levels in TB and sIL_4R may considerably prolong the half-life of IL-4 
protein. This may partly explain the high levels of TB-related IL-4 found in 
developing countries. The same considerations apply to natural antibodies to IL-4 
(sIL-4R and anti-IL-4 antibodies are discussed in section 1.6.4.2 and 1.6.4.3).
201
t—
Adjuvant effect of 
helminths
1
Th2 *-----
Environmental
m ycobacteria
i
i
Th1
I
M. tuberculosis
IL-482 IL-4 ? T reg
Balance between 
agonist and antagonist
T
Th1
t
Mixed Th1/IL-4 resp o n se  =
FAILED Th1-MEDIATED IMMUNITY
Superimposed upon a Th1-cell response, IL-4 can:-
• Downregulate iNOS, activate wrong macrophage functions, 
and permit bacterial growth
• Promote toxicity of TNF, and drive immunopathology
• Increase pulmonary fibrosis despite the presence of IFN-y
• ? Down regulates apoptosis which is bactericidal
Figure 9.1. Tuberculosis and the interleukin-4 (IL-4) hypothesis. Environmental 
mycobacteria prime Thl and Th2-cell responses, the latter being enhanced by helminth 
infections. Dose dependent exposure to M. tuberculosis will enhance both Thl and Th2 cell 
responses. IL-4 may be partially counteracted by increased expression of the splice variant 
IL-482, which occurs in latently infected individuals who do not develop disease. However, in 
others a mixed Thl-cell and IL-4 response might compromise cell-mediated immunity against 
M. tuberculosis. The result is a failure of protection and the development of disease with 
unusually high levels of IL-4 in developing countries. To what extent M. tuberculosis drives 
regulatory cells (Treg) to enhance Th2 responses remain unclear. An effective vaccine for 
citizens in developing countries might need to block the IL-4 response, rather than induce a 
Thl-cell response that is already present.
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Table 9.1. How IL-4 can explain a number of apparent paradoxes in tuberculosis.
(i) TNF-a is essential for protection against M.tuberculosis but is toxic under 
certain conditions (discussed in section chapter 1, section 1.7.4.1.).
(ii) Most existing prophylactic vaccine candidates fail as therapeutic vaccines 
(discussed in chapter 7, section 7.3.3.).
(iii) The efficacy of BCG vaccine varies indifferent geographical areas (discussed 
in chapter 1, section 1.7.5.2).
(iv) Considerable lung remodelling (fibrosis and necrosis) occurs in pulmonary 
tuberculosis despite high levels of interferon-y, which is anti-fibrotic (discussed in 
section chapter 1, section 1.7.4).
(v) Defective host immunity that allows progression to infection but not active 
disease (discussed in chapter 7, section 7.3.2.)
(vi) Death rates from tuberculosis, during the first 2 months of treatment, are 
unusually high in many developing countries [342].
9.3. Can the balance between IL-4 and IL-482 determine disease outcomes?
As IL-4 is implicated in TB-related immunopathology and disease progression in 
mice [14, 16, 364, 368] and humans [19, 356], and IL-452 is an in vitro antagonist of 
IL-4 [314], it is logical to ask whether the balance between the two (IL-4 and IL-482) 
determines disease outcomes.
Proving this hypothesis in humans is challenging. The first clue came from the 
observation that subjects with LTBI who remain healthy express high levels of IL-482 
mRNA [360, 361] and fuelled speculation that the ‘IL-4-IL-452’ hypothesis was 
tenable. Three observations in the current study support this contention. Firstly, the 
stability of IL-4, but not IL-482 mRNA, is enhanced in peripheral blood (chapter 4).
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In pulmonary tuberculosis this, previously undescribed, regulatory mechanism is 
likely to enhance the immunopathologic effect of IL-4. Secondly, TB antigen 
preferentially drives IL-4 rather than IL-482 in cultures of peripheral mononuclear 
cells obtained from TB patients (chapter 5). Thirdly, unlike IL-4, IL-482 increases 
significantly with treatment and clinical improvement, in both HIV negative (chapter 
5) and HIV+ (chapter 8 ) subjects with tuberculosis. Moreover, HIV+ subjects, most of 
whom have no radiologically apparent lung cavitation, have high levels of IL-482 in 
the lungs but not the blood (chapter 8 ). However, at apparent odds with this 
contention is the finding that the IL-4/ IL-482 ratio in subjects with TB is unchanged 
compared to controls. As discussed in chapter 5 the cross-sectional data provided in 
this study provides only a ‘snap-shot’ of the IL-4/ IL-482 ratio. It is entirely possible, 
as it is in a mouse model (R Hemado-Pandez, personal communication), that the ratio 
is different in the crucial early phase of the disease when IL-4 may tip the balance in 
favour of progression.
Collectively, these data provide circumstantial evidence for the role of IL-482 as a 
disease modifying antagonist in tuberculosis. However, studies in murine and in vitro 
models, and prospective longitudinal studies in subjects with LTBI and will be 
required to clarify whether IL-482 is a key molecule in determining TB outcomes. If 
this is borne out then IL-482 may have utility for the design of immunotherapeutic 
interventions, as a marker of disease activity and a surrogate marker of protective 
immunity.
9.4. T hl responses
Over the last decade a number of studies have shown that there are poor proliferative 
and TB antigen-specific IFN-y responses in the peripheral blood of TB patients 
compared to healthy controls (reviewed in chapter 5). Consequently, it was assumed 
that robust IFN-y responses represented a correlate of protection; vaccine candidates 
have been screened according to this rationale. Remarkably, there are only a handful 
of studies examining cytokine profiles at the site of disease, the lungs, in pulmonary 
tuberculosis and even fewer in HIV-TB co-infected patients. The data presented here 
confirm that, in contrast to whole blood, in the lungs there are high levels of IFN-y.
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Even in HIV+ subjects the problem does not appear to be a lack of IFN-y producing 
cells (chapter 8, [530]). Clearly, studies in donors with genetic defects [344] have 
shown that a certain minimum level of IFN-y is required for protection. However, the 
current study supports the notion that something else is required, and it is the nature of 
the Thl response that is important (mixed Thl/Th2 or a regulatory response, or a 
combination) not the quantity. Further evidence supporting this contention is 
discussed in detail in chapter 5 (section 5.3.4).
9.5. Implications for vaccine design and future directions
Almost all TB vaccine candidates have been screened for their Thl driving capacity 
in pathogen free laboratory mice, unlike the human situation where there are pre­
existing mixed Thl/Th2 responses. There are exceptions, which down regulate Th2 
responses whilst concurrently boosting Thl responses (M . leprae hsp65 DNA vaccine 
and multiple dose M. vaccae, discussed in chapter 7, section 7.3.2 and 7.3.3). More 
than 200 potential TB vaccine candidates have now been identified but the capacity to 
test them in humans is restricted due to limited field testing-sites and monetary 
resources. Therefore, candidates will need to be prioritised based on available 
scientific data. As such, the existing murine data and additional human data presented 
here and elsewhere (reviewed in [12]) will facilitate the prioritisation of such 
candidates for evaluation in clinical trials. In parallel, other antigens will need to be 
screened for their Th2 inducing capacity by using methods discussed in chapter 7, 
section 7.3.3 (attempts to initiate these studies have now begun). Once identified 
these antigens could be excluded from existing vaccine preparations (recombinant live 
vaccines or fusion proteins), or administered together with adjuvants that can drive 
Th2 suppressing regulatory cells or alter antigen-specific T-helper responses. 
Antigens that drive IL-462 but not IL-4 may also be important. Even if candidates that 
down regulate Th2 responses prove ineffective when used by themselves they may 
prove to be useful as adjuvants. Neutralising antibody to IL-4, reported to be 
therapeutic in the mouse model [499], is available and requires further clinical study 
in humans.
Now that therapeutic modulators of mRNA stability are a reality it would be 
instructive to determine whether post-transcriptional mRNA regulation of IL-4
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(chapter 4) or other biological molecules would be beneficial in models of TB. Data 
are required about IL-4 mRNA stability in T cell-subpopulations (lung and peripheral 
blood), and whether inhibitors of mRNA stability can attenuate markers of 
immunopathology in in vitro models. Whether the balance between IL-4 and IL-462 
is instrumental in determining disease outcomes requires further study in longitudinal 
human studies and laboratory models. Development of antibodies to distinguish 
between the variants would facilitate this process. IL-462 also requires further study 
as a potential marker of disease activity and correlate of protective immunity. To what 
extent regulatory T cells modulate Th2 profiles in tuberculosis requires further study. 
Particularly relevant to vaccine design would be to determine how TB antigens 
interact with DCs to determine Th-cell differentiation and regulation. Because of the 
close interaction between HIV and tuberculosis many of these considerations can be 
extended to HIV-TB co-infection and the role of Th2 cytokines in facilitating viral 
replication in co-infected patients requires further study. Finally, the current study has 
highlighted that, for meaningful interpretation of immunological data, future studies 
must use biological samples from the site of disease and peripheral blood.
9.7. Conclusion
The work presented in this thesis led to the development of a reproducible 
quantitative assay that will facilitate future work related to IL-4 and IL-462. The 
validation of a suitable reference will facilitate the use of real-time PCR in studies 
unrelated to tuberculosis. It has been demonstrated that a Th2-like response, 
prominent in T cells, and driven by TB antigen, is present in pulmonary tuberculosis. 
This response is associated with disease extent and is modulated by treatment. 
Furthermore, enhancement of IL-4 mRNA stability, previously undescribed in 
tuberculosis, may represent an additional mechanism by which M. tuberculosis may 
drive immunopathology. Further studies are required to determine whether IL-4 
facilitates systemic HIV progression in co-infected patients. Collectively, these data 
suggest a role for IL-4 and its antagonist, IL-462, in the pathogenesis of TB and their 
ratio as a possible marker of disease activity and outcome.
The data presented here cannot definitively prove a causal relationship between IL-4 
and tuberculosis susceptibility. Nor can it prove that an ideal vaccine is one that will
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drive a Thl response but simultaneously suppress pre-existing Th2 responses. 
However, it is hoped that that publications arising out of this work will help to 
prioritise vaccines, which downregulate Th2 responses, for clinical trial. The next 
logical step is to identify IL-4 inducing antigenic components, which can be 
manipulated for vaccine design. Funding and protocols to facilitate this goal are 
already in progress. I hope that clarification provided by the current work and future 
initiatives will one day translate into benefit for people who might otherwise succumb 
to M. tuberculosis.
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APPENDIX
Appendix 1. X-rav scoring for pulmonary tuberculosis
I  Upper zone: between a 
j horizontal line intersecting 
I the 2nd costochondral 
| junctions, and upwards 
| from this line to the lung 
| apices
M iddle zone: from the 2nd 
to the 4th costochondral 
junction
Lower zone : from the 4 th 
junction downwards
A ppendix  1.1. Radiographic scoring o f pulm onary tuberculosis.
Scoring system: For the purposes of scoring each lung was divided into 3 zones 
(shown above). The involvement in each zone was graded (0= none; 1= <1/3; 2= 
between 1/3 and 2/3 and 3= >2/3). In this way ‘airspace shadowing’ and ‘reticular 
shadowing’ was graded for all 6  zones
Cavitation in each zone was graded as present or absent, the number of cavities 
documented and further details noted (maximum cavity diameter of the cavity and 
maximum wall thickness). Furthermore, fibrotic lung contraction in each lung was 
assessed as being present or absent (tracheal deviation, hilar movement, movement of 
fissures and diaphragmatic tenting). Other features were recorded as being present or
PA Chest
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absent (pleural thickening or effusion, pericardial effusion, atelectasis, bronchiectasis 
and miliary shadowing). In this way a final ‘lung remodelling’ score (minimum 0 and 
maximum 1 0 0 ) was generated (an example of the scoring form and method is shown 
below). Chest radiographs were scored by 2 radiologists blinded to patient details and 
stage of disease.
Sample X ray scoring form: Dept, of Radioloev and Thoracic Medicine. RFH
Patient initials:
Hospital number:
Time in relation to TB treatment (initial or 6  months):
(Radiologist blinded to this information)
Note: each space must be filled (if none mark with 0 or n/a if not applicable).
Zone 1 Zone 4
9c air space shadowing:________________ 9c air space shadowing:__
9c reticular shadowing:_________________ 9c reticular shadowing:.
(air-space and reticular shadow s, 0= none, 1 = <1/3; 2 — between 1/3 and  2/3 and 3= >2/3)
Number of cavities:_________  Number of cavities:________
(mark 0  if absent) (mark 0  if absent)
Diameter of largest cavity__cm Diameter of largest cavity___cm
Maximum cavity wall thickness mm Wall thickness mm
Zone 2 Zone 5
9c air space shadowing:_____  9c air space shadowing:.
9c reticular shadowing:______  9c reticular shadowing:.
(air-space and reticular shadows, 0 = none, 1= <1/3; 2 — between 1/3 and 2/3 and 3= >2/3)
Number of cavities:_________  Number of cavities:_______
(mark 0  if absent) (mark 0  if absent)
Diameter of largest cavity cm Diameter of largest cavity cm
Maximum cavity wall thickness mm Wall thickness mm
Zone 3 Zone 6
9c air space shadowing:_____  9c air space shadowing:____
9c reticular shadowing:______  9c reticular shadowing:.
(air-space and reticular shadows, 0 — none, 1 = <1/3; 2 — between 1/3 and  2/3 and 3= >2/3)
Number of cavities:_____  Number of cavities:_______
(mark 0  if absent) (mark 0  if absent)
Diameter of largest cavity__cm Diameter of largest cavity__cm
Maximum cavity wall thickness mm Wall thickness mm
1. Evidence of fibrotic distortion (tracheal deviation, hilar displacement, fissure movement, 
diaphragmatic tenting or other)
Right lung: Yes No  Left lung: Yes___ No____
243
Feature present_________________________  Feature present___
2. Pleural reaction (thickening and/or effusion; can only conclude from 2nd film)
Right lung: Yes No  Left lung: Yes No___
Feature present_________________________  Feature present___
Extent________________________________ Extent__
(blunting of CP angle, < 50% of pleural margin, > 50% of pleural margin)
3. Other findings or comments (bronchiectasis, atelectasis, lymph nodes, pericardial effusion, 
calcification, miliary pattern, nodules)
SCORING:
a. To score extent of air space shadowing: add all 6 zones to give a raw score of 
between 0  and 18.
b. To score extent of reticular shadowing: add all 6  zones to give a raw score of between 
0  and 18.
c. Is cavitation absent or present:__________
Total number of cavities: ______________
Maximum diameter (cm): __________
Maximum wall thickness (mm): _________
[No cavities then score 0,
one to three cavities on CXR and max diameter < 3cm and max wall thickness < 
3mm then score 9,
more than three cavities or max diameter of any cavity > 3cm or max wall thickness 
of any cavity > 3mm, then score 18].
(Maximum score = 18, Minimum = 0).
d. Evidence of lung contraction absent, present 1 side or present bilaterally:
Absent score 0, present on any side score 18
Total extent of disease score: [(a+b+c+d) x 100] / 72
= __________ (lung remodelling index out of 1 0 0 )
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Appendix 2: FACS buffer
The following constituents were dissolved in 490 ml PBS (pH 7.4):
5 ml 1 % FCS
5 ml of 0.02% sodium azide
Appendix 3: Phosphate-buffered saline (PBS)
The following constituents were dissolved in 1000 ml of distilled H2 O (pH 7.4):
8  g NaCl 
1.44 g Na:HP0 4  
0.24 g KH2 PO4  
0.2 g KC1
Appendix 4: Agarose gel electrophoresis
Agarose gels (3%) were run (120 V, 300 mA for 30 min) in 50 ml tanks (5 mis lOx 
buffer TBE, 45 mis H2 O, 1.5g agarose (Gibco) and lpl ethidium bromide), with 
running buffer (lx  TBE with 15 pi ethidium bromide/litre) and 2 pi molecular weight 
marker (100 and 20 bp ladders, Sigma, UK). Buffer TBE (tris-borate-EDTA) was 
made to a final volume of 1 litre using de-ionised water, 108 g Tris base, 55 g boric 
acid, 40 ml 0.5 M EDTA (pH 8.0). Gels were scanned using a fluorescence image 
analyser (FLA-2000, Fuji Photo Film).
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